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 The 1,3,5-triazine is a privileged scaffold in that it is planar and has three-fold 
symmetry which allows for controlled modification around the ring structure with various 
substituents. In this thesis, we report on two modular inhibitor libraries that center around 
a 1,3,5-triazine core scaffolding system, which have been shown to target protein disulfide 
isomerase A1 (PDIA1), glutaredoxin-3 (GLRX3), and 6-phosphofructo-1-kinase (PFKP). 
Protein disulfide isomerase A1 (PDIA1) is a thiol-disulfide oxidoreductase localized in the 
lumen of the endoplasmic reticulum (ER), and is an important folding catalyst and 
chaperone for proteins in the secretory pathway. PDIA1 contains two active-site domains 
(a and a’), each containing a Cys-Gly-His-Cys (CGHC) active-site motif. Here, we 
synthesize a targeted library o second-generation triazine-based inhibitors to optimize the 
potency and selectivity of our lead compound, RB-11-ca. Characterization of this targeted 
library afforded an optimized PDIA1 inhibitor, KSC-34, which covalently modifies C53 in 
the a site of PDIA1 and demonstrates time-dependent inhibition of the reductase activity 
of PDIA1 in vitro with a kinact/KI = 9.66 x 103 M-1s-1. Interestingly, KSC-34 treatment 
demonstrated that a-site inhibition led to decreased secretion of amyloidogenic antibody 
light chain, thus illustrating that site-selective inhibitors like KSC-34 provide useful tools 
for delineating the pathological role and therapeutic potential of PDIA1. 
 In 2014, our lab first reported on RB7, a dichlorotriazine-based electrophilic small 
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molecule which displayed extremely high reactivity and selectivity toward lysine residues 
in the proteome. Herein, we further on this study by investigating the unique reactivity of 
RB7 through the synthesis of a second-generation small molecule electrophile library and 
investigating proteome-wide reactivity in vitro and in situ. This library afforded KSC-46, 
an RB-7 analogue with p-chlorothiophenol tuning element, which provided optimal 
proteome reactivity to use as a scaffold for the generation of a targeted library. To take 
advantage of the tuned reactivity of KSC-46, a second-generation targeted library was 
generated to target react residues in the proteome. This library yielded two molecules, 
KSC-56 and KSC-65, which were identified to target glutaredoxin-3 (GLRX3) and 6-
phosphofructo-1-kinase (PFKP), respectively. GLRX3 is a cytosolic, monothiol iron-sulfur 
cluster chaperon protein which relies on two nucleophilic cysteine residues to bind and 
transfer iron clusters. PFKP is known to catalyze the first irreversible step in glycolysis and 
regulates the flux of glucose metabolism in the cell, which makes PFKP an attract 
therapeutic target. KSC-56 was further characterized to bind to Cys261 in the C-terminal 
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Table 2.1. Mass spectrometry data for KSC-34 treated MCF-7 cells. The proteins 
shown are sorted by the spectral count difference between the KSC-34 treated and 
the DMSO treated samples. 
 





Table 4.1. Mass Spectrometry data for KSC-56 treated samples. The proteins 
shown are those that fell within the required molecular weight range of 33-43 kDa 
and is sorted by the spectral count difference between the KSC-56 treated and the 
DMSO (no probe) samples. Full data set is displayed in the appendix. 
 
Table 4.2. Mass Spectrometry data for KSC-65 treated samples. The proteins 
shown are those that fell within the required molecular weight range of 75-95 kDa 
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Figure 1.1. Domain organization of PDIA1. PDIA1 is comprised of four 
thioredoxin-like domains. The a-type domains contain CGHC active site motifs. 
PDIA1 also contains a highly acidic C-terminal extension c and a 19 amino acid 
linker between the b’ and a’ domains, termed x. 
 
Figure 1.2. (A) The oxidase activity of PDIA1 installs disulfide bonds in protein 
substrates. (B) Mechanistically, a nucleophilic thiolate anion on the protein 
substrate attacks the disulfide bond of the of the PDIA1 active site, resulting in a 
mixed disulfide bond. Another cysteine within the substrate macromolecule attacks 
the mixed disulfide, forming the intramolecular disulfide bond on the protein 
substrate. PDIA1 is subsequently released, generating dithiols within the active site 
of PDIA1. 
 
Figure 1.3. The Ero1 mediated reoxidation of PDIA1. The active site dithiols are 
reoxidized by Ero1, an FAD-binding oxidase. Ero1 transfers electrons from PDIA1 
to FAD, and subsequently to O2, producing one molecule of H2O2 and regenerating 
the FAD cofactor. 
 
Figure 1.4. (A) The reductase activity of PDIA1 reduces disulfide bonds to dithiol 
groups in protein substrates. (B) Mechanistically, one of the two nucleophilic 
cysteines in the PDIA1 active sites, Cys53 or Cys397, will attack a substrate 
disulfide bond creating a mixed disulfide. After a given amount of time, the C-
terminal cysteine in the active site, Cys56 or Cys400, will then be activated and 
attack the N-terminal cysteine. This results in oxidation of the active site of PDIA1 
and release of the reduced protein substrate. 
 
Figure 1.5. (A) The isomerase activity of PDIA1 shuffles incorrectly formed 
disulfide bonds to achieve properly folded substrates. (B) One of the two 
nucleophilic cysteines in the PDIA1 active sites, Cys53 or Cys397, will attack a 
substrate disulfide bond creating a mixed disulfide. At this point a decision is made 
to either form the correct disulfide (solid black line) or re-form the incorrect 
disulfide pair (dashed black line). Another option, is PDIA1 acts as a “clock” and 
the C-terminal active site cysteine, Cys56 or Cys400, can attack its partner and 
release the protein substrate as a dithiol (dashed blue arrows). 
 
Figure 1.6. Chemical structure of the dodecapeptide PDIA1 inhibitor, bacitracin. 
 










Figure 2.1. Domain organization of PDIA1. PDIA1 comprises two active-site a-
type domains that contain a CGHC active-site motif, together with two b-domains 
implicated in substrate recognition and binding. 
 
Figure 2.2. (A) Chemical structure of RB-11-ca, a previously reported a-site 
inhibitor of PDIA1. RB-11-ca contains a central triazine scaffold, a 
chloroacetamide reactive group for covalent cysteine modification, an alkyne 
bioorthogonal handle for CuAAC, and an octylamine diversity element. (B) 
Predicted binding pose of RB-11-ca in a domain active site of PDIA1 by the 
covalent docking algorithm from Schrodinger, Inc. 
 
Figure 2.3. Structures of second-generation PDIA1 inhibitors obtained by varying 
the diversity element of RB-11-ca. 
 
Figure 2.4. Characterization of PDIA1 second-generation library members (A) 
Library members (5 µM) were incubated with purified recombinant PDIA1 (50 
µg/mL) in PBS, and protein labeling by each compound was evaluated after 
CuAAC-mediated incorporation of a TAMRA fluorophore, SDS-PAGE, and in-gel 
fluorescence. Library members with equal or great potency than RB-11-ca 
progressed to the next step of the assay. (B) Complete gel images  illustrating only 
recombinant PDIA1 used in assay. ImageJ (NIH, Bethesda, MD) was used to 
quantify the fluorescence intensity of the PDIA1 band. All data are normalized to 
RB-11-ca lead compound. Error bars represent SD for n = 3 experiments. 
 
Figure 2.5. Characterization of PDIA1 second-generation library members. (A) 
Library members were assessed against purified, recombinant PDIA1 (50 µg/mL) 
in the background of MCF-7 cell lysates (1 mg/mL) to evaluate whether other 
cellular proteins interfere with the ability of each compound to covalently modify 
PDIA1. (B) Complete gels for part (A) illustrating proteome-wide selectivity of 
second-generation library members. ImageJ (NIH, Bethesda, MD) was used to 
quantify the fluorescence intensity of the PDIA1 band. All data are normalized to 
RB-11-ca lead compound. Error bars represent SD for n = 3 experiments. 
 
Figure 2.6. Characterization of PDIA1 second-generation library members. (A) In-
gel fluorescence studies of library members (5 µM) incubated with MCF-7 cell 
lysate (2 mg/mL) to assess potency and selectivity for endogenous PDIA1 in a 
complex proteome. (B) Complete gel images for analysis used in part (A) 
demonstrating proteome-wide selectivity of second generation library members in 
a complex proteome. ImageJ (NIH, Bethesda, MD) was used to quantify the 
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fluorescence intensity of the PDIA1 band.  All data are normalized to RB-11-ca 
lead compound. Error bars represent SD for n = 3 experiments. 
 
Figure 2.7. Characterization of PDIA1 second-generation library members. To 
assess cell permeability as well as selectivity of the library, probes (5 µM) were 
incubated with MCF-7 cells for 3 hours at 37 °C. Following cell lysis and in-gel 
fluorescence, KSC-34 was found to be ~8-fold more potent than the lead 
compound, RB-11-ca, in whole cells against PDIA1 (left panel). Coomassie gel 
(right panel is provided to show normalized protein abundance).  
 
Figure 2.8. Concentration and time-dependent inhibition of PDIA1 by KSC-34, 
RB-11-ca, and 16F16. PDIA1 reductase activity was measured using an insulin 
reduction assay in a 100 µL reaction volume containing 0.5 µM PDIA1, 0.16 mM 
insulin, and 1 mM DTT in assay buffer. Turbidity of the insulin solution was 
measured over time at various concentrations and pre-incubation times with KSC-
34. Error bars are calculated as SD from n = 2 experiments. 
 
Figure 2.9. Evaluation of the site-selectivity of KSC-34. (A) Labeling of purified 
recombinant PDIA1 WT, C397A and C53A by KSC-34. Each recombinant PDIA1 
protein (50 µg/mL) was incubated with KSC-34 (5 µM) for 1 hour, and subjected 
to CuAAC prior to in-gel fluorescence. (B) Structures of KSC-34 and 
Chloroacetamide-Rhodamine (CA-Rh). (C) PDIA1 C53A and C397A (50 µg/mL) 
in the background of MCF-7 lysates (1 mg/mL) were treated with increasing 
concentrations of KSC-34, RB-11-ca and 16F16 to quantify the selectivity for the 
a and a’ domains. Following incubation, samples were then treated with CA-Rh) to 
append a fluorophore to the residual, unmodified PDIA1 active sites. Loss of 
fluorescence indicates inhibitor binding. ImageJ (NIH) was used to quantify the 
loss in fluorescence and calculate affinities for each active site. (D) Active-site 
selectivity for KSC-34, RB-11-ca, and 16F16. KSC-34 was found to have a 30-fold 
selectivity for the a domain over the a’ domain, compared to RB-11-ca which 
exhibited a 21-fold selectivity and 16F16 which exhibited 2-fold selectivity. Error 
is calculated by PRISM as ± SEM from n = 3 experiments. 
 
Figure 2.10. Evaluation of selectivity of KSC-34. PDI isoform selectivity. KSC-34 
was found to only covalently modify PDIA1 over PDIA3 and PDIA4, two closely 
related family members. 
 
Figure 2.11. Evaluation of proteome-wide selectivity of KSC-34. Mass 
spectrometry analysis of proteins enriched in KSC-34 (5 µM) and DMSO treated 
MCF-7 cells. The spectral count difference between KSC-34-treated and DMSO-
treated samples are plotted for all proteins identified (Table 1). Errors bars show 
SD for n = 2 experiments. 
 
Figure 2.12. (A) Identification of KSC-34 cellular occupancy of PDIA1. MCF-7 
cells were treated with varying concentrations of KSC-34na. Following lysis, 
protein concentrations were normalized and subjected to treatment with KSC-34 (5 
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µM) to modify any residual PDIA1 a domain active site, C53. An EC50 of ~4 µM 
was calculated for KSC-34na labeling of PDIA1 in MCF-7 whole cells. All data 
are normalized to RB-11-ca lead compound. Error bars represent ± SD for n = 3 
experiments. (B) MTT assay data in MCF-7 cells treated with varying 
concentrations of KSC-34. The calculated EC50 of KSC-34 was determined to be 
82 µM. All data are normalized to vehicle treated cells. Error bars represent ± SD 
for n = 3 experiments. 
 
Figure 2.13. Effects of KSC-34 on cell viability and the unfolded protein response. 
(A) qPCR analysis of UPR target genes following concentration-dependent 
treatment of MCF-7 cells with KSC-34 for 3 hours at 37 °C. Data are reported as 
the mean fold change (relative to DMSO) ± SEM from three biological replicates. 
(B) XBP1 splicing assay for MCF-7 cells treated with varying concentrations of 
KSC-34 for 3 hours. 
 
Figure 2.14. Effects of KSC-34 on the unfolded protein response. qPCR analysis 
of UPR target genes following co-treatment of MCF-7 cells with KSC-34 (20 µM) 
and IRE1α inhibitor, 4µ8c. Data are reported as the mean fold change (relative to 
DMSO) ± SEM from three biological replicates. 
 
Figure 2.15. Effects of KSC-34 on the unfolded protein response. (A) Activation 
of UPR target genes in MCF-7 cells was assessed by measuring the relative mRNA 
expression levels of target genes by qRT-PCR after treating with KSC-34 (20 µM) 
for increasing time. Transcripts were normalized to the housekeeping gene RPLP2, 
and all reactions were performed in technical quadruplicate. Data are reported as 
the mean fold change (relative to DMSO) ± SEM from three biological replicates. 
(B) XBP1 splicing assay for time-course experiment, where MCF-7 cells were 
treated with 20 µM KSC-34. Gel shows three biological replicates for each 
condition. 
 
Figure 2.16. Activation of UPR target genes in A549 cells (A) or SKOV-3 cells 
stably expressing shPDIA1, shPDIA4 or shGFP (B). The relative mRNA 
expression levels of target genes were assessed by qRT-PCR after treating with 
increasing concentrations of KSC-34 or 5 µM of thapsigargin. Transcripts were 
normalized to the housekeeping gene RPLP2. (A) For A549 cells, all reactions were 
performed in technical quadruplicate, and data are reported as the mean fold change 
(relative to DMSO) ± SEM from three biological replicates. (B) For SKOV-3 cells, 
data are reported as mean fold change (relative to shGFP DMSO) ± SEM from 
reactions performed in triplicate. 
 
Figure 2.17. KSC-34 reduces secretion of destabilized ALLC from mammalian 
cells. (A) Immunoblot of anti-FLAG IPs of lysates prepared from HEK293DAX cells 
transiently transfected with FTALLC and pre-treated for 1 h with vehicle or KSC-
34 (40 µM). Cells were crosslinked for 30 min with DSP (500 µM) prior to lysis. 
Mock transfected cells are included as a control. (B) Graph showing secreted 
FTALLC (grey) and viability (blue) of HEK293Trex cells stably expressing FTALLC 
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pretreated for 4 h with KSC-34 (40 µM). Media was conditioned for 2 h in the 
presence or absence of KSC-34 (40 µM) prior to quantification of secreted FTALLC 
by ELISA. Viability was measured following media conditioning by Cell Titre Glo. 
All data are normalized to vehicle-treated cells. Error bars show SEM for n=3 
experiments. ***p<0.005. 
 
Figure 2.18. KSC-34 reduces secretion of destabilized ALLC from mammalian 
cells. Representative autoradiogram and quantification of the fraction [35S]-labeled 
FTALLC secreted from HEK293DAX cells using the experimental paradigm shown. 
Experiments were performed in the absence or presence of KSC-34 (40 µM) added 
1 h prior to labeling and then again throughout the experiment. Fraction secreted 
was calculated as described in Materials and Methods (64). Error bars show SEM 
for n=4. ***p<0.005. 
 
Figure 2.19. KSC-34 reduces secretion of destabilized ALLC from mammalian 
cells. (A) Graph showing fold change mRNA levels of PDIA1 in HEK293DAX cells 
and HEK293DAX cells shRNA-depleted of PDIA1 measured by qPCR. Error bars 
show 95% confidence interval. (B) Graph showing secreted FTALLC (grey) and 
viability (blue) of HEK293DAX cells transiently expressing FTALLC pretreated for 
4 h with KSC-34 (40 µM). HEK293DAX cells stably expressing PDIA1 shRNA are 
indicated. Media was conditioned for 2 h in the presence or absence of KSC-34 (40 
µM) prior to quantification of secreted FTALLC by ELISA. Viability was measured 
following media conditioning by Cell Titre Glo. All data are normalized to vehicle-
treated controls. Error bars show SEM for n=3 experiments. *p<0.05. (C) 
Representative autoradiogram and quantification of the fraction [35S]-labeled 
FTALLC secreted from HEK293DAX cells using the experimental paradigm shown 
in Figure 2-18. Experiments were performed in the absence or presence of KSC-34 
(40 µM) added 1 h prior to labeling and then again throughout the experiment. Error 
bars show SEM for n=4 (D) Graph showing the fraction [35S]-labeled FTALLC 
secreted at t=4 h from HEK293DAX cells transiently transfected with FTALLC 
quantified using the same experimental paradigm shown in Figure 2-18. 
HEK293DAX cells stably expressing PDIA1 shRNA are indicated. Experiments 
were performed in the absence or presence of KSC-34 (40 µM) added 1 h prior to 
labeling and then again throughout the experiment. Error bars show SEM for n=4 






Figure 3.1. (A) Chemical structure of promiscuous cysteine-reactive ABPP probe, 
iodoacetamide-alkyne. (B) Representative structure of an ABPP probe, containing 
a reactive group, a linker/binding group, and a reporter element. (C) Chemical 
structures of various common reporter elements used in ABPP for visualization 
(rhodamine, and enrichment (biotin), as well as post labeling conjugation (azide 




Figure 3.2. (A) Chemical structures of the panel of alkyne-functionalized 
chloronitrobenzene probes evaluated. (B) In-gel fluorescence study of the reactivity 
of CNBs in complex proteomes, after incorporation of rhodamine-azide (Rh-N3) 
using CuAAC. 
 
Figure 3.3. (A) Chemical structures of the panel of alkyne-functionalized 
fluoronitrobenzene, chloropyridine, chloropyrimidine, and dichlorotriazine probes 
evaluated. (B) In-gel fluorescence study of the reactivity of aryl halide probes in 
HeLa lysates at 100 µM, followed by incorporation of rhodamine-azide (Rh-N3) 
using CuAAC and separation using SDS-PAGE. 
 
Figure 3.4. (A) In-gel fluorescence studies comparing probe labeling patterns of 
RB2 (20 µM), ERW3 (20 µM), and RB7 (20 µM). (B) Competition assay with IA 
comparing probe labeling of RB2, ERW3, and RB7 prior to treatment with IA. 
 
Figure 3.5. (A) General chemical structure of small-molecule probes. Each probe 
contains three elements: (1) an alkyne handle for bio-orthogonal reporter tag 
conjugation; (2) a diversity element to direct the probes to different subsets of the 
proteome; and (3) a dichlorotriazine electrophile. (B) Chemical structures of 
diversity elements used in dichlorotriazine small-molecule probe library. 
 
Figure 3.6. (A) Chemical structure of LAS17. (B) In-gel fluorescence studies of 
LAS17 (1 µM) incubated with HeLa cell lysate (2 mg/mL) to assess potency and 
selectivity for endogenous proteins in a complex proteome. (C) HeLa cells were 
treated with LAS17 (1 µM) and subjected to in-gel fluorescence analysis to assess 
the cell permeability and selectivity of LAS17 in situ. (D) HeLa cell lysates treated 
with LAS17 (1 µM) or DMSO were subjected to CuAAC with biotin-azide, 
enriched on streptavidin beads, and subsequent LC/LC-MS/MS analysis. The top 
10 proteins with the greatest difference in average spectral counts among three trials 
for DMSO and LAS17 treated samples are listed. 
 
Figure 3.7. (A) Purified, recombinant GSTP1 was treated with LAS17 (1 µM) and 
evaluated by in-gel fluorescence. (B) In vitro GSTP1 activity assay data 







Figure 4.1. Chemical structure of dichlorotriazine compound, RB7. 
 




Figure 4.3. Structures of second-generation chlorotriazine electrophiles obtained 
by varying the tuning element of the triazine ring. 
 
Figure 4.4. Electrostatic potential maps demonstrating effect that electron 
withdrawing and electron donating groups pose on the electron distribution 
throughout the triazine-ring system. 
 
Figure 4.5. Investigating the proteome reactivity of chlorotriazines. The library of 
chlorotriazine electrophiles were incubated in MCF7 lysates (2 mg/mL) and protein 
labeling by each library member (100 µM) was evaluated after CuAAC-mediated 
incorporation of a TAMRA fluorophore, SDS-PAGE, and in-gel fluorescence. 
 
Figure 4.6. Effect of iodoacetamide (IAA) pre-treatment (0-10 mM) prior to 
labeling with IA≡ (2 µM), BBI (100 µM), and KSC-46 (100 µM). MCF7 lysates (2 
mg/mL) were incubated with IA for 1 hour, followed by treatment with each probe 
and then subhected to CuAAC and in-gel fluorescence analysis to investigate the 
residue specificity of the new chlorotriazine electrophile. 
 
Figure 4.7. (A) General chemical structure of small-molecule chlorotriazine 
library. (B) Chemical structures of diversity elements used in di-functionalized, 
chlorotriazine small-molecule probe library. 
 
Figure 4.8. Characterization of targeted library of chlorotriazine probes in vitro. 
Library members (20 µM) were incubated with MCF7 cell lysates (2 mg/mL) in 
PBS, and protein labeling by each compound was evaluated after CuAAC-mediated 
incorporation of a TAMRA fluorophore, SDS-PAGE, and in-gel fluorescence (Left 
panels). Coomassie gels shown (right panels) to show equal protein loading on gels. 
 
Figure 4.9. Characterization of targeted library of chlorotriazine probes in situ. 
Library members (20 µM) were incubated with MCF7 cells for 3 hours at 37 °C, 
and protein labeling by each compound was evaluated after in-gel fluorescence 
analysis(Left panels). Coomassie gels shown (right panels) to show equal protein 
loading on gels. 
 
Figure 4.10. General chemical structures of some classes of PFKFB3 inhibitors. 
 
Figure 4.11. (A) GLRX3 was overexpressed in HEK293T cells via transient 
transfection using pcDNA3.1(+). Cells were subsequently treated with KSC-56 (20 
µM) for 3 hours at 37 °C, following analysis by in-gel fluorescence. Overexpression 
of GLRX3 was confirmed by anti-FLAG western blot. (B) GLRX3 WT, C159S, 
and C261S were overexpressed in HEK293T cells via transient transfection using 
pcDNA3.1(+). Cells were subsequently treated with KSC-56 (20 µM) for 3 hours 
at 37 °C, following analysis by in-gel fluorescence. Overexpression of GLRX3 was 




Figure 4.12. (A) PFKP was overexpressed in HEK293T cells via transient 
transfection using pcDNA3.1(+). Cells were subsequently treated with KSC-65 (20 
µM) for 3 hours at 37 °C, following analysis by in-gel fluorescence. Overexpression 
of PFKP was confirmed by anti-FLAG western blot. (B) PFKP C179S, C411S, 
C529S, and C641S were overexpressed in HEK293T cells via transient transfection 
using pcDNA3.1(+). Cells were subsequently treated with KSC-65 (20 µM) for 3 
hours at 37 °C, following analysis by in-gel fluorescence. Overexpression of PFKP 
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Scheme 4.1. General synthetic scheme for the synthesis of second generation 
chlorotriazine electrophiles. 
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 Proper folding of nascent proteins in the cell is accelerated by protein folding 
catalysts and chaperones that inhibit protein aggregation1-2. A number of diseases may arise 
due to the accumulation of unfolded proteins in the cell3-5, including neurodegenerative6 
and prion infections7. To protect against protein misfolding and aggregation, the cell uses 
a number of mechanisms including chaperones and folding catalysts to inhibit aggregation 
and increase proper folding, along with systems in place to degrade proteins that fail to 
properly fold8. Secreted and cell-surface proteins are often stabilized by the introduction 
of disulfide bonds9. 
 Disulfide bonds are covalent bonds produced by the oxidation of two free thiols on 
cysteine side chains in proteins10-11. Disulfides usually function to stabilize tertiary protein 
structures via intramolecular bonds and quaternary protein structures when formed 
intermolecularly between two protein chains. Disulfide bonds can also play key regulatory 
roles as redox switches, controlling the activity of various enzymes10-11. Disulfide bond 
formation one of the crucial and key rate-limiting steps for the correct folding of nascent 
polypeptides12. Nearly one-third of all eurkaryotic proteins, including nearly ~80% of all 
secretory proteins, contain at least one disulfide bond in their structure10, 13. Early in protein 
folding, disulfide bond formation can be error-prone, where the wrong cysteines are 
covalently linked14-15. Another common occurrence is the correct formation of the disulfide 
bond, but formation occurs to quickly to allow the nascent protein to adopt its correct fold 
prior to disulfide bond formation16-18. The synthesis and folding of these disulfide bond 
containing proteins takes place in the lumen of the endoplasmic reticulum (ER), which is 
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more oxidizing than the cytosol, and is equipped with catalysts of disulfide formation and 
isomerization10, 19-20. 
 Protein disulfide isomerase A1 (PDIA1) was discovered as the first protein folding 
catalyst in 1963 by two independent research groups21-22. PDIA1 is localized in the ER via 
a classic KDEL ER retention sequence23, and accounts for approximately 0.8% of total 
cellular protein24. PDIA1 is a 57 kDa multi-domain thiol-disulfide oxidoreductase and 
molecular chaperone that is responsible for the catalysis of disulfide bond oxidation, 
reduction, and isomerization in its nascent protein substrates25. PDIA1 has also been 
implicated in binding and stabilizing the major histocompatibility complex (MHC) class I 
peptide-loading complex (PLC), which mediates MHC class I peptide loading26. PDIA1 is 
also the β subunit of prolyl-4-hydroxylase which catalyzes the formation of 4-
hydroxyproline in collagen biosynthesis13, 27. Recently, PDIA1 has been found to be rapidly 
secreted from platelet and endothelial cells during thrombus formation in vivo28-30. 
 
1.1 The Protein Disulfide Isomerase Family 
 The enzymes of the protein disulfide isomerase (PDI) family are thiol-disulfide 
oxidoreductases that reside in the ER. The PDI family contains both thiol-reactive and thiol 
non-reactive members31. Currently, the PDIA gene family consists of 21 family members 
varying in length, domain arrangement, and substrate specificity, but all share one common 
motif – the thioredoxin-like domain (Table 1.1)13. All human PDIs contain at least one 
thioredoxin-like domain, which can be divided into two different types, catalytic (a) and 
non-catalytic (b). Although the family name implies isomerase functionality, not every 
family member has this catalytic activity. Some family members, such as ER protein 27 
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kDa (ERp27)32 and ER protein 29 kDa (ERp29)33, are comprised of only non-catalytic 
thioredoxin domains and therefore should only possess chaperone-like activity. The a-type 
domains usually contain a –CXXC– active site motif, although some family members 
contain a –SXXC– active motif. Protein disulfide isomerase-like protein of the testis 
(PDILT) and thioredoxin-related transmembrane protein 2 (TMX2) contain these –SXXC– 
motifs, and have been found to form mixed disulfides but not possess full oxidase 
activity31. Most PDIs contain multiple thioredoxin domains, and usually a combination of 
a- and b-type domains. The inactive domains in these PDIs are mainly responsible for the 











Table 1.1. Overview of the 21 proteins in the human PDI family listed with domain 




1.2 The Discovery of PDIA1 
 PDIA1 was independently discovered by two research groups led by Brunó Straub 
and Christian Anfinsen in 196321-22. Straub found that extracts from pancreas of both 
chickens and pigeons were able to catalyze the reoxidation of reduced ribonuclease 
(RNAse). It was concluded that the extracts contain an enzyme which is able to catalyze 
the sulfhydryl-disulfide transformation and that this protein might play a role in the final 
step of protein biosynthesis22. Anfinsen’s group found that subcellular microsomal enzyme 
system from rat liver was responsible for accelerating the reactivation of reduced bovine 
pancreatic RNAse21. Furthermore, the group partially purified the microsomal enzyme 
system responsible and demonstrated that it can catalyze dithiol-disulfide exchange 
reactions34-36.  
 
1.3 The Structure of PDIA1 
 The full-length, unprocessed PDIA1 consists of 508 amino acids. The N-terminal 
17 amino acid signal peptide is cleaved off during processing upon translocation to the ER, 
leaving the mature form of PDIA1 truncated to 491 amino acids11, 25. PDIA1 is organized 
into four distinct thioredoxin-like, globular domains, a, b, b’, and a’, plus a highly acidic 
C-terminal extension c and a 19 amino acid linker between the b’ and a’ domains, termed 
x (Figure 1.1). The a and a’ domains functionally resemble thioredoxin (Trx), and contain 
redox catalytic Cys-Gly-His-Cys (CGHC) active-site motifs. The b and b’ domains, while 
resembling Trx, do not contain CGHC active-site motifs and therefore are not catalytically 
active. PDIA1 adopts a horseshoe shape structure where the a and a’ catalytic domains 












Figure 1.1. Domain organization of PDIA1. PDIA1 is comprised of four thioredoxin-like 
domains. The a-type domains contain CGHC active site motifs. PDIA1 also contains a 
highly acidic C-terminal extension c and a 19 amino acid linker between the b’ and a’ 




1.4 The Catalytic Domains of PDIA1 
 The a and a’ domains share 33.6% sequence identity and contain identical CGHC 
active site motifs25. The oxidase, reductase, and isomerase activities of PDIA1 depend on 
the thiol groups in the active sites of the a and a’ domains38-39. It is known that the two 
active sites of PDIA1 operate independently of each other. Vuori et al. investigated the 
effect of disrupting the catalytic active site in one or both domains on the catalytic activity 
of PDIA1. It was found that abolishing one active site cysteine in either domain resulted in 
a 50% loss of the oxidoreductase activity, and abolishing both active site cysteines resulted 
in a 100% loss in oxidoreductase activity of PDIA140. Due to the fact that mutation of each 
active site only resulted in a loss of 50% activity, it can be concluded that each active site 
operates independently from each other. The secondary structure of the globular domains 
of PDIA1 adopt a Trx-like fold and are arranged in a β1-α1-β2-α2-β3-α3-β4-β5-α4 fashion. 
The residues of the catalytic active sites are positioned at the top of the second helix, α2, 
leaving the N-terminal cysteine partially exposed to the solvent10. 
Characterization of this active site led to the determination that the pKa of the N-
terminal cysteine lies in the range of 4.5-5.641-42. Ruddock et al determined the pH 
dependence of the disulfide bond oxidation activity of PDIA1 was correlated to the pKa of 
the N-terminal cysteine residue in the active site of PDIA1. The data indicated a pKapp of 
5.6 for bovine PDIA141. Kortemme et al determined the pKa of the N-terminal active 
cysteine to be 4.5 for human PDI a by analyzing the pH dependence of ultraviolet-visible 
(UV/Vis) absorbance shifts or nuclear magnetic resonance (NMR) chemical shift 
perturbations (CSP)42. Furthermore, it has been demonstrated that electrostatic interactions 
in the active-site stabilize the thiolate anion. A link with the imidazole group of the histidine 
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in the CGHC motif was found to stabilize the thiolate by 1.1 kcal/mol. Further electrostatic 
interactions with partial positive charges at the N-terminus of the α-helix contribute 4.6 
kcal/mol, up to a total of 5.7 kcal/mol stabilization of the thiolate42. This stabilizing effect 
of the thiol form of the enzyme effectively destabilizes the oxidized, disulfide bond form 
of the enzyme involving that same thiol group43. The C-terminal cysteine in the active site 
of PDIA1 is known to be less solvent accessible and thus has higher pKa, effectively around 
12.825, 44. Lappi et al found that a conserved arginine, R120, moves in and out of the active 
site. Upon moving close to the active site, the pKa of the C-terminal cysteine, C56, is 
dramatically lowered to allow formation of a thiolate anion that acts as a nucleophile on 
any mixed disulfide formed by C53 with and substrate, effectively reoxidizing PDIA144. 
 The b and b’ domains do not contain a redox catalytic active site, and are needed 
primarily for spacing and substrate recruitment. The b’ domain, which contains a large 
hydrophobic cavity between helices α1 and α3 to interact with unfolded protein and peptide 
substrates, is the major substrate binding domain of PDAI131, 45. Pirneskoski et al 
demonstrated that point mutations along the substrate binding domain at positions L242, 
L244, F258, and I272 influenced peptide binding. Furthermore, the greatest effect was seen 
for the point mutation I272W. Biophysical characterization indicated no alterations in 
structure upon mutation of I272, revealing that the results are a direct effect on the substrate 
binding domain and not an observed structural effect from the mutation46. The b’ domain 
has also been demonstrated to be essential for the assembly of prolyl-4-hydroxylase (P4H). 
Truncated forms of PDIA1 were overexpressed and the minimum construct found 




PDIA1 has also been shown to possess chaperone activity, by inhibiting the 
aggregation of misfolded protein substrates at stoichiometric concentrations48-51. Dai and 
Wang demonstrated that this activity was dependent upon the b’ domain of PDIA1. This 
was confirmed by expressing a mutant form of PDIA1 with 51 amino acids truncated from 
the C-terminal end of the b’ domain to remove the substrate binding pocket. The mutant 
enzyme showed no peptide binding ability or chaperone activity against D-glyceraldehyde-
3-phosphate (GAPDH), a protein with no disulfide bonds. However, the truncated protein 
retains most of its insulin reductase activity and isomerase activity against scrambled 
RNAse52. 
 
1.5 Thiol-Disulfide Exchange Reactions of PDIA1 
 PDIA1 possess two conserved CGHC active sites in the a and a’ domains, in which 
the two cysteines can exist is the disulfide (oxidized PDIA1) or dithiol form (reduced 
PDIA1). These active sites are responsible for the enzymatic function, in which PDIA1 
facilitates the oxidation, reduction, or isomerization or disulfide bonds within protein 
substrates depending on the redox state of the active site9-10, 25. Direct evidence for PDIA1 
catalayzed thiol-disulfide exchange in vivo were first shown in two systems. Bulleid and 
Freedman demonstrated that dog pancreas microsomes, which were deficient in PDIA1, 
are defective in co-translational formation of disulfide bonds in γ-gliadin, a wheat storage 
protein. It was also shown that reconstitution of these microsomes with purified PDIA1 
reversed this observed effect53. Second, Molinari and Helenius demonstrated that PDIA1 
and other PDI-family member ERp57 (PDIA3) form mixed disulfides in vivo with 
glycoproteins in the ER of mammalian cells54. 
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 During the oxidation or reduction of its protein substrates, PDIA1 transfers either 
an oxidizing or reducing equivalent from the cysteine pairs in its active sites, which then 
in turn cycle between the oxidized and reduced states. The two amino acids between the 
cysteines in the active site in the CXXC motif contribute significantly to the reduction 
potential of the active site. PDIA1 has a reduction potential of -180 mV, making it one of 
the better oxidants in the protein disulfide isomerase family55. The oxidase activity of 
PDIA1 inserts disulfide bonds into protein substrates, which results in the pairing of two 
substrate thiol groups and the reduction of the PDIA1 active site (Figure 1.2). The oxidase 
activity of PDIA1 only require either the a or the a’ domain. The catalysis has been 
attributed to the high reactivity of the disulfide bonds, which are approximately ~500-fold 











Figure 1.2. (A) The oxidase activity of PDIA1 installs disulfide bonds in protein substrates. 
(B) Mechanistically, a nucleophilic thiolate anion on the protein substrate attacks the 
disulfide bond of the of the PDIA1 active site, resulting in a mixed disulfide bond. Another 
cysteine within the substrate macromolecule attacks the mixed disulfide, forming the 
intramolecular disulfide bond on the protein substrate. PDIA1 is subsequently released, 




 Reoxidation of the active sites of PDIA1 is then carried out by ER oxireductin 1 
(Ero1), which is a flavin adenine nucleotide (FAD) binding oxidase57. Ero1 contains two 
distinct pairs of cysteines, one located proximal to the FAD cofactor as a CXXC motif, and 
the other pair located on a flexible loop58. Through these two pairs of cysteines, Ero1 
induced reoxidation of PDIA1 is achieved via a thiol-disulfide exchange reaction with the 
cysteine pair located on the flexible loop of Ero1. This is subsequently followed by an 
electron transfer to the FAD cofactor via the cyeteine pair in the CXXC motif. The 
electrons are finally shuttled from the FADH2 to O2, producing one molecule of H2O2 and 











Figure 1.3. The Ero1 mediated reoxidation of PDIA1. The active site dithiols are 
reoxidized by Ero1, an FAD-binding oxidase. Ero1 transfers electrons from PDIA1 to 





 Due to the extremely oxidizing conditions of the endoplasmic reticulum as well as 
the reduction potential of the active site motifs, the active site cysteines of PDIA1 are 
commonly found in the oxidized (disulfide) form. Thus, PDIA1’s ability to act as a 
reductase is less common than other members of the PDI family. Contrary to the oxidase 
activity, the reductase activity utilizes the reduced dithiol groups in the active site of a or 
the a’ domain. PDIA1 will the transfer the dithiol groups to its protein substrate, and in 











Figure 1.4. (A) The reductase activity of PDIA1 reduces disulfide bonds to dithiol groups 
in protein substrates. (B) Mechanistically, one of the two nucleophilic cysteines in the 
PDIA1 active sites, Cys53 or Cys397, will attack a substrate disulfide bond creating a 
mixed disulfide. After a given amount of time, the C-terminal cysteine in the active site, 
Cys56 or Cys400, will then be activated and attack the N-terminal cysteine. This results in 




 These thiol-disulfide reactions that either install or remove disulfide bonds in 
protein substrates proceed through the formation of transient mixed disulfide bonds 
between the N-terminal cysteine of the a or a’ domain (Cys53 or Cys397) of PDIA1 and 
the protein substrate. A conserved glutamate positioned below the C-terminal cysteine 
(Cys56 or Cys400) forms a salt bridge and functions in proton transfer during the substrate 
release step in the “escape pathway”9, 25, 31, 60. During this step, the catalytic domains have 
undergone significant conformational changes, causing the pKa of the C-terminal cysteine 
to drop from 12.8 to 6.1, thus becoming nucleophilic enough to attack the N-terminal 
cysteine of the active site44, 61. 
 Interestingly, the formation of disulfide bonds early on in protein synthesis is often 
error prone. These errors can be the result of two incorrect cysteines being paired together 
to form incorrect disulfide bridges or the correct disulfides can be formed too early in 
protein synthesis, which impedes the protein from adopting the native conformation62. 
PDIA1 can correct these disulfides through disulfide bond isomerization, which allows the 
protein substrates to adopt their native conformations9. Mechanistically, the N-terminal 
cysteine of the active site attacks a cysteine in a mismatched disulfide pair forming a mixed 
heterodisulfide bond between the protein substrate and PDIA1 (Figure 1.5). Once this 
occurs, a “mechanistic decision” must occur about the fate of the covalent complex 
between the substrate and PDIA1. Either the original substrate cysteine can attack the 
heterodisulfide bond and release PDIA1 without resulting in any isomerization of the 
protein substrate disulfide, or another cysteine on the protein can attack the heterodisulfide 
bond and displace PDIA1 resulting in an isomerization through an intramolecular 
rearrangement within the protein substrate63. It is also important to note that the C-terminal 
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active site cysteine of PDIA1 can also react with the N-terminal cysteine and release of the 
substrate protein, resulting in the reduction of the original disulfide bond. In this way, the 
C-terminal cysteine in PDIA1 may act as a “clock” allowing the substrate a specified 
amount of time to succeed in an intramolecular isomerization before the substrate is just 
simply reduced and released from PDIA160. After the “escape” of PDIA1 and subsequent 
reduction of the substarte disulfide bond, reoxidation of that substrate disulfide bond in an 
alternative configuration is also considered isomerization. Through this pathway, 
isomerization is considered repeated cycles of reduction and reoxidation of the substrate 












Figure 1.5. (A) The isomerase activity of PDIA1 shuffles incorrectly formed disulfide 
bonds to achieve properly folded substrates. (B) One of the two nucleophilic cysteines in 
the PDIA1 active sites, Cys53 or Cys397, will attack a substrate disulfide bond creating a 
mixed disulfide. At this point a decision is made to either form the correct disulfide (solid 
black line) or re-form the incorrect disulfide pair (dashed black line). Another option, is 
PDIA1 acts as a “clock” and the C-terminal active site cysteine, Cys56 or Cys400, can 




1.6 The Chaperone Activity of PDIA1 
 PDIA1 has also been demonstrated to possess chaperone and anti-chaperone 
activities at stoichiometric concentrations48-51. Puig and Gilbert found that at excess 
concentrations of PDIA1, chaperone-like activity is exhibited which prevented the 
aggregation of denatured lysozyme and promoted the correct folding49. Cai et al. 
discovered that dilution of guanidinium HCl denatured GAPDH showed only a limited 
extent of refolding and reactivation. It was shown that the presence of PDIA1 in the dilution 
mixture at near stoichiometric amounts increased refolding and reactivation, and prevented 
aggregation of GAPDH48. Song and Wang have discovered that in near stoichiometric 
concentrations, PDIA1 promoted the reactivation and refolding of rhodanese, a protein 
which is a single chain folded into two domains and contains four cysteines, but no 
disulfide bonds. It was also shown that PDIA1 suppressed the aggregation of rhodanese 
during thermal inactivation of the protein50. Primm et al. have also demonstrated this 
chaperone activity on two thermally and chemically denatured proteins, alcohol 
dehydrogenase and citrate synthase. Both of these proteins do not require disulfide bonds 
for correct folding, illustrating that the chaperone activity of PDIA1 does not require the 
active site cysteines51.  
 In order to demonstrate that the chaperone-like activity of PDIA1 is not dependent 
on the active site cysteine residues of PDIA1, Quan et al. alkylated the thiol groups of 
reduced PDIA1 to inactivate the cysteine pairs from their isomerase activity. Next, it was 
demonstrated that GAPDH, a protein with no disulfide bonds, was still able to be refolded 
and reactivated even though the active site cysteines were inactivated64. Dai and Wang 
demonstrated that the chaperone-like activity was dependent upon the b’ domain of PDIA1. 
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It was confirmed through the expression of mutant PDIA1 lacking 51 amino acids from the 
C-terminal end of the b’ domain to remove the substrate binding pocket. The mutant 
enzyme showed no peptide binding ability or chaperone activity against GAPDH52.  
 In some instances, PDIA1 demonstrates “anti-chaperone” activity, in which at sub-
stoichiometric concentrations, PDIA1 will induce the aggregation of the protein substrate. 
Puig and Gilbert found that at concentrations of PDIA1 approximately ~10% of the 
substrate concentration, PDIA1 will induce aggregation of the substrate instead of 
promoting the refolding and reactivation. PDIA1 actively diverted the denatured lysozyme 
away from refolding by incorporating extensive intermolecular disulfide cross-links, 
resulting in large inactive aggregates49, 65. PDIA1 has been found to be incorporated into 
the insoluble aggregates, whereas other ER control proteins are not66. 
 
1.7 PDIA1 as a Potential Therapeutic Target 
 Dysregulation of the activity of PDIA1 has been implicated in a variety of diseases, 
including cancer25, 67-69, neurodegenerative70-73, and cardiovascular74-76 diseases. The 
analysis of published microarray datasets indicate that the expression of PDIA1 is 
overexpressed (>2-fold) in a variety of cancers when compared to normal tissue, including 
lymphoma77-79, brain, and CNS cancers67-68, 80-83, ovarian84-85, kidney86-88, and prostate89-90. 
Increased levels of PDIA1 in a variety of cancers have also been confirmed by proteomic 
analyses. Upregulation of PDIA1 was observed in patients with prostate adenocarcinoma, 
compared to normal patients with benign prostate hyperplasia91. 2-DE/MALDI-TOF 
proteome analyses studies showed that PDIA1 is overexpressed in infiltrating ductal 
carcinomas in both female92 and male93 breast tissue when compared to the respective 
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adjacent non-neoplastic tissues. It was also shown that PDIA1 is upregulated in a rat model 
of human gastric cancer induced by methylnitrosoguanidine (MNNG)94. 
 The upregulation of PDIA1 has been correlated with cancer metastasis and 
invasion. Patients with axillary lymph node metastatic breast tumors demonstrated 
significantly higher levels of PDIA1 compared to patients with normal primary breast 
tissue95. PDIA1 was also found to be overexpressed in migrating glioma cells in an in vitro 
migration assay, as well as in invasive glioma cells in both, tumor xenografts and at the 
invasive front of the glioblastoma96. 
 Recent studies have shown that, clinically, PDIA1 might have potential for use as 
a biomarker for the onset of disease. It was recently reported that PDIA1 was one of the 
most upregulated proteins in the interstitial fluids from breast tumor patients, and could 
serve as a marker for early detection97. Anti-PDIA1 monoclonal antibodies have also been 
used in the clinic as a method for the in vitro diagnosis of colorectal cancer. PDIA1 is used 
in this case for early screening, therapeutic follow-up, and for prognosis determination of 
the disease98. 
 To further this role as diagnostic tool, PDIA1 expression levels have been found to 
correlate with overall patient survival rates. Lower PDIA1 expression levels was observed 
to be correlated with significantly higher overall survival rates of patients with 
glioblastoma and breast cancers67-69. Therefore, in addition to colorectal cancer, PDIA1 
can be used as a prognostic marker in cancer biopsies of other types of cancer as well. 
Another major clinical concern in cancer treatment associated with PDIA1 is 
chemoresistence in some cancers, although the exact mechanism has yet to be determined. 
A recent study evaluated proteome-wide differences between normal HeLa cells and 
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aplidin-resistant HeLa cells (Hela-R)99. Aplidin is a macrocyclic depsipeptide originally 
isolated from Aplidium albicans, but now obtainable through total synthesis100. Proteomics 
studies determined the HeLa-R cells to have increased expression of PDIA1 compared the 
the non-aplidin-resistant, normal HeLa cells. Treatment with the PDIA1 inhibitor, 
bacitracin, abrogated the resistance and the cells were re-senesitized to the drug99. It has 
also been demonstrated that treatment of cancer cells with PDIA1 inhibitors was found to 
sensitize  cells toward etoposide induced apoptosis at normally subtoxic concentrations101. 
Together this data indicates the clear clinical relevance of PDIA1 and suggest that 
combining selective PDIA1 inhibitors with traditional anti-cancer agents could achieve a 
synergistic effect to overcome chemotherapeutic resistance. 
 Cell surface associated PDIA1 has also peaked interest in the clinic because its 
reductase activity has been implicated in human immunodeficiency virus type 1 (HIV-1) 
fusogenic events102-105. PDIA1 has been shown to cluster on the surface near the HIV-1 
primary receptor cluster of differentiation 4 (CD4), which has separate binding sites for 
PDIA1 and the glycoprotein on the envelope of HIV-1, gp120106. Gp120 of HIV-1 first 
binds to CD4, followed by the reduction of at least two of nine disulfide bonds by PDIA1. 
This results in major conformational changes in the tertiary structure of gp120, which 
enhances the ability of gp120 to interact with surface receptors C-C chemokine receptor 
type 5 (CCR5) and C-X-C chemokine receptor type 4 (CXCR4)102, 107. Furthermore, gp41, 
another viral glycoprotein bound to gp120 undergoes rearrangement into fusogenic 
intermediates and allows HIV-1 to enter into host cells107. Taken together, there is clear 




 Lately, a considerable amount of evidence has implicated the oxidation state of 
labile disulfide bonds in critical hemostatic proteins in thrombus formation108. The 
oxidation state of these labile thiol groups has been shown to be regulated by 
oxidoreductases, such as PDIA128, 109. Platelets have consequently been a cell type which 
has shown to secrete PDIA1 from the ER to the cell surface110-111. Cho et al. observed a 
time-dependent increase in expression of PDIA1 in murine thrombi following vessel 
injury. The infusion of PDIA1 inhibitor, bacitracin, or a blocking monoclonal antibody 
ablated thrombus formation and fibrin generation. These results indicated that PDIA1 is 
required in vivo for thrombus formation and fribrin generation28. Therefore, PDIA1 shows 
promise as a clinical target for small molecule inhibition of thrombus formation. To this 
end, there has been tremendous work in this field to develop selective PDIA1 inhibitors, 
both reversible and non-reversible. 
 
1.8 Inhibitors of PDIA1 
1.8.1 Antibiotic Inhibitors of PDIA1 
 The cyclic dodecapeptide antibiotic, bacitracin (Figure 1.6A), was the first ever 
PDIA1 inhibitor report in 1981112. It was demonstrated that bacitracin binds PDIA1 
through disulfide bond formation between an open thiol form of the thiazoline ring and 
Cys314/345 in the b’ substrate binding domain113. However, bacitracin was found to be 
nonspecific and non-potent for PDIA1, requiring high concentrations (~1 mM) to inhibit 
the reductase activity, with little or no inhibition of the isomerase or oxidase activity, as 

















1.8.2 Reversible Small Molecule Inhibitors of PDIA1 
 Juniferdin (Figure 1.7), a sesqueterpenoid, originally isolated from the plant Ferula 
junipernia was discovered from a high-throughput screen of ~10,000 compounds of the 
RIKEN Natural Product Depository (NPDepo). Of all of the compounds in the library 
screened, only four were identified as putative PDIA1 inhibitors, and juniferdin, as the 
most potent, was chosen as the lead compound115. Structure-activity relationship studies 
showed that any structural alterations to the sesquiterpene ring was detrimental toward the 
inhibitory effect against PDIA1. Since it has been known that the PDIA1-catalyzed 
reduction of disulfides in gp120 is crucical for HIV-21 entry into host cells103, 106, it was 
examined if juniferdin could impede HIV-1 entry by inhibiting PDIA1 activity at the cell 
surface115. Juniferdin was found to have significantly inhibited PDIA1-catalyzed reduction 
of HIV gp120, showing that it may inhibit HIV-1 entry into host cells115. 
 Another natural product, plant metabolite identified as a PDIA1 inhibitor by means 
of a high throughput insulin-based turbidimetric screen of 4,900 compounds was quercetin-
3-rutinoside (Figure 1.7)116. The inhibition of PDIA1 was found to be selective over other 
thiol isomerase with CXXC active site motifs. Using intravital microsocopy, it was 
demonstrated that quercetin-3-rutinoside blocks thrombus formation by inhibiting PDIA1, 
and that the infusion of recombinant PDIA1 reversed this anti-thrombotic effect116. Further 
studies have identified quercetin-3-rutinoside directly binds to the b’x domain of 
extracellular PDIA1, inducing a compact conformation, thus constricting the overall 
flexibility of PDIA1 and inhibiting thrombus formation117. 
 Another reversible inhibitor of PDIA1 was discovered by Eirich et al. during a 
screen of a commercial compound library, and subsequent structure-activity-relationship 
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(SAR) studies101. Compounds JP04-042 and derivative PS-89 (Figure 1.7) were identified 
via proteomics techniques as potent and selective reversible inhibitors of PDIA1, although 
it also bound other isoforms PDIA3 and PDIA4. These compounds were found to sensitize 
Jurkat (leukemic) and MDA-MB-231 (breast) cancer cell lines to sub-toxic concentrations 
of etoposide (500 nM)101. These compounds are of great interest owing to their 
irreversibility, they bind to the a and a’ domains to shield the active sites while exhibiting 


















1.8.3 Irreversible Inhibitors of PDIA1 
 In 2010, Hoffstrom et al identified 16F16 (Figure 1.6C) as an irreversible inhibitor 
of PDIA1 in a high-throughput screen of 68,887 compounds for the ability to suppress 
apoptosis in an in vitro PC12 cell-based model of Huntington’s disease (HD), in which 
apoptosis is induced by polyglutamine (polyQ) and mediate by PDIA173. 16F16 contains a 
chloroacetamide electrophile that covalently modifies a reactive cysteine in one of the 
active sites in PDIA1. Using a proteomics-amenable version of the lead compound, 
16F16A, an alkyne handle allowed for CuAAC and target identification by mass 
spectrometry as PDIA1 and PDIA3. Within the 3-12 µM range, 16F16 displayed a dose-
dependent increase in polyQ-induced apoptosis. Above 12 µM, 16F16 displayed 
significant cytotoxicity most likely owing to significant off-targets effects. Further, 16F16 
also displayed the ability to dose-dependently rescues Aβ peptide toxicity in pyramidal 
neurons when PDIA1 was inhibited73. 16F16 and derivatives have not been radiolabeled 
and are being tested as new potential positron emission tomography (PET) agents for 
imaging PDIA1 in cancer118. 
 In the result of another small screening endeavor of compounds containing vinyl 
sulfone/sulfonate electrofiles by Ge et al, P1 was serendipitously discovered as an inhibitor 
of PDIA1119. P1 and other library members were screened in MCF-7 cells, and in situ 
proteome reactivity profiles were analyzed, prior to compound target identification. P1 was 
found to bind to PDIA1 in situ and is capable of killing numerous mammalian cancer cells 
lines, GI50 ~ 4 µM119. It is important to note that proteomics studies also identified other 
PDI family members, PDIA4 and PDIA6, as targets of P1. 
30 
 
 It has also been previously reported that a class of propynoic acid carbamoyl methyl 
amides (PACMAs), which can form covalent adducts with cysteine thiol groups, have 
showed a broad range of cytotoxicity in a panel of human cancer cell lines120. Furthering 
on that discovery, Xu et al. designed a series of PACMA derivatives which displayed 
significant cytotoxicity in human ovarian cancers, and identified PACMA31 as a covalent 
modifier of PDIA1121. Using high-resolution mass-spectrometry and computational 
methods, it was predicted that PACMA31 is covalently modifying Cys397 of the a’ domain 
of PDIA1121. It was demonstrated with circular dichroism that upon treatment with 
PACMA31, significant changes to the secondary structure of PDIA1 were observed, which 
correlated to the PACMA31 dose-dependent decrease in PDIA1 activity observed. 
Interestingly, PACMA31 demonstrated tumor targeting ability in vivo in a mouse xenograft 
model of human OVCAR-8 ovarian cancer. PACMA31 significantly suppressed tumor 
growth by up to 85% and did not exhibit adverse effects on the mice121. This data 
demonstrates the implications of targeting PDIA1 as a potential for a cancer therapeutic. 
 Multiple myeloma cells secrete more disulfide-bond rich proteins than any other 
mammalian cell, thus the inhibition of PDIA1 should increase stress in the ER beyond the 
point of repair and trigger apoptosis122-123. To streamline selection of an anti-myeloma drug 
candidate, 30355 compounds were screened in a mechanistically unbiased, multi-layered 
assay. This screen identified lead compound, CCF642, with broad anti-multiple myeloma 
activity. CCF642 was found to be effective in vivo, in part, by inhibition of PDIA1124. 
 Recent interest in irreversible target binding had generated concerns over the 
selectivity of the molecules, mechanisms of action, and the distinct toxicity of covalent 
binder in vivo125. To this end, Allimuthu and Adams have recently examined the 2-
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chloropropionamide electrophile functionality, a sterically hindered version of the 
commonly used chloroacetamide126. The synthesis of a library of 26 structurally diverse 
compounds with 2-chloropropionamides displayed low proteome reactivity of this 
electrophilic functionality. One molecule, S-CW3554, selectively targeted PDIA1 and 
showed cytotoxicity to multiple myeloma cell lines. S-CW3554 is the least reactive PDIA1 
inhibitor to date, but is a candidate for optimization towards a more metabolically stable in 
vivo probe126. 
 In 2013, a previous member of the Weerapana lab reprted on RB-11-ca, a cell-
permeable, irreversible inhibitor of PDIA1127. RB-11-ca is a tri-functionalized triazine-
based covalent inhibitor that contains three elements, (1) an alkyne-handle for reporter-tag 
conjugation via copper-catalyzed azide-alkyne cycloaddition (CuAAC); (2) an octylamine 
diversity element for binding specificity; and (3) an electrophilic chloroacetamide for 
irreversible modification of nucleophilic cysteine residues. RB-11-ca was determined to 
bind to PDIA1 after CuAAC-mediated conjugation of a biotin group, avidin enrichment, 
and subsequent target identification via LC/LC-MS/MS analysis. Through site-directed-
mutagenesis, it was demonstrated that RB-11-ca selectively modifies the N-terminal 
cysteine in the a domain of PDIA1, Cys53. RB-11-ca was unique because it was the first 

















 In conclusion, PDIA1 was the first protein folding catalyst discovered in 1963. 
PDIA1 is localized in the ER by a classic KDEL ER retention sequence, and accounts for 
approximately 0.8% of total cellular protein. PDIA1 is a 57 kDa multi-domain thiol-
disulfide oxidoreductase and molecular chaperone that is responsible for disulfide bond 
oxidation, reduction and isomerization via two independent CXXC catalytic active site 
motifs. PDIA1 also possesses chaperone and anti-chaperone activity which is independent 
of the two catalytic active sites. The dysregulation of PDIA1 activity has been implicated 
in a variety of diseases including neurodegenerative, cardiovascular, and a variety of 
cancers. PDIA1 expression levels have also been found to correlate with patient prognosis 
and survival rates, as well have been of recent interest as a potential biomarker marker for 
disease onset and progression. To this end, there has been tremendous interest in the field 
to develop selective, reversible and irreversible inhibitors for PDIA1. In 2013, our lab 
reported on RB-11-ca, a cell permeable, irreversible inhibitor of PDIA1. RB-11-ca is a tri-
functionalized triazine-based covalent inhibitor with a chloroacetamide electrophile that 
was found to selectively target Cys53 in the a domain of PDIA1. To further this study, we 
have since optimized a second generation of more potent and selective triazine-based 
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 Protein disulfide isomerase A1 (PDIA1) is a thiol-disulfide oxidoreductase 
localized in the lumen of the endoplasmic reticulum (ER), and is an important folding 
catalyst and chaperone for proteins in the secretory pathway. PDIA1 contains two active-
site domains (a and a’), each containing a Cys-Gly-His-Cys (CGHC) active-site motif. The 
two active-site domains share only 37% sequence identity, and several studies point to the 
functional nonequivalence of these two regions. Numerous inhibitors for PDIA1 have been 
reported, yet the selectivity of these inhibitors toward the a and a’ sites have been poorly 
characterized. We previously identified a cysteine-reactive PDIA1 inhibitor, RB-11-ca, 
which demonstrates a-site selectivity. Here, we synthesize a targeted library to optimize 
the potency and selectivity of RB-11-ca. Characterization of this targeted library afforded 
an optimized PDIA1 inhibitor, KSC-34, which covalently modifies C53 in the a site of 
PDIA1, and demonstrates 30-fold selectivity for the a site over the a’ site. KSC-34 shows 
time-dependent inhibition of the reductase activity of PDIA1 in vitro with a kinact/KI = 9.66 
x 103 M-1s-1. KSC-34 is highly selective for PDIA1 over members of the PDI family, as 
well as other cellular cysteine-containing proteins. PDIA1 inhibition by KSC-34 has 
minimal sustained effects on the cellular unfolded protein response (UPR), indicating that 
a-site inhibition does not globally induce protein-folding associated ER stress. KSC-34 
treatment significantly decreases secretion of a destabilized, amyloidogenic antibody light 
chain, illustrating the ability of a-site selective PDIA1 inhibitors to minimize pathogenic 
amyloidogenic extracellular proteins that rely on high PDIA1 activity for proper folding 
and secretion. Given the poor understanding of the contribution of each PDIA1 active site 
to the (patho)physiological functions of PDIA1, site-selective inhibitors like KSC-34 
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 Proper folding of nascent proteins in the cell is accelerated by chaperones that serve 
to stabilize protein domains and overall structure. One such family of protein-folding 
catalysts comprise dithiol-disulfide oxidoreductases of the protein disulfide isomerase 
(PDI) family. The PDI family is primarily located in the endoplasmic reticulum (ER), and 
includes 21 proteins with at least one thioredoxin-like domain. PDIs contain two different 
types of thioredoxin-like domains, catalytic (a) and non-catalytic (b)1-2. The catalytic a 
domains of the PDIs are responsible for catalyzing the oxidation, reduction, and 
isomerization of disulfide bonds in nascent proteins. The non-catalytic b domains are rigid 
spacers between the catalytic domains that are involved in recognizing and recruiting 
unfolded protein substrates1. 
 Protein disulfide isomerase A1 (PDIA1)3-4 was the first PDI family member to be 
discovered5-6. PDIA1 is a 57 kDa oxidoreductase and molecular chaperone that localizes 
in the lumen of the ER, and accounts for roughly 0.8% of total cellular protein7. PDIA1 
catalyzes the oxidation, reduction, and isomerization of disulfide bonds between cysteine 
residues on its protein substrates. PDIA1 is organized into four globular domains, a, b, b’, 
and a’, as well as a highly acidic C-terminal extension with a KDEL ER-retention sequence 
(Figure 2.1)3-4. The a and a’ domains functionally resemble thioredoxin, and contain redox 
catalytic Cys-Gly-His-Cys (CGHC) active-site motifs. It is known that the a and a’ 
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domains operate independently of each other because mutation of either active-site cysteine 
eliminated 50% of the catalytic activity of PDIA1 in vitro, while mutations in both active 
sites completely abolished activity8. The non-catalytic domains, b and b’, are primarily for 
spacing and substrate recruitment. The b’ domain is the major substrate binding site of 
PDIA1, containing a large hydrophobic cavity between helices α1 and α3 to interact with 
unfolded protein substrates1, 9. PDIA1 has also been shown to possess chaperone activity, 
by inhibiting the aggregation of misfolded protein substrates at stoichiometric 
concentrations10-13. The chaperone activity of PDIA1 is independent of the two catalytic 
CGHC active-site motifs, but dependent on the non-catalytic b sites14. This was confirmed 
by truncation of the C-terminal b’ domain of PDIA1, which abolished all chaperone 














Figure 2.1. Domain organization of PDIA1. PDIA1 comprises two active-site a-type 
domains that contain a CGHC active-site motif, together with two b-domains implicated 




 The dysregulation of PDIA1 activity has been implicated in a variety of diseases, 
including cancer3, 16-18, cardiovascular19-21, and neurodegenerative22-25 diseases. Gene-
expression profiles indicate that PDIA1 is overexpressed (>2-fold) in a wide variety of 
cancers, including lymphoma26-28, brain, and CNS cancers16-17, 29-32, ovarian33-34, kidney35-
37, and prostate38-39. Furthermore, expression levels of PDIA1 have been correlated with 
overall patient survival rates in brain and breast cancers, whereby patients with lower 
expression levels of PDIA1 have significantly higher survival rates3, 16-18. PDIA1 is 
retained in the ER through a C-terminal KDEL retention signal sequence, however, the 
presence of PDIA1 in the extracellular milieu is well documented3, 40-41. Extracellular 
PDIA1 is involved in many biological processes such as platelet activation, thrombus 
formation, and viral infection. For example, PDIA1 can catalyze the reduction of structural 
disulfides on gp120, which results in a major conformational change, allowing the HIV 
virus to interact with the cell surface40. 
 The demonstrated role of increased PDIA1 activity in various diseases has spurred 
the development of a variety of small-molecule inhibitors targeting PDIA1. Juniferdin, 
discovered in a high-throughput screen of natural products, was found to inhibit 
extracellular PDIA1-mediated disulfide-bond reduction of gp120, thus inhibiting HIV 
entry into host cells40. Quercetin-3-rutinoside has been shown to bind to the b’x region of 
extracellular PDIA1 to induce a compact conformation, thus constricting the overall 
flexibility of PDIA1, and inhibiting thrombus formation42. T8 and derivative JP04-042 
were reported to sensitize cancer cells to sub-toxic concentrations of etoposide through 
inhibition of PDIA1 by reversible binding near the active sites43. Another reversible 
inhibitor of PDIA1, LOC14, was identified from a high-throughput screen of ~10,000 
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compounds, and reversibly binds PDIA1 to induce an oxidized conformation. This LOC14-
induced oxidative conformation has been shown to be neuroprotective in PC12 cells 
expressing mutant huntingtin protein44. PACMA31 is an irreversible PDIA1 inhibitor that 
reacts through a propynoic acid carbamoyl methyl amide moiety, and suppresses tumor 
growth in a mouse xenograft model of ovarian cancer45. S-CW3554 possesses a 2-
chloropropionamide reactive group, and has been shown to be cytotoxic to various multiple 
myeloma cell lines46. 16F16, an irreversible inhibitor that reacts with PDIA1 via a 
chloroacetamide electrophile, prevents neuronal cell death in a cell-based model of 
Huntington’s disease25. Lastly, P1, an irreversible inhibitor, which reacts via a vinyl-
sulfone electrophile, demonstrated anti-proliferative effects in a variety of cancers47. 
 In 2013, we reported RB-11-ca (Figure 2.2A), a cell-permeable, irreversible 
inhibitor of PDIA148. RB-11-ca is a tri-functionalized triazine-based covalent inhibitor that 
contains an alkyne-handle for reporter-tag conjugation via copper-catalyzed azide-alkyne 
cycloaddition (CuAAC), an octylamine diversity element for binding specificity, and an 
electrophilic chloroacetamide for irreversible modification of proximal cysteine residues. 
PDIA1 was identified as the primary target of RB-11-ca after CuAAC-mediated 
conjugation of a biotin group, avidin enrichment, and subsequent target identification via 
LC/LC-MS/MS. The specific cysteine residue targeted by RB-11-ca was determined using 
cysteine-to-alanine mutants of each cysteine residue within the CXXC motifs of the two a 
domains. RB-11-ca was confirmed to bind to C53, the N-terminal cysteine in the a domain 
of PDIA148. RB-11-ca was therefore unique in that it was the first characterized a-domain 











Figure 2.2. (A) Chemical structure of RB-11-ca, a previously reported a-site inhibitor of 
PDIA1. RB-11-ca contains a central triazine scaffold, a chloroacetamide reactive group for 
covalent cysteine modification, an alkyne bioorthogonal handle for CuAAC, and an 
octylamine diversity element. (B) Predicted binding pose of RB-11-ca in a domain active 




 Herein we report on KSC-34, an optimized PDIA1 inhibitor, which demonstrates a 
30-fold selectivity for the a domain over the a’ domain. KSC-34 also displays high 
selectivity for PDIA1 in complex proteomes with minimal engagement of other members 
of the PDI family. Given the critical role of PDIA1 in normal protein homeostasis, PDIA1 
inhibitors that shut down both active sites demonstrate high cytotoxicity. By selectively 
inhibiting a single active-site domain of PDIA1, we hypothesized that basal PDIA1 activity 
could be maintained to minimize cytotoxicity, whilst selectively inhibiting pathogenic 
functions that are dependent on elevated PDIA1 activity. We demonstrate that a-site 
selective PDIA1 inhibition shows negligible toxicity, and minimal induction of sustained 
cellular protein-folding stress as demonstrated by low activation of the unfolded protein 
response (UPR). PDIA1 inhibition by KSC-34 has the potential to display targeted effects 
on the secretion of pathogenic proteins that utilize PDIA1 for folding and secretion. In 
particular, antibody light chains contain a disulfide bond within the hydrophobic core of 
the protein, and the folding of antibody light chains has been shown to involve PDIA1 
activity49. Dysregulated light-chain secretion from a clonal expansion of plasma cells can 
lead to immunoglobulin light-chain amyloidosis50. Here we demonstrate that KSC-34 
treatment decreases secretion of a destabilized, amyloidogenic antibody light chain at non-
toxic concentrations. Together, we identify a potent and selective PDIA1 inhibitor that 
uniquely targets the a active-site domain of PDIA1 with the ability to affect the secretion 
of pathogenic proteins whose folding involves PDIA1 activity. 
 
2.2 Results and Discussion 
2.2.1 Generation of a targeted library of RB-11-ca analogs 
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 In previous published studies, we identified a cysteine-reactive triazine-based 
compound, RB-11-ca, as an a-site selective covalent modifier of PDIA148. In order to 
further optimize the selectivity and potency of RB-11-ca, we sought to develop a second-
generation library of triazine-based covalent inhibitors for PDIA1. To gain deeper insight 
into the binding mode of our lead compound, RB-11-ca (Figure 2.2A), within the a domain 
of PDIA1, we embarked on some preliminary docking studies. Only one high-resolution 
crystal structure of full-length PDIA1 is available51, and this structure was utilized to 
predict a binding model for RB-11-ca using the Covalent Dock workflow from 
Schrodinger, Inc (New York, NY) (Figure 2.2B)52. In the predicted binding pose, RB-11-
ca is covalently bound to the N-terminal cysteine (C53) of the CGHC active-site motif 
within the a domain, and the octylamine diversity element interacts with a large 
hydrophobic pocket at the domain periphery. Based on this predicted binding mode of RB-
11-ca, we hypothesized that variations to the octylamine diversity element could likely 
enhance the predicted interactions with the observed hydrophobic pocket, and serve to 
improve the potency of the compound. Therefore, a second-generation library of 15 
compounds (Figure 2.3) was synthesized according to previous methods with minor 
modifications (Scheme S1)48. These second-generation compounds contain diversity 










Figure 2.3. Structures of second-generation PDIA1 inhibitors obtained by varying the 




2.2.2 Identification of KSC-34 as a potent and selective covalent modifier of PDIA1 
 To streamline the selection of an optimized PDIA1 inhibitor, we first screened for 
compounds with improved covalent modification of PDIA1 using a gel-based fluorescence 
screening platform. Given that the extent of covalent modification of active-site cysteines 
directly correlate with PDIA1 inhibition, screening for improved covalent modifiers acts 
as a proxy for increased PDIA1 inhibition. In the first screening step, covalent modification 
of purified, recombinant PDIA1 was evaluated to identify compounds that demonstrated 
increased covalent modification of PDIA1 relative to RB-11-ca. Briefly, PDIA1 (50 
µg/mL) was incubated with RB-11-ca and second-generation library members (5 µM) for 
1 hour. After incubation, covalent modification of PDIA1 was monitored by appending a 
tetramethylrhodamine (TAMRA) fluorophore to the alkyne group of each compound using 
CuAAC53-54, followed by in-gel fluorescence to quantify the amount of compound-bound 
PDIA1 (Figure 2-4). Seven library members (KSC-4, 7, 10, 11, 24, 26 and 34) that 









Figure 2.4. Characterization of PDIA1 second-generation library members (A) Library 
members (5 µM) were incubated with purified recombinant PDIA1 (50 µg/mL) in PBS, 
and protein labeling by each compound was evaluated after CuAAC-mediated 
incorporation of a TAMRA fluorophore, SDS-PAGE, and in-gel fluorescence. Library 
members with equal or great potency than RB-11-ca progressed to the next step of the 
assay. (B) Complete gel images  illustrating only recombinant PDIA1 used in assay. ImageJ 
(NIH, Bethesda, MD) was used to quantify the fluorescence intensity of the PDIA1 band. 





 In the second screening step, library members were assessed against purified, 
recombinant PDIA1 (50 µg/mL) in the background of MCF-7 cell lysates (1 mg/mL) to 
evaluate whether other cellular proteins interfere with the ability of each compound to 
covalently modify PDIA1 (Figure 2-5). Four library members (KSC-7, 24, 26, and 34) 
possessed equal or greater potency to RB-11-ca, and thus were advanced to the next stage. 
In the third screening step, library members were evaluated in MCF-7 lysates (2 mg/mL) 
for their ability to covalently modify endogenous PDIA1 (Figure 2-6). This analysis 
afforded three library members (KSC-24, 26 and 34) that had equal or greater potency 
toward PDIA1 compared to RB-11-ca. Of these, the two most potent library members, 








Figure 2.5. Characterization of PDIA1 second-generation library members. (A) Library 
members were assessed against purified, recombinant PDIA1 (50 µg/mL) in the 
background of MCF-7 cell lysates (1 mg/mL) to evaluate whether other cellular proteins 
interfere with the ability of each compound to covalently modify PDIA1. (B) Complete 
gels for part (A) illustrating proteome-wide selectivity of second-generation library 
members. ImageJ (NIH, Bethesda, MD) was used to quantify the fluorescence intensity of 
the PDIA1 band. All data are normalized to RB-11-ca lead compound. Error bars represent 











Figure 2.6. Characterization of PDIA1 second-generation library members. (A) In-gel 
fluorescence studies of library members (5 µM) incubated with MCF-7 cell lysate (2 
mg/mL) to assess potency and selectivity for endogenous PDIA1 in a complex proteome. 
(B) Complete gel images for analysis used in part (A) demonstrating proteome-wide 
selectivity of second generation library members in a complex proteome. ImageJ (NIH, 
Bethesda, MD) was used to quantify the fluorescence intensity of the PDIA1 band.  All 





 In the fourth and final step of this multilayered assay, the cell permeability and 
ability of the compounds to engage with ER-localized PDIA1 directly in living cells was 
assessed. MCF-7 cells were treated with compound for 3 hours at 37 °C, followed by in-
gel fluorescence analysis (Figure 2-7). KSC-34, which contains a (4-
phenylbutyl)methylamine diversity element, was found to covalently modify PDIA1 
directly in living cells with approximately 8-fold increased potency compared to RB-11-
ca. The presence of a single robust fluorescent band at ~60 kD demonstrates the high 
potency and selectivity of KSC-34 for covalent modification of PDIA1 within the 











Figure 2.7. Characterization of PDIA1 second-generation library members. To assess cell 
permeability as well as selectivity of the library, probes (5 µM) were incubated with MCF-
7 cells for 3 hours at 37 °C. Following cell lysis and in-gel fluorescence, KSC-34 was found 
to be ~8-fold more potent than the lead compound, RB-11-ca, in whole cells against PDIA1 




2.2.3 KSC-34 demonstrates time-dependent inhibition of PDIA1 in vitro 
 To confirm that improved covalent modification of PDIA1 by KSC-34 correlated 
with increased inhibitory potency, we utilized an in vitro insulin turbidity assay that 
monitors PDI reductase activity55. The reduction of disulfide bonds in insulin results in 
aggregation of the insulin β chain causing a measurable increase in turbidity. Due to the 
covalent nature of RB-11-ca and KSC-34, PDIA1-induced insulin aggregation was 
monitored upon treatment with each inhibitor at varying concentrations and pre-incubation 
times. We also compared RB-11-ca and KSC-34 to the commercially available PDIA1 
inhibitor, 16F1625, which also contains a chloroacetamide electrophile for covalent 
modification of PDIA1, similar to our triazine-based compounds. KSC-34 inhibited PDIA1 
in a concentration and time-dependent manner, with a kinact/KI = 9.66 x 103 M-1 s-1 (Figure 
2-8), which is ~3-fold more potent than RB-11-ca (kinact/KI = 3.35 x 103 M-1 s-1), and 38-












Figure 2.8. Concentration and time-dependent inhibition of PDIA1 by KSC-34, RB-11-
ca, and 16F16. PDIA1 reductase activity was measured using an insulin reduction assay in 
a 100 µL reaction volume containing 0.5 µM PDIA1, 0.16 mM insulin, and 1 mM DTT in 
assay buffer. Turbidity of the insulin solution was measured over time at various 
concentrations and pre-incubation times with KSC-34. Error bars are calculated as SD from 




2.2.4 KSC-34 is a highly selective covalent modifier of PDIA1 
 Upon confirmation of the ability of KSC-34 to covalently modify and inhibit 
PDIA1 activity, we sought to determine the selectivity of KSC-34 for the a and a’ active 
sites of PDIA1. Given that our first-generation compound RB-11-ca was a-site selective, 
we expected KSC-34 to bind in a similar fashion. Site-selectivity was assessed by 
recombinantly expressing wild-type PDIA1 (WT) and cysteine-to-alanine mutants of each 
of the two active-site nucleophilic residues (C53A and C397A). Each recombinant PDIA1 
protein (50 µg/mL) was incubated with KSC-34 (5 µM) for 1 hour, and subjected to 
CuAAC prior to in-gel fluorescence (Figure 2-9A). The absence of fluorescence in the 
C53A sample indicates that the binding of KSC-34 to PDIA1 is reliant on the presence of 
C53. Therefore, KSC-34 maintains selectivity for C53 in the a domain of PDIA1 with 
minimal binding to C397 in the a’ domain. To further quantify the selectivity for the a and 
a’ domains, IC50 values were obtained for binding to each active site (Figure 2-9D). To 
attain IC50 values, PDIA1 C53A and C397A (50 µg/mL), in the background of MCF-7 
lysates (1 mg/mL), were treated with increasing concentrations of KSC-34, RB-11-ca and 
16F16. Following incubation, samples were then treated with chloroacetamide-rhodamine 
(CA-Rh) (8 µM, Figure 2-9B), to append a fluorophore to residual, unmodified active-site 
cysteines in each PDIA1 mutant. Loss in CA-Rh labeling of each active-site mutant is 
indicative of inhibitor binding, and informs on the affinity of each compound to the a and 
a’ domains. KSC-34 demonstrated a 30-fold selectivity for the a domain over the a’ 
domain, whereas RB-11-ca demonstrated a 21-fold a-domain and 16F16 demonstrated a 
2-fold selectivity for the a-domain over the a’ domain. KSC-34 is therefore the most 






Figure 2.9. Evaluation of the site-selectivity of KSC-34. (A) Labeling of purified 
recombinant PDIA1 WT, C397A and C53A by KSC-34. Each recombinant PDIA1 protein 
(50 µg/mL) was incubated with KSC-34 (5 µM) for 1 hour, and subjected to CuAAC prior 
to in-gel fluorescence. (B) Structures of KSC-34 and Chloroacetamide-Rhodamine (CA-
Rh). (C) PDIA1 C53A and C397A (50 µg/mL) in the background of MCF-7 lysates (1 
mg/mL) were treated with increasing concentrations of KSC-34, RB-11-ca and 16F16 to 
quantify the selectivity for the a and a’ domains. Following incubation, samples were then 
treated with CA-Rh) to append a fluorophore to the residual, unmodified PDIA1 active 
sites. Loss of fluorescence indicates inhibitor binding. ImageJ (NIH) was used to quantify 
the loss in fluorescence and calculate affinities for each active site. (D) Active-site 
selectivity for KSC-34, RB-11-ca, and 16F16. KSC-34 was found to have a 30-fold 
selectivity for the a domain over the a’ domain, compared to RB-11-ca which exhibited a 
21-fold selectivity and 16F16 which exhibited 2-fold selectivity. Error is calculated by 




 Owing to structural similarity amongst PDI family members, we next assessed the 
selectivity of KSC-34 for PDIA1 relative to two other PDI family members, PDIA3 and 
PDIA4, which display 34% and 36% similarity to PDIA1, respectively. Briefly, PDIA1, 
PDIA3 and PDIA4 (50 µg/mL) were incubated in the presence or absence of MCF-7 lysates 
(1 mg/mL), and subjected to CuAAC, and in-gel fluorescence (Figure 2-10). As indicated 
by the absence of fluorescence in the PDIA3 and PDIA4 samples, KSC-34 is selective for 
PDIA1 over other PDI family members. The band observed in the cell-lysate samples for 
PDIA3 and PDIA4 is the endogenous PDIA1 in the MCF-7 cell lysates, further confirming 
the selectivity of KSC-34, in that the presence of a large excess of PDIA3 and PDIA4 does 












Figure 2.10. Evaluation of selectivity of KSC-34. PDI isoform selectivity. KSC-34 was 





 To more comprehensively assess the selectivity of KSC-34 across other cellular 
PDIs, as well as any proteins bearing highly reactive cysteine residues, the protein targets 
of KSC-34 were globally investigated. To achieve this, MCF-7 cells were incubated with 
KSC-34 (5 µM) or DMSO. Upon cell lysis, KSC-34-labeled proteins were then appended 
to biotin-azide using CuAAC, enriched on streptavidin beads, subjected to on-bead tryptic 
digestion, and subsequent LC/LC-MS/MS analysis. Spectral counts (number of 
fragmentation spectra) generated for each protein in the KSC-34-treated samples were 
compared to the DMSO control (Figure 2-11, Table 1). In KSC-34-treated samples, an 
average of ~2000 spectral counts were matched to PDIA1 (with an average of ~5 spectral 
counts in the DMSO control). Importantly, the second most enriched protein was 
prostaglandin E synthase 2 (PTGES2), which was identified with an average of ~120 
spectral counts in the KSC-34-treated sample, significantly lower than that for PDIA1. 
PDIA6 was the only other PDI that was enriched by KSC-34, albeit with low spectral 
counts of ~20. KSC-34 is therefore highly selective for PDIA1 over other PDIs, as well as 
cellular proteins bearing reactive cysteines that could potentially be modified by the 










Figure 2.11. Evaluation of proteome-wide selectivity of KSC-34. Mass spectrometry 
analysis of proteins enriched in KSC-34 (5 µM) and DMSO treated MCF-7 cells. The 
spectral count difference between KSC-34-treated and DMSO-treated samples are plotted 







Table 2.1. Mass spectrometry data for KSC-34 treated MCF-7 cells. The proteins shown 
are sorted by the spectral count difference between the KSC-34 treated and the DMSO 
treated samples. 
  




P4HB P07237 9 0 5 1704 2355 2030 2025
PTGES2 Q9H7Z7 0 0 0 94 150 122 122
FAM213A Q9BRX8 0 0 0 70 143 107 107
HMOX2 P30519 0 0 0 57 75 66 66
HSP90AA1 P07900 31 13 22 63 87 75 53
HSP90AB1 P08238 40 23 32 72 96 84 53
TUBB P07437 62 82 72 89 154 122 50
ACTB P60709 215 144 180 190 247 219 39
PKM P14618 48 46 47 59 113 86 39
TUBB4B P68371 63 92 78 89 142 116 38
ATP2A2 P16615 5 2 4 34 48 41 38
EEF2 P13639 21 15 18 35 69 52 34
TUBB2B Q9BVA1 49 64 57 67 110 89 32
SELT P62341 0 0 0 19 45 32 32
HMGB1 P09429 0 8 4 18 46 32 28
RTN3 O95197 0 0 0 20 34 27 27
FASN P49327 64 43 54 57 101 79 26
ALDOA P04075 19 14 17 34 49 42 25
VDAC2 P45880 2 0 1 16 30 23 22
TKT P29401 8 8 8 24 33 29 21
PDIA6 Q15084 3 3 3 13 33 23 20
TXNDC12 O95881 0 0 0 21 17 19 19
TUBA8 Q9NY65 62 0 31 31 66 49 18
G6PD P11413 3 2 3 15 25 20 18
TXNRD1 Q16881 0 2 1 10 26 18 17
TUBB3 Q13509 44 76 60 62 90 76 16
EEF1A1 P68104 41 29 35 44 56 50 15
RTN4 Q9NQC3 0 0 0 10 20 15 15
ACTA1 P68133 52 55 54 78 58 68 15
HSPA8 P11142 22 19 21 32 36 34 14
GMPS P49915 0 0 0 13 14 14 14
FLNA P21333 67 56 62 63 86 75 13
CFL1 P23528 3 20 12 30 18 24 13
TPI1 P60174 5 10 8 14 26 20 13
SORD Q00796 0 2 1 14 12 13 12
PRKDC P78527 7 6 7 14 23 19 12
CYB5B O43169 0 0 0 5 16 11 11
PGK1 P00558 8 10 9 17 21 19 10
ASAH1 Q13510 0 0 0 9 11 10 10
RPL4 P36578 11 5 8 13 23 18 10
RPL3 P39023 4 0 2 9 15 12 10
PGAM1 P18669 0 0 0 10 9 10 10
ACTBL2 Q562R1 17 0 9 15 21 18 10
LGALS3 P17931 0 0 0 7 12 10 10
GPI P06744 4 5 5 12 15 14 9
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2.2.5 Inhibition of PDIA1 has minimal effects on the cellular unfolded protein 
response 
 Given the critical role of PDIA1 in disulfide-bond formation on nascent proteins in 
the ER, complete loss of PDIA1 activity will likely result in the accumulation of unfolded 
or misfolded proteins in the ER. Misfolded protein accumulation in the ER typically 
activates a series of complex stress-responsive signaling pathways known as the unfolded 
protein response (UPR)56-58. UPR activation involves three different pathways, which 
implicate inositol-requiring 1α (IRE1α), PKR‐like ER kinase (PERK), and activating 
transcription factor‐6α (ATF6α)59-60. Initial consequences of UPR activation include 
inhibition of translation, and increased ER protein-folding capacity. Chronic and sustained 
ER stress will eventually trigger cellular apoptosis. We sought to investigate the effects of 
KSC-34-mediated a-site inhibition of PDIA1 on each of these three arms of the UPR. 
 First, we identified an optimal concentration range of KSC-34 to utilize in our UPR 
assays, which would provide maximal PDIA1 target engagement with minimal toxicity. 
To quantify PDIA1 target occupancy at varying concentrations of KSC-34, we first 
synthesized a non-alkyne containing analog, KSC-34na, with identical PDIA1 binding 
properties to KSC-34, but lacking the biorthogonal handle for further functionalization 
with reporter tags (Figure 2-12A). To determine PDIA1 occupancy in cells, MCF-7 cells 
were treated with varying concentrations of KSC-34na. Following cell lysis, protein 
concentrations were normalized, and the lysates were incubated with KSC-34 (5 µM) to 
covalently modify any residual, non-inhibitor bound a-site C53 on PDIA1. In-gel 
fluorescence measurements were used to quantify the amount of PDIA1 that was not 
occupied by KSC-34na at each concentration. These measurements provided an EC50 of 4 
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µM for KSC-34na labeling of PDIA1 in MCF-7 cells, and demonstrated that complete 
occupation of C53 of PDIA1 in cells occurs at concentrations less than ~10 µM. To 
determine toxicity of KSC-34 at these same concentrations, MTT cell-viability assays were 
performed in MCF-7 cells, generating an EC50 value of 82 µM (Figure 2-12B), which 











Figure 2.12. (A) Identification of KSC-34 cellular occupancy of PDIA1. MCF-7 cells were 
treated with varying concentrations of KSC-34na. Following lysis, protein concentrations 
were normalized and subjected to treatment with KSC-34 (5 µM) to modify any residual 
PDIA1 a domain active site, C53. An EC50 of ~4 µM was calculated for KSC-34na labeling 
of PDIA1 in MCF-7 whole cells. All data are normalized to RB-11-ca lead compound. 
Error bars represent ± SD for n = 3 experiments. (B) MTT assay data in MCF-7 cells treated 
with varying concentrations of KSC-34. The calculated EC50 of KSC-34 was determined 
to be 82 µM. All data are normalized to vehicle treated cells. Error bars represent ± SD for 




 Upon identifying non-toxic concentrations of KSC-34 for cellular studies, 
quantitative transcriptional-profiling methods were utilized to monitor activation of known 
UPR target genes. Briefly, MCF-7 cells were treated with DMSO, thapsigargin (Tg) (5 
µM), and varying concentrations of KSC-34 (4-40 µM) for 3 hours at 37 °C. Tg is a 
sesquiterpene lactone that induces ER stress by inhibiting sarcoplasmic/endoplasmic 
reticulum calcium ATPase (SERCA). Treated cells were then subjected to qPCR analysis 
for mRNA encoding known downstream targets preferentially regulated by each of the 
three arms of the UPR, including SEC24D and ERDJ4 (IRE1α-regulated), BIP and HYOU1 
(IRE1α and ATF6-regulated), CHOP and GADD34 (PERK-regulated) and, GRP94 
(ATF6-regulated). KSC-34 treatment showed no significant activation of the PERK and 
ATF6 arms of the UPR (Figure 2-13A). Interestingly, a small but reproducible increase in 
SEC24D and ERDJ4 mRNA levels was observed (~2-fold) at >20 µM concentrations of 
KSC-34, suggesting selective activation of the IRE1α arm under these conditions, 
consistent with minor induction of XBP1 splicing upon KSC-34 treatment (Figure 2-13B). 
Treatment with an IRE1α inhibitor, 4µ8c, confirmed that the observed effects on SEC24D, 
ERDJ4, BIP, and HYOU1 were mediated directly through IRE1α (Figure 2-14). Further 
characterization determined that IRE1α activation only occurs within a short timeframe 
(<6 hours), since longer incubation times led to a loss in upregulation of IRE1α-dependent 
transcripts (Figure 2-15). Evaluation of other cell lines demonstrated that this effect is cell 
type-dependent, as no significant effects were observed in SKOV-3 and A549 cells (Figure 
2-16). Together, these data suggest that a-site inhibition of PDIA1 by KSC-34 has minimal 
effects on activation of the PERK and ATF6 arms of the UPR, with some short-lived, and 










Figure 2.13. Effects of KSC-34 on cell viability and the unfolded protein response. (A) 
qPCR analysis of UPR target genes following concentration-dependent treatment of MCF-
7 cells with KSC-34 for 3 hours at 37 °C. Data are reported as the mean fold change 
(relative to DMSO) ± SEM from three biological replicates. (B) XBP1 splicing assay for 










Figure 2.14. Effects of KSC-34 on the unfolded protein response. qPCR analysis of UPR 
target genes following co-treatment of MCF-7 cells with KSC-34 (20 µM) and IRE1α 
inhibitor, 4µ8c. Data are reported as the mean fold change (relative to DMSO) ± SEM from 








Figure 2.15. Effects of KSC-34 on the unfolded protein response. (A) Activation of UPR 
target genes in MCF-7 cells was assessed by measuring the relative mRNA expression 
levels of target genes by qRT-PCR after treating with KSC-34 (20 µM) for increasing time. 
Transcripts were normalized to the housekeeping gene RPLP2, and all reactions were 
performed in technical quadruplicate. Data are reported as the mean fold change (relative 
to DMSO) ± SEM from three biological replicates. (B) XBP1 splicing assay for time-
course experiment, where MCF-7 cells were treated with 20 µM KSC-34. Gel shows three 







Figure 2.16. Activation of UPR target genes in A549 cells (A) or SKOV-3 cells stably 
expressing shPDIA1, shPDIA4 or shGFP (B). The relative mRNA expression levels of 
target genes were assessed by qRT-PCR after treating with increasing concentrations of 
KSC-34 or 5 µM of thapsigargin. Transcripts were normalized to the housekeeping gene 
RPLP2. (A) For A549 cells, all reactions were performed in technical quadruplicate, and 
data are reported as the mean fold change (relative to DMSO) ± SEM from three biological 
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replicates. (B) For SKOV-3 cells, data are reported as mean fold change (relative to shGFP 
DMSO) ± SEM from reactions performed in triplicate.  
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2.2.6 PDIA1 Inhibition by KSC-34 decreases secretion of an amyloidogenic light chain 
 PDIA1 influences the folding of disulfide-containing secretory proteins including 
antibody light chains49, 61-63. Therefore, we sought to evaluate the functional consequence 
of KSC-34-mediated inhibition of PDIA1 in cell-culture models expressing the 
destabilized, disease-associated antibody light chain ALLC64. We first performed co-
immunoprecipitation (co-IP) experiments to determine how KSC-34-dependent inhibition 
of PDIA1 influences its interaction with flag-tagged ALLC (FTALLC) in HEK293DAX 
cells58. PDIA1 was enriched in FTALLC IPs in the absence of KSC-34, confirming that 
PDIA1 interacts with this destabilized light chain in mammalian cells (Figure 2-17A). The 
addition of KSC-34 disrupted this interaction, shown by a decrease in the co-isolation of 
PDIA1 with FTALLC (Figure 2-17A). However, the closely related ER protein PDIA4 co-
purifies with FTALLC in cells treated with or without KSC-34, demonstrating that this 
compound does not influence the interaction between these proteins. These results show 
that KSC-34 selectively disrupts the interaction between FTALLC and PDIA1, 











Figure 2.17. KSC-34 reduces secretion of destabilized ALLC from mammalian cells. (A) 
Immunoblot of anti-FLAG IPs of lysates prepared from HEK293DAX cells transiently 
transfected with FTALLC and pre-treated for 1 h with vehicle or KSC-34 (40 µM). Cells 
were crosslinked for 30 min with DSP (500 µM) prior to lysis. Mock transfected cells are 
included as a control. (B) Graph showing secreted FTALLC (grey) and viability (blue) of 
HEK293Trex cells stably expressing FTALLC pretreated for 4 h with KSC-34 (40 µM). 
Media was conditioned for 2 h in the presence or absence of KSC-34 (40 µM) prior to 
quantification of secreted FTALLC by ELISA. Viability was measured following media 
conditioning by Cell Titre Glo. All data are normalized to vehicle-treated cells. Error bars 









Figure 2.18. KSC-34 reduces secretion of destabilized ALLC from mammalian cells. 
Representative autoradiogram and quantification of the fraction [35S]-labeled FTALLC 
secreted from HEK293DAX cells using the experimental paradigm shown. Experiments 
were performed in the absence or presence of KSC-34 (40 µM) added 1 h prior to labeling 
and then again throughout the experiment. Fraction secreted was calculated as described in 




 Next, we determined whether KSC-34-dependent inhibition of PDIA1 influences 
ALLC secretion. We treated HEK293Trex cells stably expressing FTALLC with KSC-34, 
and monitored secretion by ELISA. Treatment with KSC-34 reduced levels of FTALLC in 
the conditioned media by 40%, as compared to vehicle (Figure 2-17B). This treatment did 
result in a modest 20% reduction in cellular viability, however this decrease is not sufficient 
to account for the observed changes in secreted FTALLC. To further define the impact of 
KSC-34 on FTALLC secretion, we monitored the fraction of newly-synthesized FTALLC 
secreted from HEK293DAX cells treated with or without KSC-34 using [35S] metabolic 
labeling (Figure 2-18). Pretreatment with KSC-34 reduced the fraction of [35S]-labeled 
FTALLC secreted by 30%, confirming the results observed by ELISA (Figure 2-18). Next, 
we sought to determine the PDIA1-dependence of these effects on LC secretion utilizing 
HEK293DAX cells stably expressing PDIA1 shRNA. We confirmed PDIA1 knockdown in 
these cells by qPCR (Fig. S9A). Depletion of PDIA1 attenuated the KSC-34-dependent 
reduction in FTALLC secretion measured by ELISA (Figure 6D) and [35S] metabolic 
labeling (Figure 6E and Fig. S9B). This shows that KSC-34 decreases destabilized ALLC 
secretion through a mechanism dependent on PDIA1. These data support the utility of a-
site selective PDIA1 inhibitors to selectively affect secretion of amyloidogenic proteins 






Figure 2.19. KSC-34 reduces secretion of destabilized ALLC from mammalian cells. (A) 
Graph showing fold change mRNA levels of PDIA1 in HEK293DAX cells and HEK293DAX 
cells shRNA-depleted of PDIA1 measured by qPCR. Error bars show 95% confidence 
interval. (B) Graph showing secreted FTALLC (grey) and viability (blue) of HEK293DAX 
cells transiently expressing FTALLC pretreated for 4 h with KSC-34 (40 µM). HEK293DAX 
cells stably expressing PDIA1 shRNA are indicated. Media was conditioned for 2 h in the 
presence or absence of KSC-34 (40 µM) prior to quantification of secreted FTALLC by 
ELISA. Viability was measured following media conditioning by Cell Titre Glo. All data 
are normalized to vehicle-treated controls. Error bars show SEM for n=3 experiments. 
*p<0.05. (C) Representative autoradiogram and quantification of the fraction [35S]-labeled 
FTALLC secreted from HEK293DAX cells using the experimental paradigm shown in Figure 
2-18. Experiments were performed in the absence or presence of KSC-34 (40 µM) added 
1 h prior to labeling and then again throughout the experiment. Error bars show SEM for 
n=4 (D) Graph showing the fraction [35S]-labeled FTALLC secreted at t=4 h from 
HEK293DAX cells transiently transfected with FTALLC quantified using the same 
experimental paradigm shown in Figure 2-18. HEK293DAX cells stably expressing PDIA1 
shRNA are indicated. Experiments were performed in the absence or presence of KSC-34 
88 
 
(40 µM) added 1 h prior to labeling and then again throughout the experiment. Error bars 




 In conclusion, we report the discovery and characterization of KSC-34, a potent 
and selective inhibitor of PDIA1. KSC-34 was identified from a targeted library of 
compounds generated around an initial lead compound, RB-11-ca. KSC-34 contains a (4-
phenylbutyl)methylamine diversity element for optimized binding to the a domain of 
PDIA1 with a chloroacetamide electrophile for covalent modification of C53 on PDIA1. 
Notably, the presence of a bioorthogonal alkyne handle on KSC-34 and derivatives, 
facilitated the rapid screening of these compounds for potency and selectivity both in vitro 
against purified PDIs, as well as directly in living cells. Importantly, despite the prominent 
reactivity of the chloroacetamide electrophile on KSC-34, extremely high selectivity is 
observed for PDIA1 within a complex proteome. The high inhibitory potency of KSC-34 
was confirmed in an in vitro insulin-reduction assay, where KSC-34 proved to be 
approximately 38-fold more potent than the commercially available PDIA1 inhibitor 
16F16. Importantly, KSC-34 is unique in that it displays selective binding to the a domain 
of PDIA1, and is the most site-selective PDIA1 inhibitor reported to date. KSC-34 
treatment generally results in minimal sustained activation of the UPR, although some low 
cell-specific, short-lived effects were observed with the IRE1α arm in MCF-7 cells. Lastly, 
the ability of KSC-34 to reduce the extracellular pathogenic load of amyloidogenic 
antibody light-chain is demonstrated, highlighting the potential of site-selective PDIA1 
inhibitors to have therapeutic value by selectively downregulating a subset of PDIA1 
functions in cells. The development of KSC-34 validates the potential to selectively, and 
potently pharmacologically modulate individual thioredoxin-like active-site domains 
within a single member of the PDI family. KSC-34 is a useful tool compound to further 
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interrogate the cellular functions of the a domain of PDIA1, and additionally, to explore 
the therapeutic value of site-selective PDI inhibitors. 
 
2.4 Materials and Methods 
2.4.1 General Information 
 All materials were obtained from Sigma-Aldrich, Fisher Scientific, Combi-Blocks, 
or Oakwood Chemicals, unless otherwise noted. Phosphate buffered saline (PBS) buffer, 
RPMI 1640 media, Trypsin-EDTA and Anti-Anti were purchased from Fisher Scientific 
(Pittsburgh, PA). Fetal bovine serum was purchased from Atlanta Biologicals (Flowery 
Branch, GA). All protein concentrations were determined using the DC Protein Assay kit 
from Bio-Rad (Hercules, CA). Analytical thin layer chromatography (TLC) was performed 
on EMD Millipore F254 glass-backed TLC plates (250 µm, Billerica, MA). All compounds 
were visualized on TLC under UV light and by potassium permanganate staining. Column 
chromatography was carried out using forced flow of solvent on Sorbent Technologies 
(Norcross, GA) standard grade silica gel, 40-63 µm particle size, 60 Å pore size. Proton 
and carbon NMR spectra were carried out on Varian (Palo Alto, CA) 500 MHz and 600 
MHz NMR spectrometers. Chemical shifts (δ) are reported in parts per million (ppm) with 
chemical shifts reported to internal standards: CDCl3 (7.26 ppm for 1H, 77.23 ppm for 
13C), (CD3)2CO (2.05 ppm for 1H, 29.92 ppm for 13C), CD3OD (3.31 ppm for 1H, 49.15 
ppm for 13C). Coupling constants (J) are reported in Hertz (Hz) and multiplicities are 
abbreviated as singlet (s), doublet (d), triplet (t), multiplet (m), doublet of doublets (dd), 
and doublet of triplets (dt). High resolution Mass Spectra (HRMS) were obtained at the 




2.4.2 Covalent Docking Studies 
 Covalent docking calculations were performed by the covalent docking workflow52 
by Schrodinger, Inc. For the calculations, the experimental structure of PDIA1 in its 
reduced state was used (PDB ID: 4EKZ)51. A two-dimensional structure was prepared in 
ChemDraw (Perkin-Elmer) and then converted to 3D and energy minimized with default 
settings with LigPrep (Schrodinger). Prior to calculations, RB-11-ca was manually 
positioned in the a domain active site of PDIA1 near the catalytic cysteine, for use in 
automatic grid determination. The ligand was then docked using a nucleophilic substitution 
reaction at position C53 with default pose-prediction settings. 
 
2.4.3 Cell culture and preparation of MCF-7 cell lysates 
 MCF-7 cells were cultured at 37 °C under an atmosphere of 5% CO2 in RPMI 1640 
media (Corning) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) 
and 25 µg/mL of Amphotericin B, 10,000 units/mL of penicillin, and 10,000 µg/mL 
streptomycin (Gibco Anti-Anti). The cells were then harvested and the pellets washed with 
phosphate buffered saline (PBS). After washing, the pellets were resuspended in an 
appropriate amount of PBS and then sonicated with an ultrasonic tip sonicator (Cole 
Parmer, Vernon Hills, IL). The lysates were separated by centrifugation at 45,000 rpm for 
45 minutes at 4 °C to obtain soluble and insoluble lysate fractions. The soluble fraction 
was collected and the pellet discarded. Protein concentrations were determined using the 




2.4.4 Fluorescent Gel Analysis 
 For recombinant PDI labeling gels, purified protein (50 µL, 50 µg mL-1) in PBS 
was treated with probe (1 µL of 50x stock in DMSO) for one hour. For endogenous PDI 
labeling gels, MCF-7 cell lysates (50 µL, 2 mg mL-1) in PBS were treated with probe (1 
µL of 50x stock in DMSO) for one hour. Rhodamine-azide (25 µM, 100x stock in DMSO, 
Click Chemistry Tools), was then appended to probe-labeled proteins via CuAAC; TCEP 
(1 mM, 50x stock in water), TBTA (100 µM, 17x stock in t-BuOH:DMSO 4:1), and copper 
(II) sulfate (1 mM, 50x stock in water) were added to the cell lysate. Samples were then 
incubated at room temperature for one hour to allow for the cycloaddition reaction to occur. 
An equal volume of SDS-PAGE loading buffer (2x, reducing) was added to each reaction 
and 20 µL of this solution was separated on a 10% SDS-PAGE gel. Gels were visualized 
for rhodamine fluorescence on a ChemiDoc MP imaging system (BioRad, Hercules, CA). 
Gels were then coomassie stained following a standard procedure and visualized on the 
same imager. 
 
2.4.5 In situ labeling experiments 
 MCF-7 cells were grown to ~90% confluence in 10 cm tissue culture plates. Growth 
media was removed and replaced with 5 mL RPMI. Probes in an appropriate DMSO stock 
was then added to the media to achieve the desired labeling concentration and incubated at 
37 °C under an atmosphere of 5% CO2 for 3 hours. Cells were then harvested and were 




2.4.6 KSC-34 cellular occupancy experiments 
 MCF-7 cells were labeled dose-dependently with the non-alkyne analogue, KSC-
34na, and prepared as above. After normalizing protein concentrations to 2 mg/mL across 
samples, each sample was then treated with 5 µM KSC-34 for 1 hour at room temperature. 
Samples were then subjected to click chemistry to append a fluorophore for fluorescent-
gel analysis. Gels were visualized for rhodamine fluorescence on a ChemiDoc MP imaging 
system (BioRad, Hercules, CA). Gels were then coomassie stained following a standard 
procedure and visualized on the same imager. ImageJ was used to quantify the loss of 
fluorescence intensity of the PDIA1 band and an EC50 value for cellular occupancy was 
determined using PRISM. 
 
2.4.7 PDIA1 active site selectivity experiments 
 In order to determine the active site preference for each probe, mutant recombinant 
PDIA1, C53A or C397A (50 µg/mL), was spiked into MCF-7 lysate (1 mg/mL) followed 
by dose-dependent increases of KSC-34, RB-11-ca or 16F16. Following incubation, 
samples were then incubated with Chloroacetamide-Rhodamine (8 µM, Figure 2-9B), to 
append a fluorophore to any unlabeled PDIA1. ImageJ was used to quantify the loss of 
fluorescence intensity of the PDIA1 band and IC50 values for each active site were 
determined using PRISM. 
 
2.4.8 PDI isoform selectivity experiments 
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 In order to determine the selectivity of KSC-34 for PDIA1 over other PDI family 
members, an in-gel fluorescence experiment was performed comparing labeling of PDIA1 
with KSC-34 to PDIA3 and PDIA4. The PDIs (50 µg/mL) in PBS either in the absence or 
presence of an MCF-7 lysate background (1 mg/mL) were treated with KSC-34 (5 µM) for 
one hour at room temperature. Following treatment, rhodamine-azide was appended with 
click-chemistry for fluorescent-gel analysis. Gels were visualized for rhodamine 
fluorescence on a ChemiDoc MP imaging system (BioRad, Hercules, CA). Gels were then 
coomassie stained following a standard procedure and visualized on the same imager. 
 
2.4.9 PDIA1 Insulin Reduction Activity Assay 
 PDIA1 WT (5 µM) in PBS was aliquoted as 25 µL samples. Inhibitor or DMSO 
(0.5 µL of 50x) were added to each sample to achieve a final concentration between 0 µM 
and 1,500 µM for either 5, 15, 30, 45, or 60 minutes. The samples were briefly vortexed 
and then 10 µL was taken from each sample and added to the assay plate. Fresh assay 
buffer (100 mM K2HPO4, 2 mM EDTA, pH 7.0) was prepared and 70 µL was aliquoted 
per well. Bovine insulin (Sigma-Aldrich, 10 µL, 10x, 1.6 mM) was also added to the wells. 
Following a brief shake in the plate reader, DTT (10 µL, 10x, 10 mM) was added to initiate 
the activity assay. A sample without PDIA1 and a sample without DTT were used as blank 
controls. This results in final concentrations in this assay of PDIA1 WT (0.5 µM), Insulin 
(0.16 mM), and DTT (1 mM). The assay plate was read for absorbance at 650 nm every 20 
seconds for 30 minutes, with shaking between reads. 
 For data analysis, each well was normalized to the – PDIA1 sample at each time 
point. The linear portion (400 – 800 sec) of the absorbance vs time plot was used to monitor 
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a loss in PDIA1 activity. Linear regressions for each pre-incubation time point at each 
[Inhibitor] were performed to determine the rates of the reactions (5 slopes, 5 different pre-
incubation times) for each [Inhibitor]. For each [Inhibitor], the Rate of Activity vs Pre-
incubation time was plotted. This was determined by normalizing the reaction rates of each 
sample to samples without inhibitor, to give % Rate of Control vs Pre-incubation time. A 
one-phase decay nonlinear regression was performed for each [Inhibitor] to produce a rate 
constant for inhibition, kobs. These rate constants were plotted as kobs vs [Inhibitor], and 
another nonlinear regression was performed to calculate KI and kinact. 
 
2.4.10 KSC-34 Mass Spectrometry Sample Preparation and Data Analysis 
 MCF-7 cells were grown to ~90% confluence in 15 cm tissue culture plates. Growth 
media was removed and replaced with 10 mL RPMI. KSC-34 (10 µL, 1000x stock) or 
DMSO was then added to the media to achieve the desired labeling concentration and 
incubated at 37 °C under an atmosphere of 5% CO2 for 3 hours. Cells were then harvested 
and were then prepared as lysates as described above. 
 KSC-34 labeled MCF-7 cell lysates (500 µL, 2 mg mL-1) in PBS were subjected to 
click chemistry.  Biotin azide (200 µM from 100x stock in DMSO), TCEP (1 mM, 50x 
stock in water), TBTA (100 µM, 17x stock in t-BuOH:DMSO 4:1), and copper (II) sulfate 
(1 mM, 50x stock in water) were added to the cell lysate. Samples were incubated at room 
temperature for 1 hour to allow for the cycloaddition reaction to occur. Samples were then 
centrifuged for 10 minutes at 4 °C to pellet the precipitated proteins. Protein pellets were 
then resuspended in cold methanol by tip sonication followed by centrifugation. Following 
a second methanol wash, pelleted proteins were solubilized in a 1.2% SDS/PBS solution 
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via tip sonication and incubation at 85 °C for 5 minutes. Samples were then diluted with 5 
mL PBS to lower the concentration of SDS to 0.2%. Next, samples were incubated with 
100 µL streptavidin agarose beads (Thermo Fisher Scientific, Waltham, MA) at 4 °C for 
16 hours. Samples were then washed with 0.2% SDS/PBS (5 mL), PBS (3 x 5 mL), and 
water (3 x 5 mL). The streptavidin agarose beads were pelleted between each wash step by 
centrifugation (1,400 g, 3 minutes). 
 The beads were suspended in a solution of 6 M Urea/PBS (500 µL) and 10 mM 
dithiothreitol (DTT, 20x stock in water), followed by incubation at 65 °C for 20 minutes. 
Next, iodoacetamide (20 mM, from 50x stock in water) was added to each sample and 
incubated at room temperature for 30 minutes. The beads were pelleted (1,400 g, 3 minutes) 
and resuspended in 200 µL of 2 M Urea/PBS, 1 mM CaCl2 (100x stock in water), and 2 µg 
trypsin (Promega, Madison, WI). On-bead trypsin digestion was allowed to proceed 
overnight at 37 °C with agitation. The beads were pelleted (1,400 g, 3 min) and the 
supernatant collected. The beads were washed with water (2 x 50 µL) and the washes were 
combined with the supernatant. Formic acid (15 µL, Thermo Fisher Scientific, Waltham, 
MA) was then added to each sample and the samples were stored at -20 °C until mass 
spectrometry analysis. 
 LC/LC-MS/MS analysis was performed on an LTQ Orbitrap Discovery mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to an Agilent 1200 series 
HPLC (Agilent Technologies, Santa Clara, CA). Tryptic digests were pressure loaded onto 
a 250 µm fused silica desalting column packed with 4 cm of Aqua C18 reversed phase 
resin (Phenomenex, Torrance, CA). Peptides were then eluted onto a biphasic 100 µm 
fused silica column with a 5 µm tip, packed with 10 cm of C18 and 4 cm of Partisphere 
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SCX (Whatman, Pittsburgh, PA). Elution of the peptides from the desalting column into 
the biphasic column occurred using a gradient of 5-100% Buffer B in Buffer A (Buffer A: 
95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 
0.1% formic acid). The peptides were eluted from the SCX onto the C18 resin and then 
into the mass spectrometer using four salt pushes65. The flow rate of buffer through the 
fused silica column was set to 0.25 µL min-1 and the spray voltage was set 2.75 kV. One 
full MS scan (400 – 1800 MW) was followed by 8 data dependent scans of the nth most 
intense ions with dynamic exclusion enabled. 
 Two biological replicates each of KSC-34 (5 µM) or DMSO treated MCF-7 cells 
were subjected to LC/LC-MS/MS analysis as outlined above. The generated tandem MS 
data was searched using the SEQUEST algorithm against the human UniProt database. A 
static modification of +57.0215 on cysteine was added to account for alkylation of cysteine 
residues with iodoacetamide. The SEQUEST output files were then filtered using 
DTASelect v2.0 to generate a list of proteins identified with a false-discovery rate of < 5%.  
The resulting peptides were then further filtered to display proteins identified in KSC-34 
treated samples with an average of 10 spectral counts or greater across the biological 
replicates. For each of these proteins, the change in spectral counts between KSC-34 treated 
samples and DMSO samples was calculated and the data was ranked by those proteins 
displaying the highest change in spectral counts in the KSC-34 treated samples relative to 
the DMSO treated samples. 
 
2.4.11 UPR Assays and Cell Culture 
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 MCF7 cells were cultured in RPMI-1640 supplemented with glutamine, 
penicillin/streptomycin, and 10% fetal bovine serum (FBS). Cells were treated with the 
indicated concentrations of KSC-34 (see Results section) at the indicated time points, with 
0.1% DMSO serving as negative control. To induce global ER stress, the 
sarco/endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin was used at 5 µM for 
three hours. To inhibit IRE1 activity, cells were co-treated with 4µ8C (purchased from 
Sigma-Aldrich) at the indicated concentrations for three hours. 
 
2.4.12 Quantitative RT-PCR 
 The relative mRNA expression levels of target genes were measured by quantitative 
RT-PCR (see Table 1 for a list of primers used). Cells were lysed in tissue culture plates, 
and total RNA was extracted using the Omega E.Z.N.A. Total RNA Kit I according to the 
manufacturer’s instructions. RNA concentrations were quantified and normalized to 1 µg 
total RNA for cDNA reverse transcription. Using the Applied Biosystems High-Capacity 
cDNA Reverse Transcription Kit, cDNA was synthesized in a Bio-Rad T100 Thermal 
Cycler. LightCycler 480 SYBR Green I Master reaction mix (Roche), appropriate primers 
(purchased from Sigma-Aldrich), and cDNA were used for amplification in a LightCycler 
480 Instrument II (Roche) in the MIT BioMicro Center. Primer integrity was assessed by 
thermal melt to ensure homogeneity. Transcripts were normalized to the housekeeping 
gene RPLP2, and all reactions were performed in quadruplicate. Experiments were 
repeated in biological triplicate. Data were analyzed using the ΔΔCt method and presented 




2.4.13 XBP1 Splicing Assay 
 cDNA synthesized from total RNA (as above) was amplified using the Q5 High-
Fidelity DNA Polymerase (NEB) according to the manufacturer’s instructions with the 
appropriate XBP1 primers (Table 2). Five microliters of the resultant reaction were 
separated on 2.5% agarose gels stained with GelGreen (Biotium). 
 
 
Table 2.2. Primers used for qPCR and XBP1 splicing assays. 
 
 
2.4.14 Cell culture and transfections 
 HEK293TREX, HEK293DAX,58 and HEK293DAX PDIA1 shRNA cells were cultured 
in High-Glucose Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
glutamine, penicillin/streptomycin and 10% fetal bovine serum. PDIA1 shRNA 
knockdown cells were additionally cultured with 5ug/ml puromycin. HEK293DAX cells 
were transfected with FTALLC.pcDNA3.1 using calcium phosphate, as previously 
described.64, 66 All cells were cultured under typical tissue culture conditions (37°C, 5% 
CO2). 
 
Transcript Forward Reverse 
BIP 5’- GCCTGTATTTCTAGACCTGCC-3’ 5′-TTCATCTTGCCAGCCAGTTG-3′ 
CHOP 5′-GGAGCTGGAAGCCTGGTATG-3′ 5′-GCCAGAGAAGCAGGGTCAAG-3′ 
ERDJ4 5'-CTGTATGCTGATTGGTAGAGTCAA-3’ 5'-AGTAGACAAAGGCATCATTTCCAA-3' 
GADD34 5'-TGGTAGAAGCTGGCCTGGAG-3' 5'-GGGAACTGCTGGTTTTCAGC-3' 
GRP94 5'-GGCCAGTTTGGTGTCGGTTT-3' 5'-CGTTCCCCGTCCTAGAGTGTT-3' 
HYOU1 5′-GCAGACCTGTTGGCACTGAG-3′ 5′-TCACGATCACCGGTGTTTTC-3′ 
RPLP2 5′-CCATTCAGCTCACTGATAACCTTG-3′ 5′-CGTCGCCTCCTACCTGCT-3′ 
SEC24D 5′-AGCAGACTGTCCTGGGAAGC-3′ 5'-TTTGTTTGGGGCTGGAAAAG-3′ 
XBP1 5'-CCTTGTAGTTGAGAACCAGG-3' 5'-GGGGCTTGGTATATATGTGG-3' 
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2.4.15 Cytotoxicity assays 
 HEK293TREX and HEK293DAX cells were plated at 5,000 cells/well in a poly-D-
lysine coated transparent, flat-bottomed 96 well plate. Cells were pretreated for 4 hours 
with KSC-34 or DMSO vehicle. This media was replaced with fresh media containing 
KSC-34 or vehicle and conditioned for 2 hours. Cell metabolic activity was measured using 
the CellTiter-Glo assay (Promega). CellTiter-Glo reagent was added to cell culture media 
at a 1:1 ratio and incubated for 2 min on an orbital shaker to induce cell lysis. The plate 
was then incubated at room temperature for 10 min to stabilize the luminescent signal and 
read on a Tecan F200 Pro microplate reader. 
 
2.4.16 [35S] Metabolic labeling experiments 
 HEK293DAX cells plated on poly-D-lysine coated dishes were metabolically labeled 
in DMEM-Cys/-Met (Corning CellGro, Mediatech Inc., Manassas, VA) supplemented 
with glutamine, penicillin/streptomycin, 10% dialyzed fetal bovine serum, and EasyTag 
EXPRESS [35S] Protein Labeling Mix (Perkin Elmer) for 30 min. Cells were washed twice 
with complete media and incubated in pre-warmed DMEM. At the indicated time, media 
was collected and lysates were prepared in RIPA buffer with fresh protease inhibitor 
cocktail (Roche). FLAG-tagged ALLC was immunopurified using M1 anti-FLAG agarose 
beads (Sigma Aldrich) and washed four times with RIPA buffer. The immunoisolates were 
then eluted by boiling in Laemmli buffer and separated on SDS-PAGE. The gels were then 
dried, exposed to phosphorimager plates (GE Healthcare, Pittsburgh, PA), and imaged 
with a Typhoon imager. Band intensities were quantified by densitometry in ImageQuant. 
Fraction secreted was calculated using the equation: fraction secreted = [extracellular [35S]-
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FTALLC signal at t / (extracellular [35S]- FTALLC signal at t=0 + intracellular [35S]- FTALLC 
signal at t=0)]. 
 
2.4.17 Immunoprecipitation and SDS-PAGE 
 For immunoprecipitations, cells were washed with PBS then incubated with with 
0.5 mM of the cell permeable reversible crosslinker Dithiobis(succinimidiyl propionate) 
(DSP) for 30 min at room temperature. The reaction was quenched by addition of 100 mM 
Tris pH 7.5. Lysates were then prepared in RIPA buffer and cleared by centrifugation at 
10000 x g for 15 min. Proteins were immunopurified using using M1 anti-FLAG agarose 
beads (Sigma Aldrich). After four washes in RIPA buffer, proteins were eluted by boiling 
in Laemmli buffer + 100 mM DTT and samples were separated by SDS-PAGE and 
transferred to nitrocellulose membranes. Blots were probed with the following primary 
antibodies: monoclonal mouse M2 anti-FLAG (1:500, Sigma Aldrich), rabbit polyclonal 
anti-PDIA1 (1:1000, GeneTex GTX101468, Irvine, CA), rabbit polyclonal anti-PDIA4 
(1:1000, Proteintech Group 14712-1-AP, Rosemont, IL). 
 
2.4.18 Light chain ELISA 
 HEK293TREX stably expressing FTALLC or transfected HEK293DAX cells were 
plated at 10,000 cells/well in a poly-D-lysine coated transparent, flat-bottomed 96 well 
plate. Triplicate wells were pretreated for 4 hours with 40µM KSC-34 or vehicle. Wells 
were washed twice with 100µL media and then fresh media with 40µM KSC-34 or vehicle 
was added for 2-hour conditioning. Conditioned media was harvested into a 96-well plate. 
Free LC concentrations were determined by ELISA in 96-well plates (Immulon 4HBX, 
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Thermo Fisher). Wells were coated overnight at 37 ºC with sheep polyclonal free λ LC 
antibody (Bethyl Laboratories, A80-127A) at a 1:500 dilution in 50 mM sodium carbonate 
(pH 9.6). In between all incubation steps, the plates were rinsed extensively with Tris-
buffered saline containing 0.05% Tween-20 (TBST). Plates were blocked with 5% non-fat 
dry milk in TBST for 1 hr at 37ºC. Media analytes were diluted between 5 – 200 fold in 
5% non-fat dry milk in TBST and 100 µL of each sample was added to individual wells. 
Light chain standards ranging from 3 – 300 ng/mL were prepared from purified human 
Bence Jones λ light chain (Bethyl Laboratories, P80-127). Plates were incubated at 37 ºC 
for 1.5 hr while shaking. Finally, HRP-conjugated goat anti-human λ light chain antibody 
(Bethyl Laboratories, A80-116P) was added at a 1:5,000 in 5% non-fat dry milk in TBST, 
followed by a 1.5 hr incubation of the plates at 37 ºC. The detection was carried out with 
2,2'-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS, 0.18 mg/mL) and 0.03% 
hydrogen peroxide in 100 mM sodium citrate pH 4.0. Detection solution (100 µL) was 
added to each well and the plates were incubated at room temperature. The absorbance was 
recorded at 405 nm and the values for the LC standards were fitted to a 4-parameter logistic 
function. Light chain concentrations were averaged from 3 independent replicates under 
each treatment and then normalized to vehicle conditions. 
 
2.4.19 Quantitative RT-PCR 
 Cells were treated as described at 37°C, washed with Dulbecco’s phosphate-
buffered saline, and then RNA was extracted using the RNeasy Mini Kit (Qiagen). qPCR 
reactions were performed on cDNA prepared from 500 ng of total cellular RNA using the 
QuantiTect Reverse Transcription Kit (Qiagen). The FastStart Universal SYBR Green 
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Master Mix (Roche), cDNA, and appropriate human primers for PDIA1 
(TCTTCATCGACAGCGACCAC and ATCCTCTCTGCCGTCAGCTC) purchased from 
Integrated DNA Technologies were used for amplifications (45 cycles of 1 min at 95°C, 
10 s at 95°C, 30 sec at 60°C) in an ABI 7900HT Fast Real Time PCR machine. Transcripts 
were normalized to the housekeeping gene GAPDH and all measurements were performed 
in triplicate. Data were analyzed using the RQ Manager and DataAssist 2.0 softwares (ABI, 
Foster City, CA). 
 











4,6-dichloro-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (BBI): To an ice cold solution of 
cyanuric chloride (1.0 eq, 151.1 mg, 0.8194 mmol) and diisopropylethylamine (1.1 eq, 
116.5 mg, 0.9013 mmol) in tetrahydrofuran (THF) (0.055 M, 15 mL), propargylamine (1.2 
eq, 54.2 mg, 0.9832 mmol) was added dropwise. The reaction mixture was allowed to stir 
at 0 °C for 3 hours. The solvent was removed in vacuo and the crude product was purified 
via flash chromatography to give the desired product BBI as a white solid (82.2 mg, 49%). 
1H NMR (600 MHz, Acetone-d6) δ 8.30 (s, 1H), 4.43 – 4.15 (m, 2H), 2.79 (t, J = 2.6 Hz, 
1H). 13C NMR (151 MHz, Acetone-d6) δ 171.32, 170.63, 166.91, 79.56, 73.13, 31.35. 





yl)amino)ethyl)carbamate (BBII): To a solution of BBI (1.0 eq, 79.4 mg, 0.3911 mmol) 
and sodium carbonate (2.2 eq, 91.2 mg, 0.8604 mmol) in ethanol (0.08 M, 5 mL), N-Boc-
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ethylenediamine (1.1eq, 68.9 mg, 0.4302 mmol) was added dropwise at room temperature. 
The solution was then allowed to warm to 45 °C while stirring and continued to stir for 18 
hours. After the reaction was complete, 15 mL of water was added and the reaction was 
extracted with ethyl acetate (3 x 15 mL). The organic layer was washed with brine and 
dried with MgSO4, then the solvent was removed in vacuo. The crude product was purified 
via flash chromatography to afford the desired to product, BBII as a white solid (93.2 mg, 
73%). 1H NMR (600 MHz, DMSO-d6) δ 8.12 (dt, J = 44.7, 5.8 Hz, 1H), 8.01 – 7.54 (m, 
1H), 6.82 (dt, J = 11.4, 5.9 Hz, 1H), 4.17 – 3.92 (m, 2H), 3.31 – 3.19 (m, 2H), 3.18 – 3.00 
(m, 2H), 2.50 (p, J = 1.8 Hz, 1H), 1.36 (d, J = 1.9 Hz, 9H). 13C NMR (151 MHz, DMSO-
d6) δ 168.38, 168.12, 167.78, 165.36, 164.79, 155.57, 80.87, 77.61, 72.91, 29.63, 28.21. 





yl)amino)ethyl)carbamate (KSC-4-int): To a solution of BBII (1.0 eq, 92.8 mg, 0.2840 
mmol) and diisopropylethylamine (2.5 eq, 91.8 mg, 0.7100 mmol) in THF (0.04 M, 8 mL), 
hexylamine (2.5 eq, 71.8 mg, 0.7100 mmol) was added dropwise at room temperature. The 
solution was then allowed to heat to reflux while stirring and continued to reflux for 24 
hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
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product was purified via flash chromatography to afford the desired to product, KSC-4-int 
as an oil (107.2 mg, 96%). 1H NMR (500 MHz, Chloroform-d) δ 6.01 – 4.66 (m, 4H), 4.16 
(s, 2H), 3.60 – 3.16 (m, 6H), 2.27 – 2.12 (m, 1H), 1.52 (q, J = 7.4 Hz, 2H), 1.42 (d, J = 2.0 
Hz, 9H), 1.37 – 1.25 (m, 6H), 0.87 (dt, J = 6.9, 3.3 Hz, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 166.54, 165.75, 156.33, 81.00, 79.27, 71.01, 41.53, 40.84, 40.70, 31.67, 
30.44, 29.82, 28.52, 26.73, 22.71, 14.22, 14.15. HRMS for KSC-4-int: m/z calcd. 





yl)amino)ethyl)acetamide (KSC-4): KSC-4-int was deprotected using a 50% solution of 
TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 39.9 mg, 0.1369 mmol) and triethylamine (1.5 eq, 
20.8 mg, 0.2054 mmol) in DCM (0.03 M, 5 mL), chloroacetyl chloride (1.2 eq, 18.6 mg, 
0.1643 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed  in vacuo 
and the crude product was purified by flash chromatography to give the desired product 
KSC-4 (26.3 mg, 52%). 1H NMR (600 MHz, Chloroform-d) δ 4.21 (s, 2H), 4.03 (s, 2H), 
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3.74 – 3.43 (m, 2H), 3.39 (s, 2H), 2.23 (s, 1H), 1.56 (s, 2H), 1.31 (dd, J = 16.3, 9.6 Hz, 
6H), 1.25 (d, J = 2.4 Hz, 2H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (151 MHz, Chloroform-
d) δ 166.86, 163.97, 117.49, 115.56, 79.67, 71.63, 42.71, 41.06, 39.81, 31.60, 30.43, 29.83, 





yl)amino)ethyl)carbamate (KSC-5-int): To a solution of BBII (1.0 eq, 44.0 mg, 0.1346 
mmol) and diisopropylethylamine (2.4 eq, 41.8 mg, 0.3231 mmol) in THF (0.03 M, 5 mL), 
propylamine (2.4 eq, 19.1 mg, 0.3231 mmol) was added dropwise at room temperature. 
The solution was then allowed to heat to reflux while stirring and continued to reflux for 
24 hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
product was purified via flash chromatography to afford the desired to product, KSC-5-int 
as an oil (37.4 mg, 80%). 1H NMR (600 MHz, Chloroform-d) δ 4.24 – 4.06 (m, 2H), 3.47 
(s, 2H), 3.29 (s, 4H), 2.20 (t, J = 2.5 Hz, 1H), 1.56 (q, J = 7.5 Hz, 2H), 1.41 (s, 9H), 0.93 
(t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 166.70, 166.15, 165.69, 156.32, 
81.03, 79.27, 71.00, 42.60, 41.67, 40.68, 30.47, 28.53, 23.11, 11.58. HRMS for KSC-5-







yl)amino)ethyl)acetamide (KSC-5): KSC-5-int was deprotected using a 50% solution of 
TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 31.3 mg, 0.1256 mmol) and triethylamine (1.5 eq, 
19.0 mg, 0.1884 mmol) in DCM (0.025 M, 5 mL), chloroacetyl chloride (1.2 eq, 17.0 mg, 
0.1507 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
5 (23.5 mg, 58%). 1H NMR (500 MHz, Chloroform-d) δ 4.30 – 4.12 (m, 2H), 4.04 (s, 2H), 
3.73 – 3.22 (m, 6H), 2.30 – 2.21 (m, 1H), 1.35 – 1.15 (m, 2H), 0.95 (d, J = 7.8 Hz, 3H). 
13C NMR (151 MHz, Acetone-d6) δ 167.50, 163.27, 152.84, 76.67, 74.19, 72.96, 51.02, 
45.41, 43.36, 41.60, 40.25, 39.27, 37.53, 24.38, 23.33, 14.36, 11.23. HRMS for KSC-5: 







yl)amino)ethyl)carbamate (KSC-6-int): To a solution of BBII (1.0 eq, 47.1 mg, 0.1441 
mmol) and diisopropylethylamine (2.4 eq, 44.7 mg, 0.3459 mmol) in THF (0.03 M, 5 mL), 
2-ethylbutylamine (2.4 eq, 35.0 mg, 0.3459 mmol) was added dropwise at room 
temperature. The solution was then allowed to heat to reflux while stirring and continued 
to reflux for 24 hours. After the reaction was complete, the solvent was removed in vacuo. 
The crude product was purified via flash chromatography to afford the desired to product, 
KSC-6-int as an oil (46.4 mg, 82%). 1H NMR (600 MHz, Chloroform-d) δ 4.17 (s, 2H), 
3.48 (s, 2H), 3.29 (s, 4H), 2.20 (t, J = 2.6 Hz, 1H), 1.42 (s, 9H), 1.33 (p, J = 7.2 Hz, 4H), 
1.25 (d, J = 2.7 Hz, 1H), 0.89 (t, J = 7.4 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 
166.38, 165.59, 156.32, 81.00, 79.29, 71.01, 43.15, 41.71, 41.27, 40.70, 30.52, 29.83, 







yl)amino)ethyl)acetamide (KSC-6): KSC-6-int was deprotected using a 50% solution of 
TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 34.5 mg, 0.1185 mmol) and triethylamine (1.5 eq, 
18.0 mg, 0.1778 mmol) in DCM (0.025 M, 5 mL), chloroacetyl chloride (1.2 eq, 16.1 mg, 
0.1422 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
6 (31.0 mg, 71%). 1H NMR (500 MHz, Chloroform-d) δ 4.28 – 4.10 (m, 2H), 4.04 (s, 2H), 
3.71 – 3.22 (m, 4H), 2.32 – 2.20 (m, 1H), 1.42 – 1.30 (m, 10H), 1.25 (d, J = 2.4 Hz, 3H). 
13C NMR (151 MHz, Acetone-d6) δ 167.50, 163.27, 152.84, 76.67, 74.19, 72.96, 51.02, 
45.41, 43.36, 41.60, 40.25, 39.27, 37.53, 24.38, 23.33, 14.36, 11.23. HRMS for KSC-6: 





yl)amino)ethyl)carbamate (KSC-7-int): To a solution of BBII (1.0 eq, 53.9 mg, 0.1649 
mmol) and diisopropylethylamine (2.4 eq, 51.1 mg, 0.3956 mmol) in THF (0.03 M, 5 mL), 
111 
 
4-phenylbutylamine (2.4 eq, 59.0 mg, 0.3956 mmol) was added dropwise at room 
temperature. The solution was then allowed to heat to reflux while stirring and continued 
to reflux for 24 hours. After the reaction was complete, the solvent was removed in vacuo. 
The crude product was purified via flash chromatography to afford the desired to product, 
KSC-7-int as an oil (70.7 mg, 98%). 1H NMR (600 MHz, Chloroform-d) δ 7.30 – 7.23 (m, 
2H), 7.17 (t, J = 8.1 Hz, 3H), 4.31 – 3.99 (m, 2H), 3.53 – 3.13 (m, 6H), 2.63 (t, J = 7.6 Hz, 
2H), 2.19 (s, 1H), 1.67 (q, J = 7.8 Hz, 2H), 1.58 (t, J = 7.8 Hz, 2H), 1.42 (s, 9H). 13C NMR 
(151 MHz, Chloroform-d) δ 166.15, 156.31, 142.34, 128.52, 125.88, 81.01, 79.29, 71.02, 
41.61, 40.71, 40.61, 35.69, 30.49, 29.83, 29.54, 28.81, 28.54, 14.33, 1.15. HRMS for KSC-





yl)amino)ethyl)acetamide (KSC-7): KSC-7-int was deprotected using a 50% solution of 
TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 54.6 mg, 0.1608 mmol) and triethylamine (1.5 eq, 
24.4 mg, 0.2412 mmol) in DCM (0.03 M, 5 mL), chloroacetyl chloride (1.2 eq, 21.8 mg, 
0.1930 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
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at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
7 (47.9 mg, 72%). 1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.24 (m, 2H), 7.23 – 7.10 
(m, 3H), 4.29 – 4.09 (m, 2H), 4.06 (s, 2H), 3.71 – 3.31 (m, 4H), 2.71 – 2.56 (m, 1H), 1.65 
(d, J = 16.0 Hz, 4H), 1.41 – 1.17 (m, 4H). 13C NMR (126 MHz, Chloroform-d) δ 167.00, 
141.93, 128.52, 126.04, 78.42, 72.40, 53.56, 42.72, 41.52, 40.83, 40.01, 39.34, 35.54, 





yl)amino)ethyl)carbamate (KSC-9-int): To a solution of BBII (1.0 eq, 92.8 mg, 0.2840 
mmol) and diisopropylethylamine (4.0 eq, 146.8 mg, 1.1359 mmol) in THF (0.05 M, 5 
mL), 2-phenethylamine hydrochloride (4.0 eq, 137.7 mg, 1.1359 mmol) was added 
dropwise at room temperature. The solution was then allowed to heat to reflux while 
stirring and continued to reflux for 24 hours. After the reaction was complete, the solvent 
was removed in vacuo. The crude product was purified via flash chromatography to afford 
the desired to product, KSC-9-int as an oil (57.1 mg, 49%). 1H NMR (500 MHz, 
Chloroform-d) δ 7.29 (t, J = 7.6 Hz, 2H), 7.20 (d, J = 7.2 Hz, 3H), 5.82 – 4.91 (m, 4H), 
4.15 (d, J = 17.4 Hz, 2H), 3.74 – 3.38 (m, 4H), 3.29 (s, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.19 
113 
 
(s, 1H), 1.41 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 166.87, 166.31, 165.96, 
156.58, 139.64, 129.17, 126.70, 81.29, 79.56, 71.27, 42.43, 40.95, 36.40, 30.71, 30.06, 





yl)amino)ethyl)acetamide (KSC-9): KSC-9-int was deprotected using a 50% solution of 
TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 125.5 mg, 0.4030 mmol) and triethylamine (1.3 eq, 
53.0 mg, 0.5239 mmol) in DCM (0.08 M, 5 mL), chloroacetyl chloride (1.3 eq, 59.2 mg, 
0.5239 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
9 (26.9 mg, 17%). 1H NMR (500 MHz, Chloroform-d) δ 7.46 – 7.28 (m, 3H), 7.25 – 7.18 
(m, 2H), 4.23 (m, 2H), 4.16 – 3.98 (m, 2H), 3.79 – 3.45 (m, 6H), 2.90 (dt, J = 17.7, 8.8 Hz, 
2H), 2.36 – 2.22 (m, 1H). 13C NMR (126 MHz, Chloroform-d) δ 174.40, 156.18, 137.95, 
128.60, 126.62, 101.36, 72.19, 49.42, 42.32, 39.84, 39.20, 35.38, 31.04, 30.06, 29.60, 







yl)amino)ethyl)carbamate (KSC-10-int): To a solution of BBII (1.0 eq, 51.6 mg, 0.1580 
mmol) and diisopropylethylamine (2.5 eq, 51.1 mg, 0.3950 mmol) in THF (0.03 M, 5 mL), 
dodecylamine (2.5 eq, 73.2 mg, 0.3950 mmol) was added dropwise at room temperature. 
The solution was then allowed to heat to reflux while stirring and continued to reflux for 
24 hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
product was purified via flash chromatography to afford the desired to product, KSC-10-
int as an oil (53.5 mg, 71%). 1H NMR (500 MHz, Chloroform-d) δ 5.78 – 4.84 (m, 4H), 
4.15 (s, 2H), 3.57 – 3.18 (m, 6H), 2.20 (t, J = 2.5 Hz, 1H), 1.59 – 1.46 (m, 2H), 1.41 (s, 
9H), 1.37 – 1.17 (m, 18H), 0.87 (t, J = 6.9 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 
165.93, 156.55, 134.07, 129.61, 93.58, 81.10, 79.53, 71.29, 41.78, 41.09, 32.26, 30.74, 
30.08, 30.01, 29.97, 29.94, 29.73, 29.69, 28.75, 27.29, 23.03, 14.46, 1.36. HRMS for KSC-







yl)amino)ethyl)acetamide (KSC-10): KSC-10-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 24.6 mg, 0.0656 mmol) and triethylamine (2.0 eq, 
23.3 mg, 0.1310 mmol) in DCM (0.01 M, 5 mL), chloroacetyl chloride (2.0 eq, 14.8 mg, 
0.1310 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
10 (19.1 mg, 64%). 1H NMR (600 MHz, Chloroform-d) δ 4.28 – 4.16 (m, 2H), 4.09 (s, 
2H), 3.72 – 3.48 (m, 4H), 3.47 – 3.27 (m, 2H), 2.39 – 2.16 (m, 1H), 1.70 – 1.46 (m, 2H), 
1.40 – 1.06 (m, 18H), 0.87 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 
167.40, 163.20, 156.28, 155.49, 117.09, 115.16, 72.23, 72.05, 71.93, 71.84, 42.35, 40.88, 
39.93, 31.81, 31.09, 30.28, 29.53, 29.25, 28.88, 26.59, 22.59, 14.01. HRMS for KSC-10: 







yl)amino)ethyl)carbamate (KSC-11-int): To a solution of BBII (1.0 eq, 50.9 mg, 0.1560 
mmol) and diisopropylethylamine (2.5 eq, 50.9 mg, 0.3890 mmol) in THF (0.03 M, 5 mL), 
pentadecylamine (2.5 eq, 88.6 mg, 0.3890 mmol) was added at room temperature. The 
solution was then allowed to heat to reflux while stirring and continued to reflux for 24 
hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
product was purified via flash chromatography to afford the desired to product, KSC-11-
int as an oil (59.6 mg, 74%). 1H NMR (600 MHz, Chloroform-d) δ 4.13 (d, J = 15.5 Hz, 
2H), 3.43 (d, J = 25.5 Hz, 2H), 3.37 – 3.06 (m, 4H), 2.19 (d, J = 2.5 Hz, 1H), 1.58 – 1.46 
(m, 2H), 1.40 (s, 9H), 1.23 (s, 26H), 0.85 (t, J = 7.0 Hz, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 166.78, 166.28, 165.90, 156.52, 81.35, 79.36, 71.13, 41.73, 41.00, 40.80, 
38.48, 32.21, 30.56, 30.08, 29.98, 29.94, 29.91, 29.83, 29.70, 29.65, 29.54, 28.70, 27.28, 








yl)amino)ethyl)acetamide (KSC-11): KSC-11-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 20.3 mg, 0.0487 mmol) and triethylamine (2.0 eq, 
9.9 mg, 0.0973 mmol) in DCM (0.01 M, 5 mL), chloroacetyl chloride (2.0 eq, 11.0 mg, 
0.0973 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
11 (17.6 mg, 73%). 1H NMR (500 MHz, Chloroform-d) δ 4.21 (s, 2H), 4.04 (d, J = 3.8 Hz, 
2H), 3.70 – 3.24 (m, 6H), 2.24 (s, 1H), 1.56 (s, 2H), 1.25 (s, 24H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (151 MHz, Chloroform-d) δ 170.10, 166.38, 158.26, 119.83, 117.90, 81.15, 
79.88, 79.67, 79.45, 74.96, 74.67, 45.09, 44.19, 43.60, 42.65, 41.97, 34.56, 33.82, 33.00, 








yl)amino)ethyl)carbamate (KSC-12-int): To a solution of BBII (1.0 eq, 52.0 mg, 0.1590 
mmol) and diisopropylethylamine (2.5 eq, 51.0 mg, 0.3980 mmol) in THF (0.03 M, 5 mL), 
isoamylamine (2.5 eq, 35.0 mg, 0.3980 mmol) was added dropwise at room temperature. 
The solution was then allowed to heat to reflux while stirring and continued to reflux for 
24 hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
product was purified via flash chromatography to afford the desired to product, KSC-12-
int as an oil (49.5 mg, 83%). 1H NMR (600 MHz, Chloroform-d) δ 4.16 (s, 2H), 3.58 – 
3.17 (m, 6H), 2.20 (t, J = 2.5 Hz, 1H), 1.63 (dq, J = 13.5, 6.7 Hz, 1H), 1.41 (s, 11H), 0.91 
(d, J = 6.6 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 166.00, 156.34, 80.99, 79.31, 
71.01, 41.60, 40.72, 39.02, 38.85, 30.48, 28.54, 25.81, 22.71, 22.65. HRMS for KSC-12-







yl)amino)ethyl)acetamide (KSC-12): KSC-12-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 36.4 mg, 0.1310 mmol) and triethylamine (2.0 eq, 
26.5 mg, 0.2620 mmol) in DCM (0.025 M, 5 mL), chloroacetyl chloride (2.0 eq, 29.5 mg, 
0.2620 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
12 (18.2 mg, 40%). 1H NMR (500 MHz, Chloroform-d) δ 4.18 m, 2H), 4.05 (s, 2H), 3.56 
(s, 2H), 3.52 (m, 1H), 3.46 (s, 2H), 2.27 (t, J = 10.7 Hz, 1H), 1.64 (s, 2H), 1.55 – 1.37 (m, 
2H), 0.94 (t, J = 8.1 Hz, 6H). 13C NMR (151 MHz, Chloroform-d) δ 183.42, 166.94, 
163.75, 115.53, 114.73, 42.76, 40.04, 39.56, 37.95, 31.25, 30.54, 30.30, 29.85, 25.82, 





yl)amino)ethyl)carbamate (KSC-13-int): To a solution of BBII (1.0 eq, 193.3 mg, 
120 
 
0.5915 mmol) and diisopropylethylamine (4.0 eq, 305.8 mg, 2.3661 mmol) in THF (0.1 M, 
5 mL), cyclododecylamine hydrochloride (4.0 eq, 433.8 mg, 2.3661 mmol) was added at 
room temperature. The solution was then allowed to heat to reflux while stirring and 
continued to reflux for 24 hours. After the reaction was complete, the solvent was removed 
in vacuo. The crude product was purified via flash chromatography to afford the desired to 
product, KSC-13-int as an oil (136.6 mg, 49%). 1H NMR (500 MHz, Chloroform-d) δ 4.25 
– 4.08 (m, 2H), 3.46 (s, 2H), 3.28 (s, 2H), 2.20 (t, J = 2.4 Hz, 1H), 1.86 (m, 2H), 1.71 – 
1.62 (m, 2H), 1.55 (m, 18H), 1.41 (d, J = 2.5 Hz, 9H), 1.29 – 1.21 (m, 1H). 13C NMR (126 
MHz, Chloroform-d) δ 166.29, 165.61, 156.26, 81.32, 79.04, 70.90, 55.66, 47.69, 46.07, 
41.47, 40.41, 33.27, 31.17, 30.26, 29.36, 28.41, 24.30, 23.80, 23.60, 23.46, 21.88, 21.39, 





yl)amino)ethyl)acetamide (KSC-13): KSC-13-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 107.7 mg, 0.2883 mmol) and triethylamine (1.3 eq, 
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37.9 mg, 0.3748 mmol) in DCM (0.06 M, 5 mL), chloroacetyl chloride (1.3 eq, 42.3 mg, 
0.3748 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
13 (36.0 mg, 28%). 1H NMR (500 MHz, Chloroform-d) δ 4.32 – 4.15 (m, 3H), 4.07 (s, 
2H), 3.77 – 3.42 (m, 4H), 2.04 (t, 1H), 1.59 – 1.05 (m, 22H). 13C NMR (126 MHz, 
Chloroform-d) δ 163.04, 155.11, 124.89, 117.45, 115.15, 78.69, 72.14, 60.57, 47.78, 42.53, 
39.88, 30.88, 30.63, 30.37, 29.85, 24.01, 23.76, 23.38, 23.08, 21.89, 21.68, 14.33. HRMS 





yl)amino)ethyl)carbamate (KSC-14-int): To a solution of BBII (1.0 eq, 188.5 mg, 
0.5768 mmol) and diisopropylethylamine (4.0 eq, 298.2 mg, 2.3073 mmol) in THF (0.06 
M, 10 mL), cyclooctylamine (4.0 eq, 293.6 mg, 2.3073 mmol) was added dropwise at room 
temperature. The solution was then allowed to heat to reflux while stirring and continued 
to reflux for 24 hours. After the reaction was complete, the solvent was removed in vacuo. 
The crude product was purified via flash chromatography to afford the desired to product, 
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KSC-14-int as an oil (158.3 mg, 66%). 1H NMR (500 MHz, Chloroform-d) δ 4.12 (s, 2H), 
3.44 (s, 2H), 3.24 (s, 2H), 2.17 (d, J = 2.6 Hz, 1H), 1.87 – 1.73 (m, 2H), 1.56 – 1.42 (m, 
13H), 1.36 (s, 9H). 13C NMR (126 MHz, Chloroform-d) δ 166.37, 165.62, 164.90, 156.24, 
81.22, 79.02, 70.88, 50.04, 41.56, 40.42, 32.48, 30.27, 28.40, 27.19, 25.83, 23.87. HRMS 





yl)amino)ethyl)acetamide (KSC-14): KSC-14-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 120.3 mg, 0.3791 mmol) and triethylamine (1.3 eq, 
49.9 mg, 0.4927 mmol) in DCM (0.08 M, 5 mL), chloroacetyl chloride (1.3 eq, 55.6 mg, 
0.4927 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
14 (47.6 mg, 31%). 1H NMR (500 MHz, Chloroform-d) δ 4.24 – 3.99 (m, 4H), 3.71 – 3.49 
(m, 4H), 2.57 – 2.53 (m, 1H), 2.44 (s, 1H), 1.76 – 1.44 (m, 14H). 13C NMR (126 MHz, 
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Chloroform-d) δ 163.62, 144.81, 142.28, 129.95, 128.43, 125.89, 70.64, 51.58, 39.68, 
35.79, 32.27, 30.85, 29.84, 28.84, 27.02, 25.13, 23.87, 21.76. HRMS for KSC-14: m/z 





yl)amino)ethyl)carbamate (KSC-23-int): To a solution of BBII (1.0 eq, 53.4 mg, 0.1634 
mmol) and diisopropylethylamine (4.0 eq, 84.5 mg, 0.6536 mmol) in THF (0.03 M, 5 mL), 
racemic 1-aminobutan-2-ol (4.0 eq, 58.3 mg, 0.6536 mmol) was added dropwise at room 
temperature. The solution was then allowed to heat to reflux while stirring and continued 
to reflux for 24 hours. After the reaction was complete, the solvent was removed in vacuo. 
The crude product was purified via flash chromatography to afford the desired to product, 
KSC-23-int as an oil (48.8 mg, 79%). 1H NMR (600 MHz, Chloroform-d) δ 5.57 (m, 2H), 
4.08 (dd, J = 13.1, 6.6 Hz, 2H), 3.50 (m, 3H), 3.30 – 2.92 (m, 3H), 2.18 (d, J = 2.6 Hz, 1H), 
1.48 – 1.39 (m, 1H), 1.36 (s, 9H), 0.90 (t, J = 7.6 Hz, 3H). 13C NMR (151 MHz, 
Chloroform-d) δ 166.03, 165.31, 156.35, 80.79, 79.21, 73.07, 70.98, 60.42, 46.53, 40.65, 








yl)amino)ethyl)acetamide (KSC-23): KSC-23-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 45.6 mg, 0.1632 mmol) and triethylamine (2.0 eq, 
32.3 mg, 0.3200 mmol) in DCM (0.04 M, 4 mL), chloroacetyl chloride (2.0 eq, 36.1 mg, 
0.3200 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
23 (23.4 mg, 40%). 1H NMR (600 MHz, Chloroform-d) δ 4.28 – 4.10 (m, 2H), 4.06 (s, 
2H), 3.98 – 3.69 (m, 1H), 3.68 – 3.48 (m, 4H), 2.38 – 2.20 (m, 1H), 1.76 (ddq, J = 22.3, 
15.2, 7.5 Hz, 2H), 1.34 – 1.14 (m, 3H), 0.98 (dt, J = 20.8, 8.1 Hz, 3H). 13C NMR (151 
MHz, Chloroform-d) δ 171.18, 167.42, 163.46, 156.28, 117.10, 115.17, 113.45, 72.14, 








triazin-2-yl)amino)ethyl)carbamate (KSC-24-int): To a solution of BBII (1.0 eq, 132.8 
mg, 0.4064 mmol) and diisopropylethylamine (2.0 eq, 105.0 mg, 0.8128 mmol) in THF 
(0.08 M, 5 mL), vanillylamine hydrochloride (2.0 eq, 124.5 mg, 0.8128 mmol) was added 
at room temperature. The solution was then allowed to heat to reflux while stirring and 
continued to reflux for 24 hours. After the reaction was complete, the solvent was removed 
in vacuo. The crude product was purified via flash chromatography to afford the desired to 
product, KSC-24-int as a solid (61.7 mg, 34%). 1H NMR (600 MHz, Chloroform-d) δ 6.84 
– 6.79 (m, 1H), 6.77 (s, 2H), 4.44 (s, 2H), 4.13 (s, 2H), 3.75 (s, 3H), 3.45 (s, 2H), 3.25 (s, 
2H), 2.18 (s, 1H), 1.41 (s, 9H). 13C NMR (151 MHz, Chloroform-d) δ 165.49, 156.10, 
146.77, 144.92, 130.74, 120.53, 114.72, 110.53, 79.12, 70.87, 60.29, 55.77, 44.52, 41.31, 








1,3,5-triazin-2-yl)amino)ethyl)acetamide (KSC-24): KSC-24-int was deprotected using 
a 50% solution of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in 
vacuo and the crude product remained on the vacuum overnight to remove any excess TFA. 
Then, to an ice cold solution of deprotected amine (1.0 eq, 29.7 mg, 0.0865 mmol) and 
triethylamine (1.5 eq, 13.1 mg, 0.1298 mmol) in DCM (0.04 M, 2 mL), chloroacetyl 
chloride (1.2 eq, 11.7 mg, 0.1040 mmol) in DCM (2 mL) was added dropwise over 30 min. 
The reaction was stirred at 0 °C for 3 hours. After the reaction was complete, the solvent 
was removed in vacuo and the crude product was purified by flash chromatography to give 
the desired product KSC-24 (8.0 mg, 22%). 1H NMR (600 MHz, DMSO-d6) δ 6.92 (s, 1H), 
6.71 (d, J = 21.5 Hz, 2H), 4.34 (s, 2H), 4.02 (m, 3H), 3.73 (s, 4H), 3.26 – 2.97 (m, 4H), 
2.08 (s, 1H). 13C NMR (151 MHz, DMSO-d6) δ 166.04, 147.27, 145.27, 119.64, 115.09, 
111.80, 55.57, 42.63, 33.64, 31.27, 30.68, 29.34, 28.99, 28.71, 28.52, 24.47, 22.07, 13.94. 







yl)amino)ethyl)carbamate (KSC-25-int): To a solution of BBII (1.0 eq, 130.3 mg, 
0.3999 mmol) and diisopropylethylamine (2.0 eq, 103.4 mg, 0.7999 mmol) in THF (0.08 
M, 5 mL), 3-phenyl-1-propylamine (2.0 eq, 108.2 mg, 0.7999 mmol) was added dropwise 
at room temperature. The solution was then allowed to heat to reflux while stirring and 
continued to reflux for 24 hours. After the reaction was complete, the solvent was removed 
in vacuo. The crude product was purified via flash chromatography to afford the desired to 
product, KSC-25-int as a solid (72.6 mg, 43%). 1H NMR (500 MHz, Chloroform-d) δ 7.29 
– 7.23 (m, 2H), 7.19 – 7.13 (m, 3H), 4.24 – 4.06 (m, 2H), 3.52 – 3.40 (m, 2H), 3.40 – 3.31 
(m, 4H), 3.27 (s, 2H), 2.65 (t, J = 7.8 Hz, 2H), 2.20 (t, J = 2.5 Hz, 1H), 1.41 (s, 9H). 13C 
NMR (126 MHz, Chloroform-d) δ 166.13, 165.65, 156.29, 141.73, 128.46, 128.42, 125.92, 
81.10, 79.20, 70.96, 41.54, 40.60, 40.27, 33.24, 31.44, 30.97, 30.35, 28.49. HRMS for 







yl)amino)ethyl)acetamide (KSC-25): KSC-25-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
solution of deprotected amine (1.0 eq, 55.5 mg, 0.1705 mmol) and triethylamine (3.0 eq, 
51.8 mg, 0.5116 mmol) in DCM (0.08 M, 2 mL), chloroacetyl chloride (3.0 eq, 57.8 mg, 
0.5116 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
25 (36.9 mg, 54%). 1H NMR (600 MHz, Chloroform-d) δ 7.26 (d, J = 5.7, 3.9 Hz, 2H), 
7.17 (t, J = 5.8 Hz, 3H), 4.25 – 4.08 (m, 2H), 4.07 (s, 2H), 3.54 (s, 2H), 3.49 (s, 2H), 3.46 
– 3.32 (m, 2H), 2.77 – 2.56 (m, 2H), 2.28 – 2.18 (m, 1H), 1.91 (dt, J = 25.9, 7.4 Hz, 2H). 
13C NMR (151 MHz, Chloroform-d) δ 163.23, 156.22, 141.12, 128.50, 126.15, 117.25, 
115.34, 78.63, 72.26, 42.41, 40.48, 40.24, 32.95, 31.15, 30.29, 29.83, 8.40. HRMS for 







yl)amino)ethyl)carbamate (KSC-26-int): To a solution of BBII (1.0 eq, 57.0 mg, 0.1744 
mmol) and diisopropylethylamine (2.0 eq, 45.1 mg, 0.3489 mmol) in THF (0.03 M, 5 mL), 
5-phenyl-1-pentylamine (2.0 eq, 57.0 mg, 0.3489 mmol) was added at room temperature. 
The solution was then allowed to heat to reflux while stirring and continued to reflux for 
24 hours. After the reaction was complete, the solvent was removed in vacuo. The crude 
product was purified via flash chromatography to afford the desired to product, KSC-26-
int as a solid (47.3 mg, 60%). 1H NMR (600 MHz, Chloroform-d) δ 7.26 (p, J = 5.2, 4.0 
Hz, 2H), 7.16 (d, J = 7.9 Hz, 3H), 4.29 – 4.02 (m, 2H), 3.45 (s, 2H), 3.30 (d, J = 31.8 Hz, 
4H), 2.66 – 2.50 (m, 2H), 2.18 (d, J = 20.0 Hz, 1H), 1.71 – 1.50 (m, 4H), 1.41 (d, J = 6.0 
Hz, 11H). 13C NMR (151 MHz, Chloroform-d) δ 166.08, 156.31, 142.60, 128.47, 128.38, 
125.77, 81.05, 79.26, 70.99, 41.58, 40.69, 35.96, 31.28, 30.43, 29.76, 28.53, 26.67, 22.75, 





yl)amino)ethyl)acetamide (KSC-26): KSC-26-int was deprotected using a 50% solution 
of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and the crude 
product remained on the vacuum overnight to remove any excess TFA. Then, to an ice cold 
130 
 
solution of deprotected amine (1.0 eq, 36.2 mg, 0.1024 mmol) and triethylamine (4.0 eq, 
46.2 mg, 0.4096 mmol) in DCM (0.05 M, 2 mL), chloroacetyl chloride (4.0 eq, 41.4 mg, 
0.4096 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction was stirred 
at 0 °C for 3 hours. After the reaction was complete, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography to give the desired product KSC-
26 (18.9 mg, 43%). 1H NMR (500 MHz, Chloroform-d) δ 7.29 (s, 2H), 7.22 – 7.14 (m, 
3H), 4.27 – 4.17 (m, 2H), 4.05 (s, 2H), 3.66 – 3.49 (m, 4H), 3.46 – 3.30 (m, 2H), 2.62 (dt, 
J = 12.6, 6.1 Hz, 2H), 2.26 (t, J = 2.5 Hz, 1H), 1.64 (dd, J = 17.7, 9.6 Hz, 6H). 13C NMR 
(126 MHz, Chloroform-d) δ 200.82, 139.88, 138.15, 128.77, 128.71, 126.15, 77.67, 77.41, 
77.16, 51.65, 42.93, 36.13, 31.34, 30.11, 29.30, 26.70. HRMS for KSC-26: m/z calcd. 





triazin-2-yl)amino)ethyl)carbamate (KSC-34-int): To a solution of BBII (1.0 eq, 105.8 
mg, 0.3238 mmol) and diisopropylethylamine (2.0 eq, 83.7 mg, 0.6475 mmol) in THF 
(0.06 M, 5 mL), N-methyl-4-phenyl-1-butylamine hydrochloride (2.0 eq, 129.3 mg, 0.6475 
mmol) was added at room temperature. The solution was then allowed to heat to reflux 
while stirring and continued to reflux for 24 hours. After the reaction was complete, the 
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solvent was removed in vacuo. The crude product was purified via flash chromatography 
to afford the desired to product, KSC-34-int as a solid (100.8 mg, 69%). 1H NMR (600 
MHz, Chloroform-d) δ 7.31 – 7.20 (m, 2H), 7.20 – 7.11 (m, 3H), 5.27 (m, 3H), 4.11 (q, J 
= 7.1 Hz, 2H), 3.49 (d, J = 69.7 Hz, 4H), 3.27 (s, 2H), 3.04 (s, 3H), 2.64 (q, J = 6.7, 5.2 
Hz, 2H), 2.24 – 2.08 (m, 1H), 1.62 (d, J = 7.8 Hz, 4H), 1.41 (s, 9H). 13C NMR (151 MHz, 
Chloroform-d) δ 171.16, 165.19, 156.23, 142.46, 128.46, 128.33, 125.76, 79.05, 70.72, 
60.43, 40.63, 35.74, 34.35, 30.37, 29.75, 28.71, 28.48, 27.10, 21.09, 14.26. HRMS for 





triazin-2-yl)amino)ethyl)acetamide (KSC-34): KSC-34-int was deprotected using a 
50% solution of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo 
and the crude product remained on the vacuum overnight to remove any excess TFA. Then, 
to an ice cold solution of deprotected amine (1.0 eq, 100.8 mg, 0.2852 mmol) and 
triethylamine (1.3 eq, 37.5 mg, 0.3707 mmol) in DCM (0.15 M, 2 mL), chloroacetyl 
chloride (1.3 eq, 41.9 mg, 0.3707 mmol) in DCM (2 mL) was added dropwise over 30 min. 
The reaction was stirred at 0 °C for 3 hours. After the reaction was complete, the solvent 
was removed in vacuo and the crude product was purified by flash chromatography to give 
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the desired product KSC-34 (35.3 mg, 29%). 1H NMR (600 MHz, Chloroform-d) δ 7.28 
(dt, J = 7.9, 4.0 Hz, 2H), 7.21 – 7.13 (m, 3H), 4.30 – 3.97 (m, 4H), 3.75 – 3.44 (m, 6H), 
3.15 (d, J = 3.3 Hz, 3H), 2.65 (t, J = 7.0, 3.3 Hz, 2H), 2.10 (s, 1H), 1.74 – 1.58 (m, 4H). 
13C NMR (151 MHz, Chloroform-d) δ 162.98, 162.01, 154.53, 141.82, 128.33, 128.29, 
125.85, 117.03, 115.10, 78.28, 71.44, 49.59, 49.38, 42.18, 35.51, 30.85, 30.18, 29.64, 




4,6-dichloro-N-propyl-1,3,5-triazin-2-amine (BBIna): To an ice cold solution of 
cyanuric chloride (1.0 eq, 521.0 mg, 2.8252 mmol) and diisopropylethylamine (1.1 eq, 
401.6 mg, 3.1077 mmol) in tetrahydrofuran (THF) (0.043 M, 65.4 mL), propylamine (1.2 
eq, 200.4 mg, 3.3903 mmol) was added dropwise. The reaction mixture was allowed to stir 
at 0 °C for 3 hours. The solvent was removed in vacuo and the crude product was purified 
via flash chromatography to give the desired product BBIna as a white solid (534.6 mg, 
91%). 1H NMR (600 MHz, Chloroform-d) δ 6.75 (d, J = 6.4 Hz, 1H), 3.58 – 3.20 (m, 2H), 
1.63 (h, J = 7.4 Hz, 2H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR (151 MHz, Chloroform-d) δ 








(BBIIna): To a solution of BBIna (1.0 eq, 534.6 mg, 2.5820 mmol) and sodium carbonate 
(2.2 eq, 602 mg, 5.68 mmol) in ethanol (0.09 M, 30 mL), N-Boc-ethylenediamine (1.1eq, 
445 mg, 2.84 mmol) was added dropwise at room temperature. The solution was then 
allowed to warm to 45 °C while stirring and continued to stir for 18 hours. After the reaction 
was complete, 15 mL of water was added and the reaction was extracted with ethyl acetate 
(3 x 15 mL). The organic layer was washed with brine and dried with MgSO4, then the 
solvent was removed in vacuo. The crude product was purified via flash chromatography 
to afford the desired to product, BBIIna as a white solid (695.1 mg, 81%). 1H NMR (500 
MHz, Chloroform-d) δ 6.05 (d, J = 100.2 Hz, 1H), 5.80 – 5.40 (m, 1H), 5.38 – 4.72 (m, 
1H), 3.64 – 3.43 (m, 2H), 3.43 – 3.24 (m, 4H), 1.69 – 1.52 (m, 2H), 1.43 (s, 9H), 1.04 – 
0.85 (m, 3H). 13C NMR (126 MHz, Chloroform-d) δ 197.31, 166.14, 156.46, 96.43, 46.67, 








yl)amino)ethyl)carbamate (KSC-34na-int): To a solution of BBIIna (1.0 eq, 30.2 mg, 
0.0913 mmol) and diisopropylethylamine (4.0 eq, 47.2 mg, 0.3652 mmol) in THF (0.02 M, 
5 mL), N-methyl-4-phenyl-1-butylamine hydrochloride (2.0 eq, 36.5 mg, 0.1826 mmol) 
was added at room temperature. The solution was then allowed to heat to reflux while 
stirring and continued to reflux for 24 hours. After the reaction was complete, the solvent 
was removed in vacuo. The crude product was purified via flash chromatography to afford 
the desired to product, KSC-34na-int as a solid (23.6 mg, 57%). 1H NMR (600 MHz, 
Chloroform-d) δ 7.29 – 7.24 (m, 3H), 7.19 – 7.15 (m, 3H), 5.76 (s, 1H), 4.96 (s, 1H), 4.76 
(s, 1H), 3.56 (s, 2H), 3.47 (s, 2H), 3.29 (s, 3H), 3.04 (s, 3H), 2.77 – 2.48 (m, 2H), 1.67 – 
1.58 (m, 2H), 1.42 (s, 9H), 1.26 (d, J = 1.4 Hz, 4H), 0.94 (t, J = 7.4 Hz, 3H). 13C NMR 
(151 MHz, Chloroform-d) δ 157.23, 146.95, 145.10, 131.04, 130.91, 128.33, 79.86, 79.65, 
79.44, 47.28, 45.14, 43.19, 38.33, 32.35, 31.32, 31.07, 29.73, 25.73, 14.16. HRMS for 







yl)amino)ethyl)acetamide (KSC-34na): KSC-34na-int was deprotected using a 50% 
solution of TFA/DCM (4 mL) at 25 °C for 2 hours. The solvent was removed in vacuo and 
the crude product remained on the vacuum overnight to remove any excess TFA. Then, to 
an ice cold solution of deprotected amine (1.0 eq, 81.8 mg, 0.2288 mmol) and triethylamine 
(3.0 eq, 69.5 mg, 0.6864 mmol) in DCM (0.02 M, 10 mL), chloroacetyl chloride (3.0 eq, 
77.5 mg, 0.6864 mmol) in DCM (2 mL) was added dropwise over 30 min. The reaction 
was stirred at 0 °C for 3 hours. After the reaction was complete, the solvent was removed 
in vacuo and the crude product was purified by flash chromatography to give the desired 
product KSC-34na (95.5 mg, 96%). 1H NMR (500 MHz, Chloroform-d) δ 7.28 (t, J = 7.7 
Hz, 2H), 7.20 (d, J = 7.3 Hz, 1H), 7.16 (t, J = 6.7 Hz, 2H), 3.71 – 3.47 (m, 6H), 3.39 – 3.28 
(m, 2H), 3.13 (s, 3H), 2.70 – 2.58 (m, 2H), 1.74 – 1.50 (m, 6H), 1.25 (s, 2H), 0.94 (dt, J = 
12.9, 7.5 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 166.09, 141.94, 128.55, 128.43, 
126.11, 78.00, 49.50, 42.75, 39.91, 39.35, 35.72, 35.64, 35.36, 29.86, 28.68, 26.95, 22.58, 
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 Functional amino acids that display heightened levels of nucleophilicity tend to 
play roles in catalysis and regulation. The chemical modification of these nucleophiles is 
crucial for various applications from irreversible inhibitor development to activity-based 
protein profiling (ABPP). ABPP has become a powerful chemical proteomic strategy to 
directly characterize enzymatic functionality directly in native biological systems, on a 
global scale1. ABPP relies on the design of active-site directed covalent probes to 
interrogate various families of enzymes in complex proteomes, meanwhile providing a 
quantitative, chemical readout of the functional state of the individuals enzymes in that 
particular enzyme family1. Current ABPP scaffolds utilize a wide variety of chemical 
scaffolds, general electrophiles, natural products and mechanism-based inhibitors. It is also 
important to note that because the activity of an enzyme is regulated by a variety of 
posttranslational modifications and molecular mechanisms2-4, activity-based probes report 
can report on the structure and reactivity of an enzyme active site in the context of the cell. 
 The use of covalent small molecules in drug design and ABPP relies on selective, 
protein-reactive electrophiles. To date there have been many reported, well characterized 
electrophiles including, haloacetamides5-7, maleimides7, and α,β-unsaturated ketones5 
which have all shown selectivity for cysteine thiols. Other electrophiles which have shown 
diverse reactivities toward other amino acids are sulfonate esters (aspartate, glutamate, and 
tyrosine)5, acyl phophates (lysine)8, sulfonyl fluorides (serine and tyrosine)9-10, and 
fluorophosphonates (serine)11. Many of these electrophiles demonstrate high reactivity and 
functional group specificity, covalently modifiying proteins without the presence of a 




epoxysuccinates12, spiroepoxides13, carbamates14, acyloxymethyl ketones15, 
phenoxymethyl ketones16, and β-lactams14, which require the presence of a binding motif 
to facilitate the covalent conjugation of these electrophiles toward nucleophilic proteins of 
interest. 
 
3.1 Activity-Based Protein Profiling 
 Recent advances in genomic technologies, such as chromosomal translocation and 
gene amplification, have provided insights into relative gene expression levels inside the 
cell17-18.Other genomic technologies, such as transcriptional profiling and RNA-
interference-based gene silencing (RNAi) probe gene expressional level to deduce protein 
function, yet cannot fully realize the multitude of post translational modifications that 
regulate protein activity inside the cell. ABPP is a powerful chemical proteomic approach 
to directly interrogate protein functionality in the context on the cell. ABPP relies on active-
site directed covalent probes to interrogate various enzyme families within the proteome, 
and to provide a chemical readout of the functional state of those enzymes within that 
family1. 
 
3.1.1 ABPP Probe Design Features 
 Fundamentally, ABPP probes are small-molecules that covalently label the active 
site(s) of a given enzyme or enzyme family. An ideal electrophilic ABPP probe would 
target a large subset of enzymes, as to provide a global view of the functional state of that 
particular enzyme family. However, some probes, like iodoacetamide-alkyne (IA≡, Figure 




residues. Most ABPP probes reach a desired balance between coverage and promiscuity 
by combining reactive groups and binding groups that target conserved structural features 
in an enzyme active site(s) (Figure 3.1B)1. ABPP probes can contain two different classes 
of reactive groups, general electrophiles that modify nucleophilic residues or photoreactive 
groups that label proximal residues upon irradiation with UV light. The third and final 
element that ABPP probes must possess is a reporter element, to facilitate protein target 
characterization upon labeling. Reporter elements can include fluorophores for 
visualization, a biotin group for enrichment, or a biorthogonal handle, such as an azide or 
alkyne, for use in copper assisted azide-alkyne cycloaddition (CuAAC) reactions, “click 












Figure 3-1. (A) Chemical structure of promiscuous cysteine-reactive ABPP probe, 
iodoacetamide-alkyne. (B) Representative structure of an ABPP probe, containing a 
reactive group, a linker/binding group, and a reporter element. (C) Chemical structures of 
various common reporter elements used in ABPP for visualization (rhodamine, and 






3.2 The Tunability of Reactive Aryl Halides 
 The selective covalent modification of amino acid side chains requires the 
appropriate selection of an electrophile with the suitable affinity for the specific amino acid 
of interest. Toward this end, there are numerous electrophiles with high reactivity and 
selectivity for specific residues, and some electrophiles with disparate reactivity profiles in 
the context of the proteome. Due to the widespread application for covalent electrophiles 
with distinct and tunable reactivity profiles, in 2014, our lab reported on the reactivity and 
tenability of various aryl chloride-based electrophiles19. Arylation of the nucleophilic 
residue with these electrophiles proceeds via a nucleophilic aromatic substitution (SNAr) 
mechanism, similar to that during the conjugation of glutathione to activated aryl groups 
by glutathione S-tranferases (GSTs)20.  
 Previous members of the Weerapana lab, Alex Shannon and Ranjan Banerjee, 
synthesized a panel of alkyne-functionalized aryl chloride-based electrophiles and 
systematically evaluated the reactivity and selectivity of these compounds in the context of 
the proteome19. Initial studies began by investigating the reactivity of a panel of 
chloronitrobenzene (CNB) electrophiles. It was hypothesized that these electrophiles react 
via an SNAR mechanism and thus the rate limiting step would be the formation of the 
Meisenheimer complex21-22. Therefore, it was hypothesized that the reactivity of these aryl 
halide electrophiles can be tuned by varying the position of the electron withdrawing nitro 
substituent on the aromatic ring19. To test this hypothesis, four CNBs were synthesized 
varying the nitro electron withdrawing group (EWG) in the ortho (ERW1 and ERW2), 













Figure 3-2. (A) Chemical structures of the panel of alkyne-functionalized 
chloronitrobenzene probes evaluated. (B) In-gel fluorescence study of the reactivity of 






 To evaluate the reactivity of this panel of CNBs in complex proteomes, each probe 
was incubated in HeLa cell lysates at 100 µM for 1 hr, followed by the conjugation of 
rhodamine-azide (Rh-N3) using CuAAC. Following the separation of proteins on gel via 
SDS-PAGE, visualization of probe labeled proteins was performed using in-gel 
fluorescence (Figure 3-2B). As originally hypothesized, RB2 was the most reactive 
compound amongst the panel, owing to the nitro substituent in the para position and the 
increased resonance stabilization of the Meisenheimer complex. As indicated by the gel, 
shifting the EWG to the ortho position, as in ERW1 and ERW2, still showed reactivity, 
although much lower than RB2. Also, it can be seen that shifting the EWG to the meta 
position completely abrogates the reactivity of the probe. This study demonstrates that the 
proteome reactivity of CNBs can be finely adjusted by means of modulating the electronics 
and sterics of the aryl ring system19. 
 To further this exploration into the reactivity and selectivity of aryl halide 
electrophiles, the panel was then expanded to include a fluoronitrobenzene (ERW3), 
chloropyridines (RB3 and RB4), chloropyrimidines (RB5 and RB6), and a dichlorotriazine 
(RB7) (Figure 3-3A)19. In this instance, the reactivity of these compounds will be 
determined by the resonance stabilization realized by the nitrogen(s) in the aromatic ring 
system. Upon evaluation of this panel of compounds in a proteome, it was found that the 
fluoronitrobenzene, ERW3, exhibitied similar labeling to RB2 (Figure 3-3B). It was also 
shown that the chloropyridines, RB3 and RB4, and the chloropyrimidines (RB6 and RB6) 
all exhibited significantly decreased reactivity compared to that of RB2 as demonstrated 




potent labeling of the proteome compared to RB2, demonstrating the increased resonance 













Figure 3-3. (A) Chemical structures of the panel of alkyne-functionalized 
fluoronitrobenzene, chloropyridine, chloropyrimidine, and dichlorotriazine probes 
evaluated. (B) In-gel fluorescence study of the reactivity of aryl halide probes in HeLa 
lysates at 100 µM, followed by incorporation of rhodamine-azide (Rh-N3) using CuAAC 





 Initial screening efforts of the small panel of compounds identified RB2, ERW3, 
and RB7 as aryl halides with high reactivity in the proteome. However, RB7 was 
significantly more potent than RB2 and ERW3 (Figure 3-3B) and thus could not be directly 
compared to the latter at the screening concentration of 100 µM. In order to gain clarity on 
these electrophiles and to evaluate labeling patterns, Shannon et al decreased the probe 
concentrations of RB7 to 5 µM and RB2 and ERW3 to 20 µM, in order to better evaluate 
the probes directly to each other (Figure 3-4A)19. As shown in the in-gel fluorescence study 
with equipotent labeling, the dichlorotriazine, RB7, displays a distinct labeling pattern 
compared to that of the chloronitrobenzenes, RB2 and ERW3, suggesting that RB7 is 
targeting a distinct sub-population of proteins compared to the CNBs19. p-
Chloronitrobenzene compounds have recently been used in compounds that modify 
proteins with nucleophilic cysteine residues, including peroxisome proliferator-activated 
receptor (PPARγ)23 and β-tubulin24. To investigate if these compounds were labeling 
nucleophilic cysteine residues, as expected of the CNBs, a competition-based assay with 
the highly reactive, cysteine-selective electrophile, iodoacetamide (IA) was performed. To 
do this, lysates were either treated with vehicle (DMSO) or IA (2 mM) to cap the 
nucleophilic cysteine residues, followed by labeling with the panel of electrophilic 
compounds RB2 (20 µM), ERW3 (20 µM), or RB7 (1 µM) (Figure 3-4B). As indicated 
from the assay, labeling by RB2 and ERW3 was completely abolished by pre-treatment 
with IA to cap the nucleophilic cysteine residues in the proteome19. This suggests that these 
two electrophilic compounds selectively modify cysteine residues in a complex proteome. 
Interestingly, RB7 labeling of the proteome remained intact of pre-treatment with IA, 












Figure 3-4. (A) In-gel fluorescence studies comparing probe labeling patterns of RB2 (20 
µM), ERW3 (20 µM), and RB7 (20 µM). (B) Competition assay with IA comparing probe 





 To confirm the cysteine selectivity of RB2 and to identify the preferential labeling 
of RB7, a mass-spectrometry-based platform was employed to identify the site of labeling 
within the complex proteome, tandem orthogonal proteolysis activity-based protein 
profiling (TOP-ABPP). TOP-ABPP is a chemo-proteomic method which allows for the 
parallel characterization of probe-labeled proteins and for the sites of probe modification. 
This approach uses “click” chemistry to append a multifunctional tag onto alkyne-
functionalized probes which contains a biotin group for avidin enrichmentand a tobacco 
etch virus (TEV) protease cleavage site for selective release of the probe modified peptides. 
Following labeling and enrichment on streptavidin beads, protein targets are then digested 
and identified before releasing the probe-modified peptides from the beads for site-of-
labeling identification25-26. HeLa lysates were treated with RB2 and RB7 at 100 µM an 
analyzed by TOP-ABPP methodologies. The resulting MS2 fragmentation data were 
subsequently search for probe  modifications on all nucleophilic amino acids including 
cysteine, aspartate, glutamate, histidine, lysine, serine, threonine, and tyrosine using the 
SEQUEST search algorithm19, 27. It was confirmed that RB2 predominantly labels cysteine 
residues, while RB7 shows extreme reactivity towards nucleophilic lysine residues with 
minimal cysteine modification. 
 
3.3 A Dichlorotriazine-based Inhibitor of GSTP1, LAS-17 
 To further explore the unique reactivity of the dichlorotriazine electrophile that 
Shannon et al. reported, in 2016 our lab reported on a library of covalent inhibitors based 
on the dichlorotriazine electrophilic functionality28. The small-molecules in this library 




tag conjugation; (2) a diversity element to direct the probes to different subsets of the 
proteome; and (3) a dichlorotriazine electrophile (Figure 3.5A). Crawford and Weerapana 
synthesized a small library of 20 compounds with diversity elements containing various 










Figure 3.5. (A) General chemical structure of small-molecule probes. Each probe contains 
three elements: (1) an alkyne handle for bio-orthogonal reporter tag conjugation; (2) a 
diversity element to direct the probes to different subsets of the proteome; and (3) a 
dichlorotriazine electrophile. (B) Chemical structures of diversity elements used in 





 Initial screening efforts focused on evaluating the reactivity and selectivity of the 
small-molecule probes in a complex proteome. Briefly, HeLa cell lysates (2 mg/mL) were 
treated with 1 µM of each probe for 1 hour, followed by the conjugation of rhodamine-
azide (Rh-N3) using “click” chemistry. Following the separation of the proteins by SDS-
PAGE, visualization of probe-labeled proteins was performed by in-gel fluorescence. 
These in-gel fluorescence screening studies demonstrated that several library members 
covalently labeled proteins in the complex proteome. LAS17 (Figure 3.6A), which contains 
a L-leucine methyl ester diversity element, was found to selectively labeled a low-
molecular weight protein, ~25 kDa (Figure 3.6B)28. Furthermore, to assess the cell 
permeability and selectivity of LAS17 in situ, HeLa cells were treated with LAS17 (Figure 
3.6C). Following treatment with probe (1 µM) for 1 hour, cells were subjected to lysis and 
reporter tag conjugation. After subsequent SDS-PAGE separation and in-gel fluorescence 
analysis, the presence of a single robust fluorescent band at ~25 kDa, which demonstrated 
the high reactivity and selectivity of LAS17 for covalent modification of this protein target 
within the context of the complex proteome. 
 To more comprehensively assess the reactivity and selectivity of LAS17 in the 
complex proteome, the protein target of LAS17 were globally investigated. In order to do 
this, HeLa cells were treated with LAS17 (1 µM) or DMSO. Upon cell lysis, LAS17-
labeled proteins were then appended to biotin-azide using CuAAC, enriched on 
streptavidin beads, subjected to on-bead tryptic digestion, and subsequent LC/LC-MS/MS 
analysis. Spectral counts for proteins identified in the LAS17 samples were then compared 
to the DMSO treated samples, and indicated that the protein target of LAS17 is glutathione 









Figure 3.6. (A) Chemical structure of LAS17. (B) In-gel fluorescence studies of LAS17 (1 
µM) incubated with HeLa cell lysate (2 mg/mL) to assess potency and selectivity for 
endogenous proteins in a complex proteome. (C) HeLa cells were treated with LAS17 (1 
µM) and subjected to in-gel fluorescence analysis to assess the cell permeability and 
selectivity of LAS17 in situ. (D) HeLa cell lysates treated with LAS17 (1 µM) or DMSO 
were subjected to CuAAC with biotin-azide, enriched on streptavidin beads, and 
subsequent LC/LC-MS/MS analysis. The top 10 proteins with the greatest difference in 





 GSTP1 is the most ubiquitous member of the GST protein superfamily and is 
primarily responsible for the conjugation of glutathione (GSH) to exogenous electrophiles 
as a mechanism of cellular detoxification29. Interestingly, most of the dichlorotriazine 
library labels a protein of similar molecular weight to that of GSTP1. Owing to the hyper-
reactivity of the dichlorotriazine electrophile, as demonstrated by Shannon et al., it can be 
hypothesized that GSTP1 is reacting with these probes to detoxify the cellular environment, 
thus demonstrating a need to modulate the reactivity of this electrophile so it can be more 
useful in a cellular context. High expression levels of GSTP1 have also been implicated to 
play a role in chemotherapeutic resistance30, and a variety of different cancers including 
breast, colon, and ovarian cancers have shown to have elevated levels GSTP1 relative to 
healthy tissue31. 
 To validate the protein target of LAS17, GSTP1, identified by LC/LC-MS/MS, 
human GSTP1 with an N-terminal 6X His-tag was recombinantly overexpressed and 
purified from E. coli. The purified protein was subsequently treated with LAS17 (1 µM) 
and subjected to in-gel fluorescence analysis (Figure 3.7A). The presence of a robust 
fluorescent band demonstrates that LAS17 does in fact covalently modify GSTP1, 
confirming the mass spectrometry findings28.  
 To interrogate whether the covalent linkage of LAS17 to GSTP1 correlated with 
any inhibitory effect, an in vitro activity assay was performed in which the transfer of 
glutathione (GSH) to 1-bromo-2,4,dinitrobenzene (BDNB) spectrophotometrically28. It 
was demonstrated that LAS17 could inhibit GSTP1 activity in a concentration-dependent 




dependent inhibition of GSTP1 was also monitored (data not shown), affording a second-













Figure 3.7. (A) Purified, recombinant GSTP1 was treated with LAS17 (1 µM) and 
evaluated by in-gel fluorescence. (B) In vitro GSTP1 activity assay data demonstrate that 






 In summary, functional amino acids in the cell tend to have a heightened sense of 
nucleophilicity responsible for roles in catalysis and regulation of cellular processes. 
Recent advances in genomic technologies such as transcriptional profiling and RNAi 
attempt to probe at the gene expression level to deteremine the functions of these 
nucleophilic residues and their corresponding proteins. However, due to the myriad of post-
translational modifications and mechanisms, genomic approaches cannot fully realize the 
functional state of a given protein in a complex proteome. These technological advances 
have given rise to ABPP, which is a powerful chemical proteomic method that uses small-
molecule covalent probes to directly interrogate the functionality of a given protein/protein 
family. Due to the covalent nature of the small-molecule probes used, ABPP can directly 
report on the structure and reactivity of an enzyme active site in the context of a complex 
proteome. In order to perturb to a wide variety of protein reactivities in the proteome, ABPP 
relies on the use of selective, protein-reactive electrophiles. To date there have been many 
reported, well characterized electrophiles targeting a variety of nucleophilic amino acids 
with disparate reactivity profiles. In 2014, our lab demonstrated that a small panel of aryl 
halide electrophiles could possess a range of proteome reactivity, and selectivity for 
nucleophilic residues. RB2 was found to be a potent, selective electrophile against cysteine 
residues and RB7 was found to extremely reactive and selective towards lysine residues in 
a complex proteome. Interestingly, it was also demonstrated that the reactivity profiles of 
these types of aryl halides can be tuned by varying the electronics and sterics of the aryl 
ring system. Modulation of the electronics of the aryl ring to stabilize the SNAR transition 




EWG. In 2016, our lab furthered the investigation of the dichlorotriazine electrophiles and 
reported on a panel of inhibitors that contained that electrophilic functionality. One small-
molecule, LAS17, was found to potenltly and selectively label GSTP1 in the context of the 
complex proteome. Further studies demonstrated that LAS17 inhibited GSTP1 activity in 
a concentration- and time-dependent manner. The primary role of GSTP1 in the cell is to 
conjugate glutathione to exogenous electrophiles as a mechanism of cellular detoxification, 
indicating the dichlorotriazine motif is too reactive for use as a probe scaffold. As such, 
modulation of the dichlorotriazine ring system to further optimize the electronics and tune 
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INVESTIGATING THE REACTIVITY AND SELECTIVITY OF 







 The use of the covalent modifications of proteins by small molecules has numerous 
applications in drug design1-3, imaging4, and activity-based protein profiling5-6. The 
modifications on proteins occur at sites of heightened nucleophilicity, which tend to be 
functional amino acids that play a role in catalysis or the regulation of cellular processes. 
Activity-based protein profiling (ABPP) is a powerful chemical proteomic technique that 
relies on potent, selective electrophiles to directly interrogate the functional state of an 
enzyme or enzyme family in a biological system. To date, may electrophiles have 
demonstrated high reactivity and functional group specificity including haloacetamides7-9, 
α,β-unsaturated ketones7, and maleimides9 which have all shown selectivity for cysteine 
residues. Additional electrophiles have also been discovered which target other 
nucleophilic residues in the proteome, such as sulfonate esters which react with aspartates, 
glutamates, and tyrosines7; acyl phosphates which has been shown to react with lysines in 
the kinome10; sulfonyl fluorides which react with serines and tyrosines11-12; and 
fluorophosphonates which have been shown to react with nucleophilic serines in serine 
hydrolases13. Many of the aforementioned electrophilic groups demonstrate high reactivity, 
and as such can react with nucleophilic amino acids in the proteome without the presence 
of a binding element to position the electrophile on the protein of interest. Other 
electrophiles, while still reactive enough to modify proteins in a complex proteome, require 
the presence of a binding motif to facilitate the reaction. These functional groups include 
epoxysuccinates which covalently bind to cysteine proteases14; spiroepoxides, which have 
been shown to label the glycolytic enzyme, phosphoglycerate mutase15; carbamates and β-




ketones, which have been shown to label diverse cysteine proteases17; and phenoxymethyl 
ketones, which have been used in labeling cysteine containing cathepsin proteases18. 
 Previous reports from our lab have looked at the reactivity and selectivity of aryl 
halides in the complex proteome. Shannon et al. synthesized a panel of aryl halide 
electrophiles to investigate proteome reactivity and residue specificity19. These studies 
initially looked at a small subset of chloronitrobenzene (CNB) derivatives, varying the 
position of the electron withdrawing nitro substituent. As originally hypothesized, the CNB 
with the nitro in the para position had the highest reactivity in the proteome, presumably 
through the resonance stabilization of the Meisenheimer-complex20-21. Shifting the nitro 
group to the meta position destabilizes the Meisenheimer-complex and thus the reactivity 
of RB1 is completely abrogated. Further investigation of another panel of aryl halides 
containing a fluoronitrobenzene, chloropyridines, chloropyrimidines, and a 
dichlorotriazine. Interestingly, the dichlorotriazine electrophile, RB7 (Figure 4.1), 
demonstrated hyper reactivity in the complex proteome via in-gel fluorescence analysis. 
RB7 also displayed a unique action in that it was identified to label predominantly lysine 
residues in the complex proteome by LC/LC-MS/MS analysis, with little cysteine 
modification19. This study was vital in showing that the reactivity of aryl halide compounds 
that react with proteins through an SNAR mechanism can be tuned by modulating the 





















 Furthering on the unique reactivity of the dichlorotriazine, Crawford et al. reported 
in 2016 on a probe library based on the dichlorotriazine electrophilic motif22. A panel of 
20 dichlorotriazine-based probes were synthesized each containing a varied diversity 
element to direct the probe to a different subset of the proteome, as well as an alkyne handle 
for subsequent reporter tag conjugation via CuAAC. Initial screening of the library in HeLa 
cell lysates afforded, LAS17, which has an L-leucine methyl ester diversity element, to be 
potent and selective for a low molecular weight protein. Subsequent identification through 
proteomic approaches identified the protein target of LAS17 to be glutathione S-tranferase 
Pi (GSTP1)22. GSTP1 is the most ubiquitous member of the GST protein superfamily, and 
is primarily responsible for conjugation glutathione to exogenous electrophiles to detoxify 
the cellular environment23. Owing to the hyper reactivity of the dichlorotriazine 
electrophilic motif, it was interesting that most of the library member synthesized by 
Crawford et al. seemed to label a low molecular band, assumed to be GSTP1. Therefore, 
the reactivity of these electrophiles needs to be tuned down so the cell does not target them 
for deactivation, and this can presumably be done by varying the electron withdrawing 
(EWG) and electron donating groups (EDG) on the triazine ring to modulate the 
electronics. 
 Nucleophilic aromatic substitution (SNAR) reactions are an important class of 
synthetic organic reactions and their mechanisms have been well investigated20-21, 24-25. The 
reaction follows a simple, two-step addition-elimination mechanism (Figure 4.2). Simple 
aryl halide moieties are activated through the placement of strong EWG on the aromatic 
ring in the ortho- or para- positions. The presence of the EWG helps to stabilize the 




nucleophilic attack on the aromatic ring. Absence of EWG groups on the aromatic ring 
prohibit this reaction intermediate from forming, thus inhibiting the reaction from 
proceeding. Therefore, it can be hypothesized that variation of the EWG on the aromatic 
ring can tune the reactivity of the electrophile through modulation of the electronics of the 
ring system. Subsequently, the study of this chapter will be to tune the reactivity of the 
dichlorotriazine electrophile previously studied in our lab by varying EWG and EDG 




















4.2 Results and Discussion 
4.2.1 Generation of a Library of Chlorotriazine Electrophiles 
 In a previous study, we identified a dichlorotriazine-based electrophile, RB7, with 
high proteome reactivity and selectivity towards nucleophilic lysine residues19. Currently, 
the dichlorotriazine electrophile is too reactive to use as a scaffold to target functional 
residues. In order to optimize the potency and selectivity of RB7 (Figure 4.1), we sought 
to develop a second generation of chlorotriazine electrophiles. These electrophiles are 
expected to react via an SNAR mechanism, whereby the rate limiting step is the formation 
of the Meisenheimer-complex20-21. Therefore, as shown in previous studies by Shannon et 
al.19, we should be able to tune the reactivity by varying electron withdrawing groups 
(EWG) and electron donating groups (EDG) in the position of one chlorine atom, thus 
generating a chlorotriazine electrophile. With this in mind, a second-generation 
chlorotriazine library was synthesized with EWG and EDG tuning elements in th 
containing hydrocarbons, branched hydrocarbons, benzyl-functionalized hydrocarbons, 
amines, functionalized-mercaptans, and functionalized-thiophenols (Figure 4.3). To gain 
deeper insight into the electronics of the triazine ring of RB7, we enlisted some preliminary 
computational calculations. Electrostatic potential maps (ESPs) were generated with 
Gaussian 0926 to view electron density modulation at the electrophilic carbon position as 
the EWG/EDG was varied (Figure 4.4). The electron density maps demonstrate by 
computation that by varying the strength of the EWG and EDG in the para position, we 
can modulate the electronics of the triazine ring, and therefore should be able to tune the 










Figure 4.3. Structures of second-generation chlorotriazine electrophiles obtained by 









Figure 4.4. Electrostatic potential maps demonstrating effect that electron withdrawing 






4.2.2 Identification of KSC-46 as an Optimized Chlorotriazine Scaffold 
 To streamline the selection of an optimized electrophilic scaffold, we screened the 
proteome reactivity of the library of chlorotriazines and RB7 using a gel-based 
fluorescence screening platform. Briefly, MCF7 cell lysates (2 mg/mL) were incubated 
with each probe (100 µM) for 1 hour. After incubation, the reactivity of each probe was 
monitored by appending a tetramethylrhodamine (TAMRA) fluorophore to the alkyne 
group of each compound using CuAAC27-28, separating the proteins on SDS-PAGE, and 
visualizing protein labeling using in-gel fluorescence (Figure 4.5). As indicated by the 
computational calculations, electrophiles containing tuning elements with alkyl, benzyl, or 
amino groups did not withdraw enough electron density from the triazine ring, and thus 
had poor proteome reactivity. As anticipated from the calculations, the sulfur containing 
tuning elements (KSC-41, 42, 43, 46, 47, 48) had the appropriate range of electron 
withdrawing ability to tune the reactivity of the electrophile. Furthermore, KSC-46 which 
contains a p-chlorothiophenol tuning element was found to be the optimal electrophile for 









Figure 4.5. Investigating the proteome reactivity of chlorotriazines. The library of 
chlorotriazine electrophiles were incubated in MCF7 lysates (2 mg/mL) and protein 
labeling by each library member (100 µM) was evaluated after CuAAC-mediated 





4.2.3 Interrogation of Cysteine Reactivity of KSC-46 
 Previously, RB7 was found to be extremely potent and selective toward lysine 
residues. To investigate if KSC-46 maintains this amino acid specificity, we performed a 
competition assay with a highly know reactive cysteine-specific electrophile, 
iodoacetamide (IA). KSC-46 was compared to RB7 and also IA≡, a known promiscuous 
cysteine-reactive electrophile. To achieve this competition, MCF7 lysates were pretreated 
with IA (0 – 10 mM) for 1 hour, followed by treatment with KSC-46 (100 µM), RB7 (100 
µM) or IA≡ (2 µM) for 1 hour (Figure 4.6). As expected, pretreatment with IA completely 
abrogates labeling of cysteine residues by IA≡ yet does not affect labeling of RB7 which 
is labeling predominantly lysine residues. Interestingly, KSC-46 labeling initially 
decreases upon IA pretreatment, indicating KSC-46 covalently binds cysteine residues. 
However, labeling is not completely abolished until high concentrations of IA. These data 
thereby indicate that KSC-46 does not selectively label lysine residues like the 















Figure 4.6. Effect of iodoacetamide (IAA) pre-treatment (0-10 mM) prior to labeling with 
IA≡ (2 µM), BBI (100 µM), and KSC-46 (100 µM). MCF7 lysates (2 mg/mL) were 
incubated with IA for 1 hour, followed by treatment with each probe and then subhected 






4.2.4 Generation of a Library of Chlorotriazine Probes using the KSC-46 
Electrophilic Scaffold 
 With the electronics of the triazine ring optimized, using the p-chlorothiophenol 
tuning element to generate KSC-46, we turn to utilize this tuned reactivity through the 
development of a small-molecule probe library to covalently target functional residues in 
a complex proteome. Our library of small-molecule probes each contain four distinct 
elements (Figure 4.7A): (1) a p-chlorothiophenol tuning element to optimize the reactivity 
of the chlorotriazine electrophile, (2) a chlorotriazine reactive group for covalent 
modification, (3) an alkyne handle for downstream reporter tag conjugation via CuAAC, 
and (4) varaiable diversity element to direct the probes to different subsets of the proteome. 
The diversity elements chosen were varied across the library and incorporate a multitude 
of physicochemical properties to direct the probes to different subsets of the proteome 
(Figure 4.7B). Detailed information regarding the synthesis of library members can be 








Figure 4.7. (A) General chemical structure of small-molecule chlorotriazine library. (B) 
Chemical structures of diversity elements used in di-functionalized, chlorotriazine small-





4.2.5 Assessing the Potency and Selectivity of Chlorotriazine Library 
 Our first goal was to assess the reactivity and selectivity of these di-functionalized 
triazine compounds in MCF7 cell lysates using a gel-based screening platform. Briefly, 
MCF7 cell lysates (2 mg/mL) were incubated with each probe (10 µM) for 1 hour. After 
incubation, the reactivity and selectivity of each probe was monitored by appending a 
TAMRA fluorophore to the alkyne group of each compound using CuAAC, followed by 
visualization by in-gel fluorescence. This small molecule library demonstrated covalent 
attachment to target proteins in the complex proteome (Figure 4.8), however, these small-
molecules proved to not possess much selectivity in vitro. Previous studies have established 
that the in vitro reactivity and selectivity of a given electrophile, is not indicative of the in 









Figure 4.8. Characterization of targeted library of chlorotriazine probes in vitro. Library 
members (20 µM) were incubated with MCF7 cell lysates (2 mg/mL) in PBS, and protein 
labeling by each compound was evaluated after CuAAC-mediated incorporation of a 
TAMRA fluorophore, SDS-PAGE, and in-gel fluorescence (Left panels). Coomassie gels 





 With this in mind, we next decided to assess to potency, selectivity, and cell 
permeability of this library in situ in MCF7 cells using the same gel-based screening 
platform. Briefly, MCF7 cells were treated with each probe for 3 hours at 37 °C, followed 
by in-gel fluorescence analysis (Figure 4.9). KSC-56, which contains a furfurylamine 
diversity element, demonstrated high selectivity toward a single protein target ~39 kDa. 
Interestingly, KSC-65, which contains a phenylsulfonylpyrrolidine diversity element, 
demonstrated high selectivity toward a protein target ~75 kDa. These studies highlight the 
cell permeability of the chlorotriazine compounds and their ability to selectively target 









Figure 4.9. Characterization of targeted library of chlorotriazine probes in situ. Library 
members (20 µM) were incubated with MCF7 cells for 3 hours at 37 °C, and protein 
labeling by each compound was evaluated after in-gel fluorescence analysis(Left panels). 






4.2.6 Identification of the Protein targets of KSC-56 and KSC-65 
 We follow up on target identification for these two compounds in our library, KSC-
56 and KSC-65, which demonstrated high selectivity toward a single protein target in 
MCF7 cells. To achieve this, we employed a mass spectrometry-based method in which 
MCF7 cells were incubated with DMSO, KSC-56 (20 µM), or KSC-65 (20 µM). Upon cell 
lysis, probe-labeled proteins were then appended to biotin-azide using CuAAC, enriched 
on streptavidin beads, subjected to on-bead tryptic digestion, and subsequent LC/LC-
MS/MS analysis. Spectral counts (number of fragmentation spectra) generated for each 
protein for the probe-labeled samples were compared to the DMSO control sample (Tables 
4-1, 4-2, Appendix Tables 4-1, 4-2). In the KSC-56-treated samples, mass spectrometry 
studies identified the ~39 kDa target of this probe as glutaredoxin-3 (GLRX3). In the KSC-
56-treated samples, an average of ~305 spectral counts were matched to GLRX3 (with an 
average of ~5 spectral counts in the DMSO control). In the KSC-65-treated samples, mass 
spectrometry studies identified the ~75 kDa target of this probe as 6-phospofructokinase, 
platelet type (PFKP). In the KSC-65-treated samples, an average of ~398 spectral counts 
were matched to PFKP (with an average of ~33 spectral counts in the DMSO control). It 
is important to note that other proteins in the proteome were enriched by each probe, 












Table 4.1. Mass Spectrometry data for KSC-56 treated samples. The proteins shown are 
those that fell within the required molecular weight range of 33-43 kDa and is sorted by 
the spectral count difference between the KSC-56 treated and the DMSO (no probe) 
samples. Full data set is displayed in the appendix. 
  





GLRX3 GLRX3 Glutaredoxin-3 5.4 335 37432 0 312 312
ACTB ACTB Actin, cytoplasmic 1 5.5 375 41737 28 188 160
ALDOA ALDOA Fructose-bisphosphate aldolase A 8.1 364 39420 10 84 74
PCBP1 PCBP1 Poly(rC)-binding protein 1 7.1 356 37498 1 58 57
Uncharacterized Uncharacterized protein 5.7 379 40447 0 51 51
PCBP2 PCBP2 Poly(rC)-binding protein 2 6.8 365 38580 0 30 30
HMOX2 HMOX2 Heme oxygenase 2 5.4 316 36033 0 29 29
ACTA1 ACTA1 Actin, alpha skeletal muscle 5.4 377 42051 0 28 28
ACTA2 ACTA2 Actin, aortic smooth muscle 5.4 377 42009 0 28 28
GAPDH GAPDH Glyceraldehyde-3-phosphate dehydrogenase 8.5 335 36053 6 23 17
AIP AIP AH receptor-interacting protein 6.3 330 37636 0 12 12
CRKL CRKL Crk-like protein 6.7 303 33777 0 12 12
PRMT1 PRMT1 Protein arginine N-methyltransferase 1 5.4 361 41516 0 11 11











Table 4.2. Mass Spectrometry data for KSC-65 treated samples. The proteins shown are 
those that fell within the required molecular weight range of 75-95 kDa and is sorted by 
the spectral count difference between the KSC-65 treated and the DMSO (no probe) 
samples. Full data set is displayed in the appendix. 
 
  






Q01813 PFKP PFKP 6-phosphofructokinase type C 7.6 784 85596 2 546 545
P08238 HSP90AB1 HSP90AB1 Heat shock protein HSP 90-beta 5 724 83264 11 203 192
P05165 PCCA PCCA Propionyl-CoA carboxylase alpha chain, mitochondrial7.5 728 80059 94 264 170
Q96RQ3 MCCC1 MCCC1 Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial7.8 725 80473 157 321 164
P07900 HSP90AA1 HSP90AA1 Heat shock protein HSP 90-alpha 5 732 84660 7 153 146
P13639 EEF2 EEF2 Elongation factor 2 6.8 858 95338 17 81 64
P17858 PFKL PFKL 6-phosphofructokinase, liver type 7.5 780 85018 3 55 52
P14625 HSP90B1 HSP90B1 Endoplasmin 4.8 803 92469 4 23 19




4.2.7 Glutaredoxin 3 
 Cells contain hundreds of proteins that require iron cofactors for activity in the form 
of heme iron-sulfur (Fe/S) clusters, and ferrous/ferric ions, yet the pathways that distribute 
these cofactors remain incompletely defined29. Recent studies in both baker’s yeast and in 
vertebrates demonstrate that there are many proteins involved in the biogenesis and cellular 
distribution cytosolic Fe/S clusters30-31. One class of proteins has been implicated in the 
trafficking of both Fe/S clusters and Fe ions in the cell, the monothiol glutaredoxins 
(Grxs)32-36. Two different classes of Grxs have been identified, dithiol (–CPYC–) and 
monothiol (–CGFS–)37. Dithiol Grxs have been shown to reduce protein disulfides and 
mixed-disulfides with glutathione, regulating protein function function37. The functions of 
monothiol Grxs hasn’t been as well characterized. Although monothiol Grxs contain the 
functional residues necessary to catalyze the reduction of mixed disulfide bonds between 
GSH and substrate proteins, most of them lack this enzymatic activity entirely38.  
 Monothiol Grxs can be further categorized into two sub-groups, single domain 
monothiols Grxs and multidomain monothiol Grxs. Single domain monothiol Grxs consist 
of only one Grx domain. Multidomain monothiol Grxs consist of one N-terminal 
thioredoxin (Trx)-like domain and one to three C-terminal monothiol Grx domains37, 39. In 
humans, two monothiol Grxs are present, GLRX3 and GLRX540. GLRX5 is located in the 
mitochondria and acts as a [2Fe-2S] cluster transfer protein in the ISC machinery41. 
GLRX3, located in the cytoplasm, consists of three domains: one N-terminal Trx-like 
domains and two C-terminal Grx domains, each of which are able to bind a glutathione-




 Recent interest in the biochemical characterization of GLRX3 has demonstrated 
that GLRX3-deficient human cells show a severe dysregulation of cytosolic iron 
metabolism through iron-regulatory protein 1 (IRP1), which in turn up-regulated the 
expression of the iron importer, transferrin receptor (TfR), and down-regulated the 
expression of the iron storage protein, ferritin43. In another study, Banci et al. demonstrated 
that GLRX3 can have a functional role in cytosolic [2Fe-2S] cluster trafficking through the 
transfer of clusters to its binding partner anamorsin, (CIAPIN-1)42. It was also 
demonstrated through electron paramagnetic resonance studies (EPR) and chemical shift 
perturbation assays that the association between the two partner proteins occurs between 
the N-terminal domains, and that the transfer mechanism was facilitated by a protein-
protein complex between the N-terminal domains42. Furthermore, Frey et al.  demonstrated 
that GLRX3 and BolA-like protein 2 (BOLA2) form a complex in human cells which is 
dependent upon the bridging of a coordinating [2Fe-2S] cluster29. Studies indicates that 
GLRX3-[2Fe-2S]-BOLA2 complexes can serves as a rapidly expandable pool of Fe/S 
clusters, based on cellular iron availability. Finally, Fe/S coordination by GLRX3-BOLA2 
did not depend on anamorsin, alternatively the GLRX3-BOL2 bound anamorsin and 
facilitated Fe/S transfer which demonstrate the chaperone ability of the GLRX3-BOLA2 
complex29. 
 Initially, GLRX3 was described as an interacting partner of protein kinase C-Θ 
(PKCΘ). In T cells, GLRX3 inhibited the activiation of c-Jun N-terminal kinase and 
subsequently the activation of transcription factors AP-1 and Nf-κB44. Further 
investigation between GLRX3 signal transduction and iron availability is needed to 




animal models of cardiac hypertrophy, and the overexpression of GLRX3 protected from 
cardiac hypertrophy45-46. Heterozygous Grx+/− mice are much more predisposed to 
developing cardiac hypertrophy than homozygous Grx+/+ mice45. Interestingly, GLRX3 has 
also proven essential for embryonic development in mice. Homozygous Grx−/− mice die 
between embryonic days (ED) 12.5 and 14.545. It is worth noting that ED 12.5 indicates 
the beginning of erythropoiesis in the fetal liver43. 
 
4.2.8 Phosphofructokinase-1 
 6-phosphofructo-1-kinase (PFK-1) is the key rate-limiting regulatory enzyme of 
glycolysis which catalyzes the phosphorylation of fructose 6-phosphate (F6P) to fructose-
1,6-bisphosphate (F1,6BP)47. Localizing at the beginning of the glycolytic pathway and 
catalyzing an irreversible, adenosine triphosphate (ATP)-dependent reaction make this 
enzyme a key regulator. In mammalian cells, PFK-1 exists in three isoforms: muscle 
(PFKM), liver (PFKL), and platelet (PFKP)48. The genes for each isoform are located on 
different chromosomes and display tissue specific expression. Interestingly, in muscle 
tissue only PFKM is present, but in all other tissues, all three isoforms are present in tissue 
specific ratios48. PFK-1 activity is finely regulated by more than 20 allosteric regulators 
including adenine nucleotides, cyclic adenosine monophosphate (cAMP), citrate, acyl-
CoA, F1,6BP, and glucose-1,6-bisphosphate (G1,6BP). The most potent modulator of 
PFK-1 activity is ATP, which directly inhibits PFK-1 in order to cause negative feedback 
when cellular energy is abundant49. In 1980, fructose-2,6-bisphosphate (F2,6BP) was 
discovered as an allosteric activator of PFK-150. F2,6BP allosterically activates PFK-1 by 




for its substrate, F6P50. F2,6BP can relieve inhibition of PFK-1 by ATP, thus allowing cells 
to maintain a high glycolytic flux even in elevated physiological concentrations of ATP51. 
 Recent biochemical characterization has demonstrated that PFK-1 assembles into a 
tetrameric structure in a concentration- and ligand-dependent manner. Furthermore, 
allosteric activators of PFK-1 have been shown to promote the formation of the tetrameric 
complex, whereas allosteric inhibitors favor the formation of an inactive dimeric form52-53. 
Recent studies by Webb et al, have demonstrated through site-directed-mutagenesis that 
PFKP-F649L particles form dimers, and lose ~98% of the catalytic activity compared to 
the WT PFKP, which forms a tertrameric complex54. Crystal structures of the two 
complexes suggest that an electrostatic interaction between R613 of one subunit and E657 
of the adjacent subunit are important for the enzymatic function. This salt bridge was only 
present in WT PFKP tetramers and not in the PFKP-F649L dimers54. 
 Cancer cells rely on aerobic glycolysis to provide the energy and building blocks 
required to support the rapid proliferation55. Accordingly, PFK-1 activity has been 
demonstrated to be increased in a variety of cancers and primary tumors56, and the 
expression of PFK-1 has been shown to be upregulated in breast57 and liver57 cancers. Due 
to this role of PFK-1 upregulation in cancer metabolism, it has since become a target for 
therapeutic intervention, albeit by indirectly targeting the bifunctional enzyme, 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3)58. PFKBF3 posseses 
both kinase and phosphatase functionality, and it is responsible for converting F6P to 
F2,6PBP, the major allosteric activator of PFK-147. Therefore, targeting PFKFB3 could 
significantly inhibit the glycotlytic pathway. To this end, there have been many advances 




range. These derivatives include a variety of different classes of compounds including 
benzopyrans, naphthalene, heteroaryl and bisarylsulfonamides, and pyridinyl derivatives 






















4.2.9 Validation of GLRX3 as the Protein Target of KSC-56 and Identification of the 
Site-of-Labeling  
 In order to verify the protein target of KSC-56 identified by mass spectrometry, 
GLRX3, we overexpressed the wild-type form of the protein with a C-terminal FLAG-tag 
using transient transfection in HEK293T cells using pcDNA3.1(+). Briefly, HEK293T 
cells overexpressing GLRX3 were treated with DMSO or KSC-56 (20 µM) for 3 hours at 
37 °C. Following cell lysis, a fluorophore was appended to probe-labeled proteins via 
CuAAC and visualized with in-gel fluorescence. The presence of a fluorescent band in the 
GLRX3-FLAG overexpressed sample, which is absent in the mock-transfected control 
confirms that GLRX3 is the protein target of KSC-56. The overexpression of GLRX3-
FLAG was confirmed by western blot with an anti-FLAG antibody (Cell Signaling 
Technologies) (Figure 4.11A). 
 In an effort to elucidate the site of labeling of GLRX3 by KSC-56, the two 
nucleophilic cysteine residues in the Grx domains (Cys159 and Cys261) were mutated to 
serine residue to afford GLRX3 mutants C159S and C261S. HEK293T cells 
overexpressing GLRX3 WT, C159S, or C261S were treated with DMSO or KSC-56 (20 
µM) for 3 hours at 37 °C. Following cell lysis, a fluorophore was appended to probe-
labeled proteins via CuAAC and visualized with in-gel fluorescence. The presence of a 
robust fluorescent band in the GLRX3 WT and C159S samples indicate that KSC-56 is 
labeling these proteins, and clearly not targeting Cys159 in the first Grx domain of GLRX3 
(Figure 4.11B). However, a clear loss of fluorescence labeling in the GLRX3 C261S 
sample indicate that KSC-56 is in targeting the second Grx domain and covalently binding 













Figure 4.11. (A) GLRX3 was overexpressed in HEK293T cells via transient transfection 
using pcDNA3.1(+). Cells were subsequently treated with KSC-56 (20 µM) for 3 hours at 
37 °C, following analysis by in-gel fluorescence. Overexpression of GLRX3 was 
confirmed by anti-FLAG western blot. (B) GLRX3 WT, C159S, and C261S were 
overexpressed in HEK293T cells via transient transfection using pcDNA3.1(+). Cells were 
subsequently treated with KSC-56 (20 µM) for 3 hours at 37 °C, following analysis by in-





4.2.10 Validation of PFKP as the Protein Target of KSC-65 and Identification of the 
Site-of-Labeling  
 In order to verify the protein target of KSC-65 identified by mass spectrometry, 
PFKP, we overexpressed the wild-type form of the protein with a C-terminal FLAG-tag 
using transient transfection in HEK293T cells using pcDNA3.1(+). Briefly, HEK293T 
cells overexpressing PFKP were treated with DMSO or KSC-65 (20 µM) for 3 hours at 37 
°C. Following cell lysis, a fluorophore was appended to probe-labeled proteins via CuAAC 
and visualized with in-gel fluorescence. The presence of a fluorescent band in the PFKP-
FLAG overexpressed sample, which is absent in the mock-transfected control confirms 
that PFKP is the protein target of KSC-56. The overexpression of PFKP was confirmed by 
western blot with an anti-FLAG antibody (Figure 4.12A). 
 Previous work in the Weerapana lab by Alex Shannon identified five reactive 
cysteine residues on PFKP: Cys179, Cys360, Cys411, Cys529, and Cys641. In an effort to 
identify the site of labeling on PFKP by KSC-65, four of the five reactive cysteine residues 
(Cys179, Cys411, Cys529, and Cys641) were mutated to serine residue to afford the PFKP 
mutants C179S, C411S, C529S, and C641S. HEK293T cells overexpressing PFKP C179S, 
C411S, C529S, and C641S were treated with DMSO or KSC-65 (20 µM) for 3 hours at 37 
°C. Following cell lysis, a fluorophore was appended to probe-labeled proteins via CuAAC 
and visualized with in-gel fluorescence. The presence of a robust fluorescent band in each 
of the PFKP transfected samples treated with probe that KSC-565 is not targeting any of 
these four previously identified reactive cysteine residues (Figure 4.12B). Future work will 
initially need focused on the identification of the site-of-labeling of KSC-65 on PFKP as 










Figure 4.12. (A) PFKP was overexpressed in HEK293T cells via transient transfection 
using pcDNA3.1(+). Cells were subsequently treated with KSC-65 (20 µM) for 3 hours at 
37 °C, following analysis by in-gel fluorescence. Overexpression of PFKP was confirmed 
by anti-FLAG western blot. (B) PFKP C179S, C411S, C529S, and C641S were 
overexpressed in HEK293T cells via transient transfection using pcDNA3.1(+). Cells were 
subsequently treated with KSC-65 (20 µM) for 3 hours at 37 °C, following analysis by in-






 In summary, we report the discovery and characterization of a class on 
chlorotriazine-based electrophiles in which the reactivities are tuned by varying the EWG 
and EDG ‘tuning elements’ to modulate the electronics of the triazine ring system. KSC-
46, which contains a p-chlorothiophenol tuning element for optimized reactivity in the 
complex proteome. KSC-46 demonstrated a unique reactivity profile, in an IA competition 
based assay, demonstrates that KSC-46 preferentially binds nucleophilic cysteine residues, 
but also labels other nucleophilic residues in the proteome as well. KSC-46 and the other 
second generation library members also contain a biorthogonal alkyne handle, which 
facilitated the rapid screening of this library of electrophiles in vitro and in live cells. 
Furthering on this, a library of small-molecule probes utilizing the p-chlorothiophenol 
tuning element was synthesized with varying directing groups to direct the library to 
different subsets of the proteome. Screening of this library in situ afforded two compounds, 
KSC-56 which contains a furfurylamine diversity element and KSC-65 which contains a 
phenylsulfonylpyrrolidine diversity element, that selectively target proteins in the complex 
proteome. Identification of these protein targets by LC/LC-MS/MS revealed the target of 
KSC-56 is glutaredoxin 3 (GLRX3) and the target of KSC-65 is 6-phosphofructo-1-kinase 
(PFKP). Overexpression of each target in HEK239T cells via transient transfection and 
subsequent labeling with each probe confirmed the target identification provided by the 
mass spectrometry studies. Mutation of the two nucleophilic cysteine residues in the Grx 
domains of GLRX3 followed by subsequent labeling with KSC-56 identified the site-of-
labeling of the probe was Cys261 in the C-terminal Grx domain. In the future it will be 




partner proteins and in turn interrogate the effect on cysteine reacitivity on a global scale. 
Previous work in the Weerapana lab identified five reactive cysteine residues on PFKP. 
Following up on four of the five cysteine through site directed mutation revealed that none 
of the four cysteines investigated were the site-of-labeling of KSC-65. Future work with 
PFKP will begin with identification of the site-of-labeling of the probe. Also, in 
collaboration with the Nomura lab at UC Berkeley, we are investigating PFKP inhibition 
through polar metabolomics studies and isotope tracing, focused around glycolytic 
intermediates. 
 
4.4 Materials and Methods 
4.4.1 General Information 
All materials were obtained from Sigma-Aldrich, Fisher Scientific, Combi-
Blocks, or Oakwood Chemicals, unless otherwise noted. Phosphate buffered saline (PBS) 
buffer, RPMI 1640 media, Trypsin-EDTA and Anti-Anti were purchased from Fisher 
Scientific (Pittsburgh, PA). Fetal bovine serum was purchased from Atlanta Biologicals 
(Flowery Branch, GA). All protein concentrations were determined using the DC Protein 
Assay kit from Bio-Rad (Hercules, CA). Analytical thin layer chromatography (TLC) 
was performed on EMD Millipore F254 glass-backed TLC plates (250 µm, Billerica, MA). 
All compounds were visualized on TLC under UV light and by potassium permanganate 
staining. Column chromatography was carried out using forced flow of solvent on 
Sorbent Technologies (Norcross, GA) standard grade silica gel, 40-63 µm particle size, 




CA) 500 MHz and 600 MHz NMR spectrometers. Chemical shifts (δ) are reported in 
parts per million (ppm) with chemical shifts reported to internal standards: CDCl3 (7.26 
ppm for 1H, 77.23 ppm for 13C), (CD3)2CO (2.05 ppm for 1H, 29.92 ppm for 13C), 
CD3OD (3.31 ppm for 1H, 49.15 ppm for 13C). Coupling constants (J) are reported in 
Hertz (Hz) and multiplicities are abbreviated as singlet (s), doublet (d), triplet (t), 
multiplet (m), doublet of doublets (dd), and doublet of triplets (dt). High resolution Mass 
Spectra (HRMS) were obtained at the Mass Spectrometry Facility at Boston College 
(Chestnut Hill, MA). 
 
4.4.2 Cell culture and preparation of MCF-7 cell lysates 
 MCF-7 cells were cultured at 37 °C under an atmosphere of 5% CO2 in RPMI 1640 
media (Corning) supplemented with 10% fetal bovine serum (FBS, Atlanta Biologicals) 
and 25 µg/mL of Amphotericin B, 10,000 units/mL of penicillin, and 10,000 µg/mL 
streptomycin (Gibco Anti-Anti).  The cells were then harvested and the pellets washed with 
phosphate buffered saline (PBS).  After washing, the pellets were resuspended in an 
appropriate amount of PBS and then sonicated with an ultrasonic tip sonicator (Cole 
Parmer, Vernon Hills, IL).  The lysates were separated by centrifugation at 45,000 rpm for 
45 minutes at 4 °C to obtain soluble and insoluble lysate fractions.  The soluble fraction 
was collected and the pellet discarded.  Protein concentrations were determined using the 
DC Protein Assay kit (Bio-Rad, Hercules, CA). 
 




 MCF-7 cell lysates (50 µL, 2 mg mL-1) in PBS were treated with probe (1 µL of 
50x stock in DMSO) for one hour. Rhodamine-azide (Click Chemistry Tools) was then 
appended to probe labeled proteins via CuAAC; Rhodamine-azide (25 µM, 100x stock in 
DMSO), TCEP (1 mM, 50x stock in water), TBTA (100 µM, 17x stock in t-BuOH:DMSO 
4:1), and copper (II) sulfate (1 mM, 50x stock in water) were added to the cell lysate. 
Samples were then incubated at room temperature for one hour to allow for the 
cycloaddition reaction to occur. An equal volume of SDS-PAGE loading buffer (2x, 
reducing) was added to each reaction and 20 µL of this solution was separated on a 10% 
SDS-PAGE gel. Gels were visualized for rhodamine fluorescence on a ChemiDoc MP 
imaging system (BioRad, Hercules, CA). Gels were then coomassie stained following a 
standard procedure and visualized on the same imager. 
 
4.4.4 In situ labeling experiments 
 MCF-7 cells were grown to ~90% confluence in 10 cm tissue culture plates. Growth 
media was removed and replaced with 5 mL RPMI. Probes in an appropriate DMSO stock 
was then added to the media to achieve the desired labeling concentration and incubated at 
37 °C under an atmosphere of 5% CO2 for 3 hours. Cells were then harvested and were 
then prepared as lysates as described above. 
 
4.4.5 KSC-56 or KSC-65 Mass Spectrometry Sample Preparation and Data Analysis 
 MCF-7 cells were grown to ~90% confluence in 15 cm tissue culture plates. Growth 
media was removed and replaced with 10 mL RPMI. KSC-56 or KSC-65 (10 µL, 1000x 




and incubated at 37 °C under an atmosphere of 5% CO2 for 3 hours. Cells were then 
harvested and were then prepared as lysates as described above. 
 Probe-labeled MCF-7 cell lysates (500 µL, 2 mg mL-1) in PBS were subjected to 
CuAAC.  Biotin azide (200 µM from 100x stock in DMSO), TCEP (1 mM, 50x stock in 
water), TBTA (100 µM, 17x stock in t-BuOH:DMSO 4:1), and copper (II) sulfate (1 mM, 
50x stock in water) were added to the cell lysate. Samples were incubated at room 
temperature for 1 hour to allow for the cycloaddition reaction to occur. Samples were then 
centrifuged for 10 minutes at 4 °C to pellet the precipitated proteins. Protein pellets were 
then resuspended in cold methanol by tip sonication followed by centrifugation. Following 
a second methanol wash, pelleted proteins were solubilized in a 1.2% SDS/PBS solution 
via tip sonication and incubation at 85 °C for 5 minutes. Samples were then diluted with 5 
mL PBS to lower the concentration of SDS to 0.2%. Next, samples were incubated with 
100 µL streptavidin agarose beads (Thermo Fisher Scientific, Waltham, MA) at 4 °C for 
16 hours. Samples were then washed with 0.2% SDS/PBS (5 mL), PBS (3 x 5 mL), and 
water (3 x 5 mL). The streptavidin agarose beads were pelleted between each wash step by 
centrifugation (1,400 g, 3 minutes). 
 The beads were suspended in a solution of 6 M Urea/PBS (500 µL) and 10 mM 
dithiothreitol (DTT, 20x stock in water), followed by incubation at 65 °C for 20 minutes. 
Next, iodoacetamide (20 mM, from 50x stock in water) was added to each sample and 
incubated at room temperature for 30 minutes. The beads were pelleted (1,400 g, 3 minutes) 
and resuspended in 200 µL of 2 M Urea/PBS, 1 mM CaCl2 (100x stock in water), and 2 
µg trypsin (Promega, Madison, WI). On-bead trypsin digestion was allowed to proceed 




supernatant collected. The beads were washed with water (2 x 50 µL) and the washes were 
combined with the supernatant. Formic acid (15 µL, Thermo Fisher Scientific, Waltham, 
MA) was then added to each sample and the samples were stored at -20 °C until mass 
spectrometry analysis. 
 LC/LC-MS/MS analysis was performed on an LTQ Orbitrap Discovery mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA) coupled to an Agilent 1200 series 
HPLC (Agilent Technologies, Santa Clara, CA). Tryptic digests were pressure loaded onto 
a 250 µm fused silica desalting column packed with 4 cm of Aqua C18 reversed phase 
resin (Phenomenex, Torrance, CA). Peptides were then eluted onto a biphasic 100 µm 
fused silica column with a 5 µm tip, packed with 10 cm of C18 and 4 cm of Partisphere 
SCX (Whatman, Pittsburgh, PA). Elution of the peptides from the desalting column into 
the biphasic column occurred using a gradient of 5-100% Buffer B in Buffer A (Buffer A: 
95% water, 5% acetonitrile, 0.1% formic acid; Buffer B: 20% water, 80% acetonitrile, 
0.1% formic acid). The peptides were eluted from the SCX onto the C18 resin and then 
into the mass spectrometer using four salt pushes66. The flow rate of buffer through the 
fused silica column was set to 0.25 µL min-1 and the spray voltage was set 2.75 kV. One 
full MS scan (400 – 1800 MW) was followed by 8 data dependent scans of the nth most 
intense ions with dynamic exclusion enabled. 
 Two biological replicates each of KSC-56 (5 µM), KSC-65 (5 µM), or DMSO 
treated MCF-7 cells were subjected to LC/LC-MS/MS analysis as outlined above. The 
generated tandem MS data was searched using the SEQUEST algorithm against the human 
UniProt database. A static modification of +57.0215 on cysteine was added to account for 




filtered using DTASelect v2.0 to generate a list of proteins identified with a false-discovery 
rate of < 5%.  The resulting peptides were then further filtered to display proteins identified 
in KSC-34 treated samples with an average of 10 spectral counts or greater across the 
biological replicates. For each of these proteins, the change in spectral counts between 
probe-treated samples and DMSO samples was calculated and the data was ranked by those 
proteins displaying the highest change in spectral counts in the probe-treated samples 
relative to the DMSO treated samples. 
 
4.4.6 Cloning 
 The cDNA for GLRX3 and PFKP were obtained from GE Life Sciences. The genes 
were subcloned into a pcDNA3.1(+) mammalian expression vector. The constructur for 
subcloning into the vector was generated by polymerase chain reaction (PCR) from the 
corresponding cDNA using the following primers: 
GLRX3-WT-FLAG pcDNA3.1 (+): Forward - 5’ 
ATCCAAGCTCGGATCCACCATGGCGGCGGGGGC 3’; Reverse with FLAG - 5’ 
CGGCCAGCGGGTTTAAACTCACTTGTCGTCATCGTCTTTGTAGTCATTTTCTCC
TCTCAGTA 3’ 
PFKP-WT-FLAG pcDNA3.1 (+): Forward - 5’ 






Site directed mutagenesis was performed to obtain the cysteine to serine mutants used in 
the site-of-labeling experiments, using the following primers: 
GLRX3-C159S-FLAG pcDNA3.1 (+): Forward - 5’ CGGTTTCAGCAAGCAGATGG 3’; 
Reverse - 5’ CTGCGTGGTTCTTGAGGAGTTC 3’ 
GLRX3-C261S-FLAG pcDNA3.1 (+): Forward - 5’ CGGATTCAGCAAACAAATTCTG 
3’; Reverse - 5’ CTTTTTGCTTCCTGTTTGTTTCC 3’ 
PFKP-C179S-FLAG pcDNA3.1 (+): Forward - 5’ CGGCACCGACATGACC 3’; Reverse 
- 5’ CTGAAATCATTGTCGATGGAGC 3’ 
PFKP-C411S-FLAG pcDNA3.1 (+): Forward - 5’ CAACGTAGCTGTCATCAACGTG 
3’; Reverse - 5’ CTATTGGTCTTTGGGATCTGATCA 3’ 
PFKP-C529S-FLAG pcDNA3.1 (+): Forward - 5’ CGTCCCCATGGTCATGG 3’; 
Reverse - 5’ CTGAACTCCTCGTGCTTCTCC 3’ 
PFKP-C641S-FLAG pcDNA3.1 (+): Forward - 5’ 
CAGTGAAAACTACACCACCGACTT 3’; Reverse - 5’ 
CTGCTCTCATTTCTGAGCACAAG 3’. All constructs were verified 
by DNA sequencing (Genewiz, Cambridge, MA). 
 



















2,4-dichloro-6-methyl-1,3,5-triazine (KSC-3-int): To a solution of cyanuric chloride 
(561.7 mg mg, 3.045 mmol) in dichloromethane (10 mL), methylmagnesium bromide (3 
M, 4.06 mL) was added at -20 °C and stirred for 4h, then stirred 4h at room temperature. 
Crude residue was extracted via liquid-liquid extraction. Solvents were removed in vacuo 
and crude product was purified with flash chromatography to afford the desired compound, 
KSC-3-int, as a yellow solid (234.8 mg, 47%). 1H NMR (500 MHz, Chloroform-d) δ 2.70 




4-chloro-6-methyl-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-3): To a solution of 
KSC-3-int (122.8 mg, 0.7488 mmol) and diisopropylethylamine (145.2 mg, 1.1232 mmol) 
in THF (10 mL), propargylamine (61.9 µL, 1.1232 mmol) was added at room temperature 
and stirred overnight. The solvent was removed in vacuo and the crude product was 




solid (136.7 mg, 61%). 1H NMR (500 MHz, Chloroform-d) δ 5.65 (s, 1H), 4.28 (ddd, J = 




2-(tert-butyl)-4,6-dichloro-1,3,5-triazine (KSC-38-int): To a solution of cyanuric 
chloride (492.5 mg, 2.6707 mmol) and copper iodide (25.4 mg, 0.1335 mmol) in THF (3 
mL), 1.7 M tert-Butylmagnesium chloride (1.65 mL, 2.8042 mmol) was added at -10 °C. 
Upon addition of the Grignard, the flask was removed from ice bath and allowed to warm 
to room temperature. The reaction was stirred for 30 minutes. Crude residue was extracted 
via liquid-liquid extraction. Solvent was removed in vacuo and crude product was purified 
with flash chromatography to afford the desired compound, KSC-38-int, as a colorless oil 
(215.7 mg, 39%). 1H NMR (600 MHz, Chloroform-d) δ 1.34 (d, J = 2.7 Hz, 9H). 13C NMR 
(151 MHz, cdcl3) δ 190.27, 171.51, 76.95, 40.07. HRMS for KSC-38-int: m/z calcd. 







4-(tert-butyl)-6-chloro-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-38): To a 
solution of KSC-38-int (185.9 mg, 0.9021 mmol) and diisopropylethylamine (152.6 mg, 
1.1810 mmol) in THF (3 mL), propargylamine (59.6 µL, 1.0825 mmol) was added at -20 
°C and stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product 
was purified with flash chromatography to afford the desired compound, KSC-38, as a 
white solid (178.8 mg, 86%). 1H NMR (600 MHz, Chloroform-d) δ 4.26 (ddd, J = 33.7, 
5.7, 2.5 Hz, 2H), 2.33 – 2.06 (m, 1H), 1.27 (d, J = 34.0 Hz, 9H). 13C NMR (151 MHz, 
Chloroform-d) δ 190.58, 189.73, 173.47, 172.51, 168.32, 168.21, 81.92, 81.42, 79.94, 
79.72, 79.51, 74.83, 73.92, 42.20, 41.77, 33.55, 33.46, 33.38, 32.30, 31.16, 31.14. HRMS 




2,4-dichloro-6-phenyl-1,3,5-triazine (KSC-35-int): To a solution of cyanuric chloride 
(503.9 mg, 2.7325 mmol) in a 1:1 v/v mixture of THF and diethyl ether (30 mL) and 
benzene (31 mL), phenylmagnesium bromide (3 M, 1.08 mL) was added at 0 °C and stirred 
for 4h, then stirred 4h at room temperature. Crude residue was extracted via liquid-liquid 
extraction. Solvents were removed in vacuo and crude product was purified with flash 
chromatography to afford the desired compound, KSC-35-int, as a white solid (33.5 mg, 




1.4 Hz, 1H), 7.58 – 7.47 (m, 2H). 13C NMR (151 MHz, Chloroform-d) δ 175.17, 172.40, 
135.08, 132.99, 130.28, 129.41, 77.58, 77.37, 77.16. HRMS for KSC-35-int: m/z calcd. 




4-chloro-6-phenyl-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-35): To a solution 
of KSC-35-int (50.0 mg, 0.2212 mmol) and diisopropylethylamine (31.4 mg, 0.2433 
mmol) in THF (2.5 mL), propargylamine (14.6 µL, 0.2654 mmol) was added. The reaction 
mixture was stirred at -20 °C (dry ice bath of 9:1 ethylene glycol/ethanol) for 3h. After 3h, 
the solvent was removed in vacuo affording a crude white solid. The crude product was 
purified by flash chromatography (1:1 dichloromethane/pentane) to give 40.4 mg (0.1651 
mmol, 71%) of the desired compound, KSC-35, as a white solid. 1H NMR (600 MHz, 
Acetone-d6) δ 8.43 (ddt, J = 63.6, 7.2, 1.4 Hz, 2H), 7.92 (d, J = 82.8 Hz, 1H), 7.76 – 7.46 
(m, 3H), 4.38 (ddd, J = 72.8, 5.9, 2.5 Hz, 2H), 2.75 (q, J = 2.6 Hz, 1H); 13C NMR (151 
MHz, Acetone-d6) δ 136.04, 133.97, 133.83, 129.90, 129.65, 129.62, 129.60, 72.78, 72.68, 
31.41, 31.22, 30.52, 30.39, 30.26, 30.13, 30.00, 29.88, 29.75, 29.62. HRMS for KSC-35: 







2,4-dichloro-6-(p-tolyl)-1,3,5-triazine (KSC-39-int): To a solution of cyanuric chloride 
(500.1 mg, 2.7119 mmol) in a 1:1 v/v mixture of THF and diethyl ether (30 mL) and 
benzene (31 mL), p-tolylmagnesium bromide (0.5 M, 6.51 mL) was added at 0 °C and 
stirred for 4h, then stirred 4h at room temperature. Crude residue was extracted via liquid-
liquid extraction. Solvents were removed in vacuo and crude product was purified with 
flash chromatography to afford the desired compound, KSC-39-int, as a white solid (217.4 
mg, 33%). 1H NMR (600 MHz, Chloroform-d) δ 8.41 – 8.22 (m, 2H), 7.27 (d, J = 8.0 Hz, 
2H), 2.42 (s, 3H). 13C NMR (151 MHz, cdcl3) δ 174.66, 172.52, 171.85, 146.06, 129.98, 







4-chloro-N-(prop-2-yn-1-yl)-6-(p-tolyl)-1,3,5-triazin-2-amine (KSC-39): To a solution 
of KSC-39-int (45.0mg, 0.1874 mmol) and diisopropylethylamine (26.6 mg, 0.2061 
mmol) in THF (3 mL), propargylamine (7.0 µL, 0.1280 mmol) was added at -20 °C and 
stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product was 
purified with flash chromatography to afford the desired compound, KSC-39, as a white 
solid (13.2 mg, 27%). 1H NMR (600 MHz, DMSO-d6) δ 8.36 – 8.16 (m, 2H), 7.38 (td, J = 
5.7, 5.1, 2.6 Hz, 2H), 4.21 (ddd, J = 79.4, 5.8, 2.5 Hz, 2H), 2.41 (d, J = 5.4 Hz, 3H), 2.10 




2,4-dichloro-6-(4-fluorophenyl)-1,3,5-triazine (KSC-40-int): To a solution of cyanuric 
chloride (520.2 mg, 2.8209 mmol) in a 1:1 v/v mixture of THF and diethyl ether (30 mL) 
and benzene (31 mL), 4-Fluorophenylmagnesium bromide (2 M, 1.69 mL) was added at 0 
°C and stirred for 4h, then stirred 4h at room temperature. Crude residue was extracted via 
liquid-liquid extraction. Solvents were removed in vacuo and crude product was purified 
with flash chromatography to afford the desired compound, KSC-40-int, as a white solid 
(380.1 mg, 55%). 1H NMR (500 MHz, Chloroform-d) δ 8.59 – 8.51 (m, 2H), 7.24 – 7.17 









4-chloro-6-(4-fluorophenyl)-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-40): To a 
solution of KSC-40-int (49.6 mg, 0.2032 mmol) and diisopropylethylamine (28.9 mg, 
0.2236 mmol) in THF (3 mL), propargylamine (13.4 µL, 0.2439 mmol) was added at -20 
°C and stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product 
was purified with flash chromatography to afford the desired compound, KSC-40, as a 
white solid (28.8 mg, 54%). 1H NMR (600 MHz, Acetone-d6) δ 8.60 – 8.33 (m, 2H), 7.39 
– 7.18 (m, 2H), 4.37 (ddd, J = 70.1, 5.9, 2.5 Hz, 2H), 2.81 (s, 1H). 13C NMR (151 MHz, 
acetone) δ 172.52, 172.15, 171.49, 167.73, 167.28, 166.06, 132.58, 116.66, 80.62, 80.52, 







6-chloro-N2-methyl-N4-(prop-2-yn-1-yl)-1,3,5-triazine-2,4-diamine (KSC-37): To a 
solution of RB7 (102.2 mg, 0.5029 mmol) and sodium carbonate (117.3 mg, 1.1014 mmol) 
in ethanol (7 mL), aniline (56.4μL 0.5532 mmol) was added at room temperature. The 
reaction mixture was heated to 45 °C for 18h. Crude residue was extracted via liquid-liquid 
extraction. Solvent was removed in vacuo and crude residue was purified with flash 
chromatography to afford the desired compound, KSC-37, as a white solid (22.4 mg, 23%). 
1H NMR (600 MHz, Acetone-d6) δ 4.27 (ddd, J = 34.1, 6.0, 2.5 Hz, 2H), 2.70 (dt, J = 6.6, 
2.5 Hz, 1H), 1.31 (s, 3H). 13C NMR (151 MHz, acetone) δ 187.95, 187.36, 171.28, 170.87, 
166.94, 166.82, 72.28, 72.13, 39.87, 39.56, 30.94, 30.72, 28.67, 28.62. HRMS for KSC-




6-chloro-N2-phenyl-N4-(prop-2-yn-1-yl)-1,3,5-triazine-2,4-diamine (KSC-36): To a 
solution of RB7 (103.3 mg, 0.5088 mmol) and sodium carbonate (119 mg, 1.1194 mmol) 
in ethanol (6 mL), aniline (51.1μL 0.5597 mmol) was added at room temperature. The 
reaction mixture was heated to 45 °C for 18h. Crude residue was extracted via liquid-liquid 




chromatography to afford the desired compound, KSC-36, as a white solid (48.9 mg, 37%). 
1H NMR (600 MHz, Acetone-d6) δ 8.93 (d, J = 84.3 Hz, 1H), 8.03 – 7.70 (m, 2H), 7.34 
(dt, J = 25.2, 7.8 Hz, 2H), 7.08 (dt, J = 15.0, 7.4 Hz, 1H), 4.34 – 4.09 (m, 2H), 2.83 (s, 1H). 




2-(benzylthio)-4,6-dichloro-1,3,5-triazine (KSC-41-int): To a solution of cyanuric 
chloride (1.01 g, 5.4601 mmol) and diisopropylethylamine (776.2 mg, 6.0061 mmol) in 
THF (5 mL), a solution of benzyl mercaptan (678.2 mg, 5.4601 mmol) in THF (5 mL) was 
added dropwise by addition funnel at 0 °C over 30 minutes followed by stirring at 0 °C for 
3h. The solvent was removed in vacuo and the crude product was purified with flash 
chromatography to afford the desired compound, KSC-41-int, as a white solid (931.7 mg, 
63%) 1H NMR (600 MHz, Chloroform-d) δ 7.42 – 7.38 (m, 2H), 7.36 – 7.31 (m, 2H), 7.30 
– 7.26 (m, 1H), 4.41 (s, 2H). 13C NMR (151 MHz, Chloroform-d) δ 185.79, 170.20, 135.26, 
129.39, 128.99, 128.88, 128.07, 77.58, 77.37, 77.16, 35.70. HRMS for KSC-41-int: m/z 







4-(benzylthio)-6-chloro-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-41): To a 
solution of KSC-41-int (389.1 mg, 1.4927 mmol) and diisopropylethylamine (203.3 mg, 
1.5727 mmol) in THF (10 mL), propargylamine (274 µL, 1.7157 mmol) was added at -20 
°C and stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product 
was purified with flash chromatography to afford the desired compound, KSC-41, as a 
white solid (195.4 mg, 47%). 1H NMR (500 MHz, Acetone-d6, mixture of rotamers) δ 7.87 
(dt, J = 44.5, 5.8 Hz, 1H), 7.53 – 7.37 (m, 2H), 7.36 – 7.28 (m, 2H), 7.28 – 7.22 (m, 1H), 
4.41 (d, J = 47.2 Hz, 2H), 4.28 (ddd, J = 22.9, 5.9, 2.5 Hz, 2H), 2.75 (dt, J = 11.9, 2.5 Hz, 
1H). 13C NMR (126 MHz, Acetone-d6, mixture of rotamers) δ 183.46, 182.66, 169.78, 
169.22, 165.44, 165.27, 138.36, 138.28, 129.99, 129.94, 129.42, 129.37, 128.18, 80.38, 





4-(benzylsulfinyl)-6-chloro-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-45): To a 
solution of KSC-41 (28.7 mg, 0.0970 mmol) was dissolved in DCM (3 mL) at room 
temperature. mCPBA (25.5 mg, 1.4806 mmol) was added in one portion. The reaction was 




was purified via flash chromatography to afford the desired compound, KSC-45, as a white 
solid (13.8 mg, 46%). 1H NMR (600 MHz, DMSO-d6, mixture of rotamers) δ 7.35 (dt, J = 
4.8, 2.1 Hz, 3H), 7.23 (ddd, J = 12.9, 6.5, 2.9 Hz, 2H), 4.58 – 4.22 (m, 2H), 4.14 (ddd, J = 
10.2, 5.5, 2.7 Hz, 2H), 3.26 (dt, J = 19.8, 2.5 Hz, 1H). 13C NMR (151 MHz, DMSO-d6, 
mixture of rotamers) δ 183.30, 182.65, 169.32, 169.05, 164.66, 164.36, 130.24, 130.18, 
128.43, 128.38, 128.19, 128.15, 79.51, 79.33, 74.14, 73.98, 58.41, 58.23, 30.26, 30.21. 





KSC-41 (44.0 mg, 0.1513 mmol) was dissolved in DCM (0.3M), and allowed to cool to 0 
°C while stirring. mCPBA (60.1 mg, 0.3480 mmol) was added in one portion. The reaction 
was allowed to stir for 12 hr while warming to room temperature. Crude residue was 
extracted via liquid-liquid extraction and the solvent removed in vacuo. The product was 
purified via flash chromatography to yield a white solid, KSC-42, as a white solid (26.4 
mg, 0.0818 mmol, 54%). 1H NMR (500 MHz, Chloroform-d, mixture of rotamers) δ 7.51 
– 7.39 (m, 2H), 7.36 (qd, J = 2.9, 1.6 Hz, 3H), 6.74 – 6.37 (m, 1H), 4.73 (d, J = 16.4 Hz, 
2H), 4.31 (ddd, J = 14.6, 5.7, 2.6 Hz, 2H), 2.31 (dt, J = 6.5, 2.5 Hz, 1H). 13C NMR (126 




165.90, 131.90, 131.88, 131.31, 129.99, 129.63, 129.33, 129.29, 126.34, 126.14, 73.58, 





2,4-dichloro-6-(phenylthio)-1,3,5-triazine (KSC-43-int): To a solution of cyanuric 
chloride (1.05 g, 5.6696 mmol) and diisopropylethylamine (580 µL, 6.2366 mmol) in THF 
(60 mL), a solution of thiophenol (624.7 mg, 5.6696 mmol) in THF (5 mL) was added 
dropwise by addition funnel at 0 °C over 30 minutes followed by stirring at 0 °C for 3h. 
The solvent was removed in vacuo and the crude product was purified with flash 
chromatography to afford the desired compound, KSC-43-int, as a white solid (1.1918 g, 
81%). 1H NMR (600 MHz, Chloroform-d) δ 7.58 – 7.54 (m, 2H), 7.53 – 7.48 (m, 2H), 7.48 
– 7.45 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 186.77, 170.74, 135.43, 130.95, 







4-chloro-6-(phenylthio)-N-(prop-2-yn-1-yl)-1,3,5-triazin-2-amine (KSC-43): To a 
solution of KSC-43-int (197.4 mg, 0.7648 mmol) and diisopropylethylamine (108.7 mg, 
0.8412 mmol) in THF (11 mL), propargylamine (59 µL, 0.9177 mmol) was added at -20 
°C and stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product 
was purified with flash chromatography to afford the desired compound, KSC-43, as a 
white solid (169.5 mg, 80%). 1H NMR (500 MHz, Chloroform-d, mixture of rotamers) δ 
7.62 – 7.52 (m, 2H), 7.45 – 7.39 (m, 3H), 7.07 (t, J = 5.9 Hz, 1H), 4.05 (ddd, J = 126.1, 
5.8, 2.5 Hz, 2H), 2.28 – 2.11 (m, 1H). 13C NMR (126 MHz, Chloroform-d, mixture of 
rotamers) δ 183.53, 182.45, 169.33, 168.25, 164.07, 163.70, 135.20, 129.59, 129.56, 
129.00, 128.84, 127.13, 126.96, 78.64, 78.28, 72.15, 71.33, 30.65, 30.45, 29.52. HRMS 




2,4-dichloro-6-((4-chlorophenyl)thio)-1,3,5-triazine (KSC-46-int): To a solution of 
cyanuric chloride (211.8 mg, 1.0845 mmol) and diisopropylethylamine (208 µL, 1.1930 
mmol) in THF (11 mL), a solution of p-chlorothiophenol (172.5 mg, 1.1930 mmol) in THF 
(5 mL) was added dropwise by addition funnel at 0 °C over 30 minutes followed by stirring 




flash chromatography to afford the desired compound, KSC-46-int, as a white solid (317.3 
mg, 58%). 1H NMR (500 MHz, DMSO-d6) δ 7.62 – 7.58 (m, 2H), 7.58 – 7.54 (m, 2H). 13C 
NMR (126 MHz, DMSO-d6) δ 169.00, 137.53, 135.51, 129.40, 124.07. HRMS for KSC-





46): To a solution of KSC-46-int (51.4 mg, 0.1757 mmol) and diisopropylethylamine (25.0 
mg, 0.1933 mmol) in THF (5 mL), propargylamine (13.5 µL, 0.2108 mmol) was added at 
-20 °C and stirred for 3h. After 3h, the solvent was removed in vacuo and the crude product 
was purified with flash chromatography to afford the desired compound, KSC-46, as a 
white solid (54.7 mg, 89%). 1H NMR (500 MHz, Chloroform-d, mixture of rotamers) δ 
8.38 – 8.21 (m, 1H), 8.15 – 8.02 (m, 2H), 8.02 – 7.90 (m, 2H), 4.56 (ddd, J = 92.2, 5.9, 2.3 
Hz, 2H), 3.29 – 3.11 (m, 1H). 13C NMR (126 MHz, Chloroform-d, mixture of rotamers) δ 
192.73, 192.10, 179.67, 179.20, 175.23, 174.98, 147.52, 147.41, 146.03, 139.82, 139.75, 








2,4-dichloro-6-((3,5-dichlorophenyl)thio)-1,3,5-triazine (KSC-47-int): To a solution of 
cyanuric chloride (222.3 mg, 1.2093 mmol) and diisopropylethylamine (232 µL, 1.3302 
mmol) in THF (12 mL), a solution of m,m-dichlorothiophenol (238.2 mg, 1.3302 mmol) in 
THF (5 mL) was added dropwise by addition funnel at 0 °C over 30 minutes followed by 
stirring at 0 °C for 3h. The solvent was removed in vacuo and the crude product was 
purified with flash chromatography to afford the desired compound, KSC-47-int, as a 
white solid (395.4 mg, 45%). 1H NMR (500 MHz, DMSO-d6) δ 7.86 – 7.78 (m, 1H), 7.76 
– 7.70 (m, 2H). 13C NMR (126 MHz, DMSO-d6) δ 168.41, 151.69, 134.24, 133.92, 130.05, 








(KSC-47): To a solution of KSC-47-int (47.2 mg, 0.1443 mmol) and 
diisopropylethylamine (20.5 mg, 0.1588 mmol) in THF (5 mL), propargylamine (11 µL, 
0.1732 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-47, as a white solid (13.5 mg, 27%). 1H NMR (500 MHz, 
Acetone-d6, mixture of rotamers) δ 8.06 – 7.84 (m, 1H), 7.68 (dd, J = 25.4, 2.0 Hz, 2H), 
7.62 (dt, J = 3.7, 1.9 Hz, 1H), 4.37 – 3.93 (m, 2H), 2.70 (dt, J = 23.6, 2.5 Hz, 1H). 13C 
NMR (126 MHz, Acetone-d6, mixture of rotamers) δ 182.20, 181.57, 170.05, 165.31, 
135.68, 135.64, 134.25, 134.21, 132.13, 130.39, 80.03, 79.83, 72.76, 72.58, 31.09, 30.97. 




2,4-dichloro-6-((2,4-dichlorophenyl)thio)-1,3,5-triazine (KSC-48-int): To a solution of 
cyanuric chloride (978.0 mg, 5.3036 mmol) and diisopropylethylamine (1.02 mL, 5.8339 
mmol) in THF (50 mL), a solution of o,p-dichlorothiophenol (1044.7 mg, 5.8339 mmol) 
in THF (5 mL) was added dropwise by addition funnel at 0 °C over 30 minutes followed 
by stirring at 0 °C for 3h. The solvent was removed in vacuo and the crude product was 




white solid (317.3 mg, 58%). 1H NMR (500 MHz, Acetone-d6) δ 7.84 (d, J = 8.4 Hz, 1H), 
7.80 (d, J = 2.2 Hz, 1H), 7.60 – 7.56 (m, 1H). 13C NMR (126 MHz, Acetone-d6) δ 198.10, 





(KSC-48): To a solution of KSC-48-int (64.0 mg, 0.1957 mmol) and 
diisopropylethylamine (27.8 mg, 0.2153 mmol) in THF (5 mL), propargylamine (15 µL, 
0.2349 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-48, as a white solid (66.3 mg, 98%). 1H NMR (600 MHz, 
Chloroform-d, mixture of rotamers) δ 7.63 – 7.57 (m, 1H), 7.55 (dd, J = 8.5, 2.3 Hz, 1H), 
7.30 (ddd, J = 8.4, 6.3, 2.2 Hz, 1H), 4.07 (ddd, J = 160.7, 5.7, 2.5 Hz, 2H), 2.23 (dt, J = 
50.4, 2.5 Hz, 1H). 13C NMR (151 MHz, Chloroform-d, mixture of rotamers) δ 181.75, 
180.80, 169.56, 168.70, 164.16, 163.86, 140.56, 138.30, 138.24, 137.09, 130.15, 130.01, 
127.67, 127.55, 125.43, 125.25, 78.22, 72.47, 71.78, 30.86, 30.74, 29.63. HRMS for KSC-







2,4-dichloro-6-(prop-2-yn-1-yloxy)-1,3,5-triazine (KSC-44): To a solution of cyanuric 
chloride (1.1788 g, 6.3925 mmol) and potassium carbonate (971.9 mg, 7.0317 mmol) in 
THF (60 mL), propargyl alcohol (394.2 mg, 7.0317 mmol) was added dropwise at 0 °C 
followed by stirring at 0 °C for 30h. Crude residue was extracted via liquid-liquid 
extraction. The solvent was removed in vacuo and the crude product was purified with 
flash chromatography to afford the desired compound, KSC-44, as a white solid (1.135 g, 
87%). 1H NMR (500 MHz, Chloroform-d) δ 5.07 (d, J = 2.5 Hz, 2H), 2.57 (t, J = 2.4 Hz, 
1H). 13C NMR (126 MHz, Chloroform-d) δ 172.28, 171.26, 170.19, 75.47, 57.10. HRMS 




N-benzylprop-2-yn-1-amine (KSC-50-int): To a suspension of (Bromomethyl)benzene 
(1.03 g, 6.0263 mmol) and potassium carbonate (999.4 mg, 7.2316 mmol) in acetonitrile 
(20 mL), propargylamine (995.8 mg, 18.0789 mmol) was added in one addition and the 
reaction was heated to reflux while stirring for 24h. Crude residue was extracted via liquid-




with flash chromatography to afford the desired compound, KSC-50-int, as a solid (439.5 
mg, 50%). 1H NMR (600 MHz, Chloroform-d) δ 7.41 – 7.35 (m, 2H), 7.34 (dd, J = 8.4, 
6.7 Hz, 2H), 7.30 – 7.24 (m, 1H), 3.87 (d, J = 1.6 Hz, 2H), 3.40 (dd, J = 2.5, 1.1 Hz, 2H), 
2.30 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 139.46, 128.33, 127.04, 






(KSC-50): To a solution of KSC-46-int (49.6 mg, 0.2000 mmol) and 
diisopropylethylamine (24.1 mg, 0.1865 mmol) in THF (5 mL), KSC-50-int (29.5 mg, 
0.2034 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-50, as a white solid (61.4 mg, 90%). 1H NMR (600 MHz, 
Chloroform-d, mixture of rotamers) δ 7.77 – 6.94 (m, 8H), 5.12 – 4.66 (m, 2H), 4.43 – 4.09 
(m, 2H), 2.31 – 2.08 (m, 1H). 13C NMR (151 MHz, Chloroform-d, mixture of rotamers) δ 




128.35, 128.07, 127.88, 127.80, 127.74, 127.32, 127.24, 79.28, 79.17, 71.34, 71.22, 48.64, 




N-(5-(prop-2-yn-1-ylamino)pyridin-2-yl)acetamide (KSC-52-int): To a suspension of 
2-Acetamido-5-Aminopyridine (391.5 mg, 2.9590 mmol), sodium iodide (194.1 mg, 1.290 
mmol), and potassium carbonate (894.7 mg, 6.470 mmol) in acetonitrile (7 mL), tosylated 
propargyl alcohol (598.9 mg, 2.8500 mmol) was added dropwise and the reaction was 
heated to reflux while stirring for 12h. Crude residue was extracted via liquid-liquid 
extraction. The solvent was removed in vacuo and the crude product was purified with 
flash chromatography to afford the desired compound, KSC-52-int, as a yellow solid 








yl)amino)pyridin-2-yl)acetamide (KSC-52): To a solution of KSC-46-int (50.4 mg, 
0.1723 mmol) and diisopropylethylamine (24.5 mg, 0.1895 mmol) in THF (5 mL), KSC-
52-int (39.1 mg, 0.2067 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent 
was removed in vacuo and the crude product was purified with flash chromatography to 
afford the desired compound, KSC-52, as a white solid (68.4 mg, 89%). 1H NMR (600 
MHz, Acetone-d6, mixture of rotamers) δ 9.68 – 9.55 (m, 1H), 8.35 – 8.07 (m, 2H), 7.85 – 
7.50 (m, 2H), 7.40 – 7.17 (m, 2H), 4.65 (dd, J = 127.8, 2.5 Hz, 2H), 2.83 (td, J = 7.7, 3.7 
Hz, 1H), 2.23 (d, J = 29.6 Hz, 3H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) 
δ 182.94, 169.84, 165.22, 152.32, 147.85, 137.95, 137.87, 137.29, 136.24, 133.73, 130.36, 
130.00, 126.76, 114.24, 114.10, 79.07, 74.93, 74.70, 40.98, 40.29, 30.74, 30.49, 24.62, 




N-(2-morpholinoethyl)prop-2-yn-1-amine (KSC-53-int): To a suspension of 
propargylbromide (600.0 mg, 4.0350 mmol) and potassium carbonate (613.4 mg, 4.4385 
mmol) in acetonitrile (10 mL), 4-(2-Aminoethyl)morpholine (1.576 g, 12.1049 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 




KSC-53-int, as a solid (517.6 mg, 61%). 1H NMR (500 MHz, Chloroform-d) δ 3.54 (t, J 
= 4.7 Hz, 4H), 3.29 (d, J = 2.6 Hz, 2H), 2.64 (t, J = 6.1 Hz, 2H), 2.35 (t, J = 6.1 Hz, 2H), 
2.30 (t, J = 4.5 Hz, 4H), 2.10 (s, 1H). 13C NMR (126 MHz, Chloroform-d) δ 81.82, 70.96, 






triazin-2-amine (KSC-53):  To a solution of KSC-46-int (50.4 mg, 0.1723 mmol) and 
diisopropylethylamine (24.5 mg, 0.1895 mmol) in THF (5 mL), KSC-53-int (34.8 mg, 
0.2067 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-53, as a white solid (62.1 mg, 85%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 8.12 (dd, J = 8.6, 0.8 Hz, 2H), 7.99 (dd, J = 19.4, 8.6 
Hz, 2H), 4.86 (dd, J = 118.4, 2.5 Hz, 3H), 4.08 – 3.95 (m, 5H), 3.25 (dt, J = 22.2, 2.5 Hz, 







4-cyclohexyl-N-(prop-2-yn-1-yl)aniline (KSC-55-int): To a suspension of 
propargylbromide (119.5 mg, 1.0045 mmol) and potassium carbonate (157.7 mg, 1.105 
mmol) in acetonitrile (4 mL), 4-Cyclohexylaniline (528.2 g, 3.0136 mmol) was added in 
one addition and the reaction was heated to reflux while stirring for 24h. Crude residue was 
extracted via liquid-liquid extraction. The solvent was removed in vacuo and the crude 
product was purified with flash chromatography to afford the desired compound, KSC-55-
int, as a solid (99.9 mg, 47%). 1H NMR (600 MHz, Chloroform-d) δ 7.11 – 7.06 (m, 2H), 
6.69 – 6.63 (m, 2H), 3.93 (d, J = 2.4 Hz, 2H), 3.78 (s, 1H), 2.51 – 2.36 (m, 1H), 2.23 (t, J 
= 2.4 Hz, 1H), 1.95 – 1.79 (m, 4H), 1.75 (dddd, J = 12.6, 4.5, 3.0, 1.4 Hz, 1H), 1.47 – 1.32 
(m, 4H), 1.31 – 1.19 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 144.75, 138.41, 
127.39, 113.45, 81.21, 71.10, 43.55, 34.62, 33.81, 26.91, 26.14. HRMS for KSC-53-int: 








triazin-2-amine (KSC-55):  To a solution of KSC-46-int (32.8 mg, 0.1121 mmol) and 
diisopropylethylamine (15.9 mg, 0.1233 mmol) in THF (3 mL), KSC-55-int (28.7 mg, 
0.1345 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-55, as a white solid (53.1 mg, 100%). 1H NMR (600 MHz, 
Chloroform-d, mixture of rotamers) δ 7.51 (dd, J = 109.9, 8.1 Hz, 2H), 7.28 – 7.17 (m, 
3H), 7.13 – 6.99 (m, 3H), 4.47 (dd, J = 191.4, 2.4 Hz, 2H), 2.26 – 2.18 (m, 1H), 2.01 – 
1.72 (m, 5H). 13C NMR (151 MHz, Chloroform-d, mixture of rotamers) δ 182.26, 182.05, 
169.32, 169.08, 167.85, 163.72, 147.82, 147.57, 138.49, 138.38, 136.83, 136.15, 136.07, 
135.46, 132.57, 130.99, 129.37, 128.98, 128.92, 127.88, 127.39, 126.42, 126.37, 126.28, 
126.04, 78.82, 78.62, 77.37, 77.16, 76.95, 72.65, 72.11, 68.27, 44.29, 44.18, 41.03, 40.35, 
38.86, 34.56, 34.46, 30.50, 29.83, 29.06, 26.99, 26.96, 26.24, 23.88, 23.11, 14.19, 11.10. 




N-(furan-2-ylmethyl)prop-2-yn-1-amine (KSC-56-int): To a suspension of 
propargylbromide (225.0 mg, 1.8900 mmol) and potassium carbonate (287.5 mg, 2.0800 
mmol) in acetonitrile (6 mL), Furfurylamine (551.1 g, 5.6700 mmol) was added in one 
addition and the reaction was heated to reflux while stirring for 24h. Crude residue was 




product was purified with flash chromatography to afford the desired compound, KSC-56-
int, as a solid (103.7 mg, 41%). 1H NMR (600 MHz, Chloroform-d) δ 7.33 (dd, J = 1.9, 
0.9 Hz, 1H), 6.27 (dd, J = 3.2, 1.8 Hz, 1H), 6.23 – 6.09 (m, 1H), 3.84 (d, J = 0.8 Hz, 2H), 
3.38 (d, J = 2.4 Hz, 2H), 2.22 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 
152.74, 141.82, 109.92, 107.26, 81.45, 71.51, 44.36, 36.90. HRMS for KSC-53-int: m/z 





triazin-2-amine (KSC-56): To a solution of KSC-46-int (86.2 mg, 0.2947 mmol) and 
diisopropylethylamine (41.9 mg, 0.3242 mmol) in THF (9 mL), KSC-56-int (47.8 mg, 
0.3536 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-56, as a yellow solid (97.5 mg, 85%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 7.74 – 7.59 (m, 2H), 7.58 – 7.49 (m, 2H), 7.48 (ddd, J 
= 3.5, 1.9, 0.8 Hz, 1H), 6.48 – 6.37 (m, 1H), 6.37 – 6.06 (m, 1H), 4.78 (d, J = 137.4 Hz, 
2H), 4.31 (dd, J = 153.6, 2.5 Hz, 2H), 2.75 (dt, J = 35.5, 2.5 Hz, 1H). 13C NMR (151 MHz, 




150.50, 150.42, 143.91, 143.75, 138.07, 137.97, 137.91, 136.71, 136.61, 130.31, 130.29, 
127.45, 127.42, 111.48, 111.40, 110.41, 109.87, 78.69, 78.67, 74.19, 73.84, 43.34, 43.24, 




(R)-N-(2-phenylpropyl)prop-2-yn-1-amine (KSC-57-int): To a suspension of 
propargylbromide (183.3 mg, 1.2327 mmol) and potassium carbonate (187.4 mg, 1.3560 
mmol) in acetonitrile (6 mL), (R)-2-phenylpropan-1-amine (500.0 mg, 3.6980 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 
the crude product was purified with flash chromatography to afford the desired compound, 
KSC-57-int, as a solid (121.8 mg, 57%). 1H NMR (500 MHz, Chloroform-d) δ 7.32 (t, J 
= 7.5 Hz, 2H), 7.23 (dd, J = 12.5, 7.3 Hz, 3H), 3.39 (t, J = 2.7 Hz, 2H), 2.94 (dd, J = 7.5, 
4.3 Hz, 2H), 2.84 (dd, J = 9.5, 5.9 Hz, 1H), 2.19 (d, J = 2.4 Hz, 1H), 1.29 (d, J = 6.1 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 144.91, 128.42, 127.01, 126.26, 82.00, 71.06, 








triazin-2-amine (KSC-57): To a solution of KSC-46-int (46.8 mg, 0.1600 mmol) and 
diisopropylethylamine (22.7 mg, 0.1760 mmol) in THF (5 mL), KSC-57-int (33.3 mg, 
0.1920 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 




1-phenyl-2-(prop-2-yn-1-ylamino)ethan-1-ol (KSC-58-int): To a suspension of 
propargylbromide (96.0 mg, 0.6458 mmol) and potassium carbonate (214.2 mg, 1.5499 
mmol) in acetonitrile (6 mL), 2-amino-1-phenylethan-1-ol (265.8 mg, 1.9373 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 




KSC-58-int, as a solid (44.9 mg, 40%). 1H NMR (600 MHz, Chloroform-d) δ 7.39 – 7.31 
(m, 4H), 7.30 – 7.23 (m, 1H), 4.75 (dd, J = 8.9, 3.6 Hz, 1H), 3.42 (d, J = 2.4 Hz, 2H), 2.95 
(dd, J = 12.1, 3.6 Hz, 1H), 2.81 (dd, J = 12.2, 8.9 Hz, 1H), 2.21 (t, J = 2.5 Hz, 1H). 13C 
NMR (151 MHz, Chloroform-d) δ 142.31, 128.29, 128.23, 127.46, 125.82, 125.72, 81.54, 





phenylethan-1-ol (KSC-58): To a solution of KSC-46-int (62.5 mg, 0.2135 mmol) and 
diisopropylethylamine (30.4 mg, 0.2349 mmol) in THF (6 mL), KSC-58-int (44.9 mg, 
0.2349 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-58, as a white solid (69.2 mg, 78%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 7.73 – 7.62 (m, 2H), 7.58 – 7.49 (m, 2H), 7.48 – 7.40 
(m, 1H), 7.35 (td, J = 7.7, 1.5 Hz, 2H), 7.30 – 7.23 (m, 1H), 7.14 – 7.07 (m, 1H), 5.18 – 
4.78 (m, 1H), 4.79 – 4.55 (m, 1H), 4.54 – 4.14 (m, 1H), 3.98 – 3.47 (m, 2H), 2.77 (dt, J = 
20.8, 2.5 Hz, 1H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) δ 206.26, 182.80, 




129.25, 129.21, 128.47, 128.37, 127.49, 126.85, 126.70, 79.27, 79.23, 73.89, 73.65, 72.42, 
72.03, 55.02, 54.59, 54.56, 38.61, 38.51, 30.36, 30.23, 30.10, 29.97, 29.85, 29.72, 29.59. 




N-(naphthalen-1-ylmethyl)prop-2-yn-1-amine (KSC-59-int): To a suspension of 
propargylbromide (64.5 mg, 0.4338 mmol) and potassium carbonate (143.9 mg, 1.0412 
mmol) in acetonitrile (6 mL), Naphthalen-1-ylmethanamine (204.6 mg, 1.3015 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 
the crude product was purified with flash chromatography to afford the desired compound, 
KSC-59-int, as a solid. 1H NMR (600 MHz, Acetone-d6) δ 8.31 – 8.26 (m, 1H), 7.92 – 
7.87 (m, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.54 – 7.48 (m, 3H), 7.43 (dd, J = 8.2, 6.9 Hz, 1H), 
4.31 (s, 2H), 3.47 (d, J = 2.4 Hz, 2H), 2.73 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, 
Acetone-d6) δ 136.58, 134.82, 133.00, 129.21, 128.43, 127.05, 126.54, 126.36, 126.12, 









1,3,5-triazin-2-amine (KSC-59):  To a solution of KSC-46-int (61.3 mg, 0.2335 mmol) 
and diisopropylethylamine (33.2 mg, 0.2568 mmol) in THF (7 mL), KSC-59-int (54.7 mg, 
0.2802 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-59, as a white solid (56.5 mg, 78%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 8.22 – 7.77 (m, 3H), 7.71 – 7.63 (m, 1H), 7.62 – 7.53 
(m, 2H), 7.53 – 7.48 (m, 1H), 7.48 – 7.36 (m, 3H), 7.29 (dd, J = 7.0, 1.2 Hz, 1H), 7.04 – 
6.93 (m, 1H), 5.28 (d, J = 154.2 Hz, 2H), 4.30 (dd, J = 168.0, 2.5 Hz, 2H), 2.77 (dt, J = 
35.6, 2.5 Hz, 1H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) δ 184.79, 184.66, 
171.80, 171.55, 166.33, 166.28, 139.50, 139.14, 138.20, 138.00, 136.65, 136.56, 134.13, 
133.92, 133.56, 133.40, 131.90, 131.60, 131.43, 131.37, 131.19, 130.91, 129.22, 129.18, 
129.06, 128.72, 128.70, 128.65, 128.60, 127.99, 127.91, 127.83, 127.78, 125.90, 125.68, 








N-(prop-2-yn-1-yl)hexan-1-amine (KSC-60-int): To a suspension of propargylbromide 
(323.3 mg, 2.7180 mmol) and potassium carbonate (819 mg, 5.9290 mmol) in acetonitrile 
(8 mL), hexylamine (250 mg, 2.4710 mmol) was added in one addition and the reaction 
was heated to reflux while stirring for 24h. Crude residue was extracted via liquid-liquid 
extraction. The solvent was removed in vacuo and the crude product was purified with 
flash chromatography to afford the desired compound, KSC-60-int, as a solid (192.3 mg, 
51%). 1H NMR (500 MHz, Chloroform-d) δ 3.40 (d, J = 2.4 Hz, 2H), 2.66 (t, J = 7.2 Hz, 
2H), 2.21 – 2.10 (m, 1H), 1.52 – 1.39 (m, 2H), 1.37 – 1.15 (m, 6H), 0.86 (t, J = 6.8 Hz, 
3H). 13C NMR (126 MHz, Chloroform-d) δ 82.72, 71.45, 49.10, 38.54, 32.11, 30.17, 27.35, 





(KSC-60):  To a solution of KSC-46-int (70.0 mg, 0.2394 mmol) and 
diisopropylethylamine (34.0 mg, 0.2633 mmol) in THF (3 mL), KSC-60-int (40 mg, 
0.2873 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 




desired compound, KSC-60, as a an oil (69.0 mg, 73%). 1H NMR (600 MHz, Acetone-d6, 
mixture of rotamers) δ 7.72 – 7.61 (m, 2H), 7.59 – 7.48 (m, 2H), 4.31 (dd, J = 124.3, 2.5 
Hz, 2H), 3.74 – 3.26 (m, 2H), 2.76 (dt, J = 17.8, 2.5 Hz, 1H), 1.48 – 1.26 (m, 6H), 1.25 – 
1.01 (m, 3H), 0.90 – 0.84 (m, 3H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) 
δ 206.05, 182.81, 182.23, 169.67, 169.35, 164.11, 163.95, 138.15, 137.73, 136.56, 136.32, 
130.15, 130.06, 127.47, 127.43, 79.27, 73.59, 73.33, 48.43, 47.74, 37.20, 37.00, 32.34, 
32.13, 27.71, 27.57, 27.11, 26.94, 23.31, 23.18, 14.34, 14.28. HRMS for KSC-60: m/z 




N-(2-(2-methoxyphenoxy)ethyl)prop-2-yn-1-amine (KSC-61-int): To a suspension of 
propargylbromide (100 mg, 0.8406 mmol) and potassium carbonate (139.4 mg, 0.1008 
mmol) in acetonitrile (8 mL), 2-(2-Methoxy)ethylamine (281.1 mg, 1.6812 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 
the crude product was purified with flash chromatography to afford the desired compound, 
KSC-61-int, as a solid (100.3 mg, 58%). 1H NMR (600 MHz, Chloroform-d) δ 6.96 – 6.90 
(m, 2H), 6.88 (ddd, J = 7.9, 6.1, 1.7 Hz, 2H), 4.13 (t, J = 5.3 Hz, 2H), 3.84 (s, 3H), 3.50 (d, 




Chloroform-d) δ 149.66, 148.13, 121.47, 120.70, 114.19, 111.76, 81.87, 71.33, 68.74, 





yl)-1,3,5-triazin-2-amine (KSC-61): To a solution of KSC-46-int (55.3 mg, 0.1890 
mmol) and diisopropylethylamine (26.8. mg, 0.2079 mmol) in THF (5 mL), KSC-61-int 
(46.5 mg, 0.2268 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was 
removed in vacuo and the crude product was purified with flash chromatography to afford 
the desired compound, KSC-61, as a white solid (83.0 mg, 95%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 7.69 – 7.62 (m, 2H), 7.55 – 7.45 (m, 2H), 7.00 – 6.81 
(m, 4H), 4.54 (dd, J = 122.7, 2.5 Hz, 2H), 4.15 (dt, J = 106.0, 5.5 Hz, 2H), 3.91 (dt, J = 
107.2, 5.5 Hz, 3H), 3.79 (d, J = 15.3 Hz, 4H), 2.79 (dt, J = 22.0, 2.5 Hz, 1H). 13C NMR 
(151 MHz, Acetone-d6, mixture of rotamers) δ 206.08, 182.76, 182.50, 169.70, 169.55, 
164.39, 164.30, 150.68, 150.60, 149.09, 137.94, 137.76, 136.52, 136.40, 130.10, 130.08, 
127.45, 127.35, 122.46, 122.36, 121.58, 121.54, 114.74, 114.35, 113.11, 113.02, 79.23, 
79.18, 73.88, 73.60, 67.32, 66.88, 56.13, 56.09, 47.05, 46.63, 38.20, 37.97. HRMS for 







N-(4-(benzyloxy)phenethyl)prop-2-yn-1-amine (KSC-62-int): To a suspension of 
propargylbromide (88.1 mg, 0.5928 mmol) and potassium carbonate (163.9 mg, 1.1856 
mmol) in acetonitrile (4 mL), 2-(4-(benzyloxy)phenyl)ethan-1-amine (112.2 mg, 0.4940 
mmol) was added in one addition and the reaction was heated to reflux while stirring for 
24h. Crude residue was extracted via liquid-liquid extraction. The solvent was removed in 
vacuo and the crude product was purified with flash chromatography to afford the desired 
compound, KSC-62-int, as a solid (31.4 mg, 24%). 1H NMR (600 MHz, Chloroform-d) δ 
7.48 – 7.42 (m, 2H), 7.43 – 7.36 (m, 2H), 7.36 – 7.30 (m, 1H), 7.18 – 7.11 (m, 2H), 6.97 – 
6.89 (m, 2H), 5.05 (s, 2H), 3.44 (dd, J = 2.5, 1.0 Hz, 2H), 2.95 (t, J = 7.1 Hz, 2H), 2.77 (t, 
J = 7.1 Hz, 2H), 2.25 – 2.17 (m, 1H). 13C NMR (151 MHz, Chloroform-d) δ 157.64, 137.47, 
132.39, 129.96, 128.88, 128.22, 127.77, 115.22, 82.43, 71.64, 70.36, 50.27, 38.46, 35.57. 








1,3,5-triazin-2-amine (KSC-62):  To a solution of KSC-46-int (27.8 mg, 0.0952 mmol) 
and diisopropylethylamine (13.5. mg, 0.1047 mmol) in THF (3 mL), KSC-62-int (30.3 
mg, 0.1142 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was 
removed in vacuo and the crude product was purified with flash chromatography to afford 
the desired compound, KSC-62, as a white solid (43.0 mg, 87%). 1H NMR (600 MHz, 
Acetone-d6, mixture of rotamers) δ 7.73 – 7.63 (m, 2H), 7.58 – 7.50 (m, 2H), 7.50 – 7.42 
(m, 2H), 7.39 (q, J = 7.8 Hz, 2H), 7.35 – 7.28 (m, 1H), 7.22 – 7.17 (m, 1H), 6.97 – 6.92 
(m, 2H), 6.92 – 6.86 (m, 1H), 5.10 (d, J = 12.5 Hz, 2H), 4.29 (dd, J = 144.9, 2.5 Hz, 2H), 
3.90 – 3.57 (m, 2H), 2.80 (ddd, J = 20.5, 4.7, 2.0 Hz, 1H), 2.73 – 2.66 (m, 2H). 13C NMR 
(151 MHz, Acetone-d6, mixture of rotamers) δ 169.36, 164.14, 158.46, 138.51, 137.96, 
137.74, 131.42, 130.69, 130.54, 130.36, 130.11, 129.28, 128.57, 128.35, 115.80, 81.38, 





N-([1,1'-biphenyl]-2-ylmethyl)prop-2-yn-1-amine (KSC-63-int): To a suspension of 




mmol) in acetonitrile (3.5 mL), 2-phenylbenzylamine hydrochloride (160.6 mg, 0.7310 
mmol) was added in one addition and the reaction was heated to reflux while stirring for 
24h. Crude residue was extracted via liquid-liquid extraction. The solvent was removed in 
vacuo and the crude product was purified with flash chromatography to afford the desired 
compound, KSC-63-int, as a solid (32 mg, 20%). 1H NMR (600 MHz, Chloroform-d) δ 
7.50 (dd, J = 7.5, 1.5 Hz, 1H), 7.45 – 7.30 (m, 7H), 7.29 – 7.24 (m, 1H), 3.81 (s, 2H), 3.33 
(d, J = 2.4 Hz, 2H), 2.13 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, Chloroform-d) δ 142.16, 
141.21, 136.94, 130.28, 129.47, 129.29, 128.26, 127.63, 127.20, 127.17, 82.14, 71.45, 





1,3,5-triazin-2-amine (KSC-63): To a solution of KSC-46-int (35.3 mg, 0.1205 mmol) 
and diisopropylethylamine (17.1. mg, 0.1325 mmol) in THF (3 mL), KSC-63-int (35.3 
mg, 0.1205 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was 
removed in vacuo and the crude product was purified with flash chromatography to afford 
the desired compound, KSC-63, as a white solid (55.0 mg, 96%). 1H NMR (600 MHz, 




(m, 3H), 5.23 (d, J = 147.0 Hz, 2H), 4.54 (dd, J = 156.4, 2.5 Hz, 2H), 3.08 (dt, J = 25.3, 
2.5 Hz, 1H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) δ 192.41, 191.97, 
179.33, 179.14, 174.14, 173.97, 152.82, 152.47, 151.10, 151.05, 147.41, 147.37, 146.03, 
143.67, 143.24, 140.70, 140.67, 139.77, 139.68, 139.40, 139.25, 138.87, 138.72, 138.67, 
138.25, 138.23, 138.16, 138.07, 137.69, 137.05, 136.97, 88.09, 83.70, 83.37, 58.08, 57.79, 





4-(4-chlorophenoxy)-N-(prop-2-yn-1-yl)aniline (KSC-64-int): To a suspension of 
propargylbromide (161.7 mg, 1.3590 mmol) and potassium carbonate (375.7 mg, 2.7182 
mmol) in acetonitrile (5 mL), 4-amino-4-chlorodiphenylether (248.8 mg, 1.1326 mmol) 
was added in one addition and the reaction was heated to reflux while stirring for 24h. 
Crude residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo 
and the crude product was purified with flash chromatography to afford the desired 
compound, KSC-64-int, as a solid (73 mg, 25%). 1H NMR (600 MHz, Acetone-d6) δ 7.34 
– 7.24 (m, 2H), 6.94 – 6.84 (m, 4H), 6.82 – 6.73 (m, 2H), 5.25 (t, J = 6.4 Hz, 1H), 3.96 
(dd, J = 6.3, 2.4 Hz, 2H), 2.63 (t, J = 2.4 Hz, 1H). 13C NMR (151 MHz, Acetone-d6) δ 
159.08, 147.96, 145.89, 130.27, 127.05, 121.80, 119.10, 114.98, 82.41, 72.05, 33.78. 








yl)-1,3,5-triazin-2-amine (KSC-64): To a solution of KSC-46-int (22.4 mg, 0.0766 
mmol) and diisopropylethylamine (10.9. mg, 0.0843 mmol) in THF (2 mL), KSC-64-int 
(23.7 mg, 0.0920 mmol) was added at -20 °C and stirred for 3h. After 3h, the solvent was 
removed in vacuo and the crude product was purified with flash chromatography to afford 
the desired compound, KSC-64, as a white solid (27.9 mg, 71%). 1H NMR (500 MHz, 
Acetone-d6, mixture of rotamers) δ 7.64 (dd, J = 81.3, 8.0 Hz, 2H), 7.44 (ddd, J = 21.4, 
12.7, 8.4 Hz, 4H), 7.31 (dd, J = 32.9, 8.3 Hz, 2H), 7.18 – 6.93 (m, 4H), 4.62 (dd, J = 120.3, 
2.5 Hz, 2H), 2.86 – 2.75 (m, 1H). 13C NMR (126 MHz, Acetone-d6, mixture of rotamers) 
δ 181.84, 163.86, 156.18, 155.55, 136.92, 136.34, 129.94, 129.29, 129.05, 128.96, 128.71, 







N-(prop-2-yn-1-yl)-3-(pyrrolidin-1-ylsulfonyl)aniline (KSC-65-int): To a suspension of 
propargylbromide (100 mg, 0.8406 mmol) and potassium carbonate (139.4 mg, 0.1009 
mmol) in acetonitrile (5 mL), (aminophenyl)sulfonyl pyrrolidine (380.4 mg, 0.1681 mmol) 
was added in one addition and the reaction was heated to reflux while stirring for 24h. 
Crude residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo 
and the crude product was purified with flash chromatography to afford the desired 
compound, KSC-65-int, as a solid (100.9 mg, 45%). 1H NMR (600 MHz, Chloroform-d) 
δ 7.31 (t, J = 7.9 Hz, 1H), 7.17 (dd, J = 7.9, 1.4 Hz, 1H), 7.10 (t, J = 2.0 Hz, 1H), 6.85 (dd, 
J = 8.2, 2.4 Hz, 1H), 4.34 (t, J = 6.1 Hz, 1H), 3.96 (dd, J = 6.0, 2.4 Hz, 2H), 3.30 – 3.17 
(m, 4H), 2.21 (t, J = 2.4 Hz, 1H), 1.76 – 1.69 (m, 4H). 13C NMR (151 MHz, Chloroform-
d) δ 147.63, 137.75, 130.04, 117.64, 117.30, 111.90, 80.49, 71.98, 48.26, 33.63, 25.51. 









mg, 0.1661 mmol) and diisopropylethylamine (23.6. mg, 0.1827 mmol) in THF (5 mL), 
KSC-65-int (52.7 mg, 0.1993 mol) was added at -20 °C and stirred for 3h. After 3h, the 
solvent was removed in vacuo and the crude product was purified with flash 
chromatography to afford the desired compound, KSC-65, as a white solid (58.7 mg, 68%). 
1H NMR (500 MHz, Acetone-d6, mixture of rotamers) δ 8.21 – 7.10 (m, 8H), 4.73 (d, J = 
109.3 Hz, 2H), 3.22 (d, J = 5.9 Hz, 4H), 2.90 – 2.73 (m, 1H), 1.81 – 1.66 (m, 4H). 13C 
NMR (126 MHz, Acetone-d6, mixture of rotamers) δ 169.73, 164.72, 142.37, 137.76, 
137.35, 132.73, 130.88, 130.12, 127.98, 127.28, 78.99, 74.79, 74.57, 48.85, 25.85. HRMS 




4-(phenylsulfonyl)-N-(prop-2-yn-1-yl)aniline (KSC-66-int):  To a suspension of 
propargylbromide (175.8 mg, 1.1821 mmol) and potassium carbonate (178.2 mg, 1.2896 
mmol) in acetonitrile (5 mL), 4-(phenylsulfonyl)aniline (250.7 mg, 1.0746 mmol) was 
added in one addition and the reaction was heated to reflux while stirring for 24h. Crude 
residue was extracted via liquid-liquid extraction. The solvent was removed in vacuo and 
the crude product was purified with flash chromatography to afford the desired compound, 
KSC-66-int, as a solid (71.8 mg, 25%). 1H NMR (500 MHz, Chloroform-d) δ 7.92 – 7.81 




2.5 Hz, 2H), 2.23 (t, J = 2.4 Hz, 1H). 13C NMR (126 MHz, Chloroform-d) δ 150.87, 143.00, 
132.60, 129.75, 129.18, 127.14, 112.69, 79.61, 72.06, 32.97. HRMS for KSC-66-int: m/z 





1,3,5-triazin-2-amine (KSC-66): To a solution of KSC-46-int (64.3 mg, 0.2199 mmol) 
and diisopropylethylamine (31.3. mg, 0.2419 mmol) in THF (5 mL), KSC-66-int (71.6 
mg, 0.2639 mol) was added at -20 °C and stirred for 3h. After 3h, the solvent was removed 
in vacuo and the crude product was purified with flash chromatography to afford the 
desired compound, KSC-65, as a white solid. 1H NMR (600 MHz, Acetone-d6, mixture of 
rotamers) δ 8.12 – 7.95 (m, 5H), 7.77 – 7.52 (m, 8H), 2.81 (t, J = 2.5 Hz, 2H), 2.05 (p, J = 
2.2 Hz, 1H). 13C NMR (151 MHz, Acetone-d6, mixture of rotamers) δ 183.37, 169.88, 
164.64, 146.28, 142.84, 137.70, 136.71, 134.60, 130.66, 130.33, 129.56, 128.76, 127.06, 
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Appendix. Mass Spectometry Tables 
 
Appendix Table 4.1. Mass Spectrometry data for KSC-56 treated samples. The proteins shown 
are those that displayed an average spectral count of 10 or greater in the KSC-56 treated sample. 
The data is sorted by the spectral count difference between the KSC-56 treated and the DMSO 
(no probe) samples. 













O76003 GLRX3 GLRX3 Glutaredoxin-3 5.
4 
335 37432 0 312 312 
P49327 FASN FASN Fatty acid synthase 6.
4 
2511 273424 17 283 266 
P08238 HSP90AB1 HSP90AB1 Heat shock 
protein HSP 90-beta 
5 724 83264 11 224 214 




451 50136 16 189 173 
P60709 ACTB ACTB Actin, cytoplasmic 1 5.
5 
375 41737 28 188 160 




448 49924 26 177 152 
P07900 HSP90AA1 HSP90AA1 Heat shock 
protein HSP 90-alpha 
5 732 84660 7 157 150 
P78527 PRKDC PRKDC DNA-dependent 




4128 469093 0 135 135 
P21333 FLNA FLNA Filamin-A 6.
1 
2647 280737 29 161 132 




1675 191613 7 125 118 
P05165 PCCA PCCA Propionyl-CoA 




728 80059 94 199 105 
Q9BVA
1 




445 49953 0 105 105 
P13639 EEF2 EEF2 Elongation factor 2 6.
8 








725 80473 157 247 90 
P15924 DSP DSP Desmoplakin 6.
8 
2871 331774 4 91 87 




531 57937 36 123 87 
P07437 TUBB TUBB Tubulin beta chain 4.
9 
444 49671 63 149 86 




445 49831 64 146 82 
P04075 ALDOA ALDOA Fructose-
bisphosphate aldolase A 
8.
1 
364 39420 10 84 74 
259 
 




784 85596 2 73 72 
P07339 CTSD CTSD Cathepsin D 6.
5 
412 44552 0 68 68 
Q9NY6
5 




449 50094 19 82 63 
Q05639 EEF1A2 EEF1A2 Elongation factor 1-
alpha 2 
9 463 50470 0 61 61 
P21266 GSTM3 GSTM3 Glutathione S-
transferase Mu 3 
5.
5 
225 26560 0 59 59 




2671 292756 2 59 58 




356 37498 1 58 57 
Q15149 PLEC PLEC Plectin 6 4684 531796 9 65 56 
Q8TEX
9 
IPO4 IPO4 Importin-4 5 1081 118715 2 57 55 
Q16881 TXNRD1 TXNRD1 Thioredoxin 
reductase 1, cytoplasmic 
7.
4 
649 70756 0 51 51 
O75369 FLNB FLNB Filamin-B 5.
7 





379 40447 0 51 51 
Q14204 DYNC1H1 DYNC1H1 Cytoplasmic 
dynein 1 heavy chain 1 
6.
4 








563 61333 3 47 44 
Q8TCU
6 
PREX1 PREX1 Phosphatidylinositol 
3,4,5-trisphosphate-




1659 186202 1 45 44 
P35579 MYH9 MYH9 Myosin-9 5.
6 
1960 226530 7 50 44 
P27708 CAD CAD CAD protein 6.
5 
2225 242981 0 42 42 




641 70052 8 50 42 
P11142 HSPA8 HSPA8 Heat shock cognate 
71 kDa protein 
5.
5 
646 70898 14 55 42 





533 56651 4 44 40 
P08243 ASNS ASNS Asparagine synthetase 6.
9 
561 64370 0 39 39 




515 59257 2 39 38 
Q7Z6Z7 HUWE1 HUWE1 E3 ubiquitin-
protein ligase HUWE1 
5.
2 
4374 481896 0 37 37 




2346 265551 243 280 37 
P22314 UBA1 UBA1 Ubiquitin-like 
modifier-activating enzyme 1 
5.
8 
1058 117849 8 44 37 
260 
 
Q13509 TUBB3 TUBB3 Tubulin beta-3 chain 4.
9 
450 50433 62 98 37 





1394 157904 6 42 36 
Q14980 NUMA1 NUMA1 Nuclear mitotic 
apparatus protein 1 
5.
8 
2115 238257 0 35 35 





5890 629114 0 35 35 
Q14145 KEAP1 KEAP1 Kelch-like ECH-
associated protein 1 
6.
4 
624 69666 0 34 34 
P23528 CFL1 CFL1 Cofilin-1 8.
1 
166 18502 0 33 33 





780 85018 3 36 33 
P06733 ENO1 ENO1 Alpha-enolase 7.
4 
434 47169 6 38 33 
P68104 EEF1A1 EEF1A1 Elongation factor 1-
alpha 1 
9 462 50141 54 87 33 
Q06830 PRDX1 PRDX1 Peroxiredoxin-1 8.
1 
199 22110 1 33 32 




205 22783 12 43 31 
O00410 IPO5 IPO5 Importin-5 4.
9 
1097 123630 2 32 31 




1401 157182 0 30 30 




365 38580 0 30 30 
P30519 HMOX2 HMOX2 Heme oxygenase 2 5.
4 
316 36033 0 29 29 
Q6AI08 HEATR6 HEATR6 HEAT repeat-
containing protein 6 
7 1181 128781 0 28 28 




377 42051 0 28 28 




377 42009 0 28 28 
P42224 STAT1 STAT1 Signal transducer 




750 87335 1 28 27 
Q86VP6 CAND1 CAND1 Cullin-associated 
NEDD8-dissociated protein 1 
5.
8 
1230 136375 2 28 27 
O14980 XPO1 XPO1 Exportin-1 6.
1 
1071 123386 0 26 26 




573 61055 10 35 25 




679 73681 4 26 23 
Q9Y490 TLN1 TLN1 Talin-1 6.
1 
2541 269765 2 23 22 
O00299 CLIC1 CLIC1 Chloride intracellular 
channel protein 1 
5.
2 
241 26923 0 22 22 
261 
 




876 97170 2 23 22 




286 30791 4 25 22 
P07737 PFN1 PFN1 Profilin-1 8.
3 
140 15054 6 27 21 




968 106810 3 23 21 
Q9Y5L
0 
TNPO3 TNPO3 Transportin-3 5.
6 
923 104203 0 21 21 




406 46154 2 23 21 




1621 181674 0 20 20 
P53396 ACLY ACLY ATP-citrate synthase 7.
3 
1101 120839 1 21 20 





1657 189251 3 23 20 
Q9HAV
4 
XPO5 XPO5 Exportin-5 5.
8 
1204 136311 0 20 20 
P55060 CSE1L CSE1L Exportin-2 5.
8 
971 110417 3 23 20 
Q02790 FKBP4 FKBP4 Peptidyl-prolyl cis-
trans isomerase FKBP4 
5.
4 
459 51805 2 22 20 
Q9UL4
6 
PSME2 PSME2 Proteasome activator 
complex subunit 2 
5.
7 
239 27402 0 20 20 




858 96865 3 22 20 
Q5TH6
9 
ARFGEF3 ARFGEF3 Brefeldin A-
inhibited guanine nucleotide-
exchange protein 3 
5.
8 
2177 240649 0 19 19 





483 53140 0 18 18 




6 1290 148532 0 18 18 




1217 135577 0 18 18 




944 106874 0 18 18 
E9PPU0 EPPK1 EPPK1 Epiplakin 6 2420 264622 3 20 18 




437 50119 8 25 18 




1178 129634 516 533 17 
P14625 HSP90B1 HSP90B1 Endoplasmin 4.
8 
803 92469 4 21 17 





621 68857 0 17 17 
262 
 




335 36053 6 23 17 




274 30868 0 17 17 
Q96T76 MMS19 MMS19 MMS19 nucleotide 




1030 113289 0 16 16 





1512 170590 1 17 16 
P38606 ATP6V1A ATP6V1A V-type proton 
ATPase catalytic subunit A 
5.
5 
617 68304 0 16 16 




241 27566 0 16 16 
P30153 PPP2R1A PPP2R1A Serine/threonine-
protein phosphatase 2A 65 




589 65309 0 15 15 




840 94331 3 18 15 
Q7L576 CYFIP1 CYFIP1 Cytoplasmic FMR1-
interacting protein 1 
6.
9 
1253 145182 0 15 15 
Q06323 PSME1 PSME1 Proteasome activator 
complex subunit 1 
6 249 28723 0 14 14 





1338 144734 1 15 14 
Q13200 PSMD2 PSMD2 26S proteasome non-
ATPase regulatory subunit 2 
5.
2 
908 100200 0 14 14 





699 78806 0 14 14 
P48506 GCLC GCLC Glutamate--cysteine 
ligase catalytic subunit 
6.
1 
637 72766 0 14 14 




215 24894 0 13 13 
Q53FA3 HSPA1L HSPA1L Heat shock 70kDa 
protein 1-like variant 
6.
3 
641 70404 3 16 13 
Q6PJG
6 
BRAT1 BRAT1 BRCA1-associated 
ATM activator 1 
5.
3 
821 88119 0 13 13 




543 62639 4 17 13 
Q5TFE
4 
NT5DC1 NT5DC1 5'-nucleotidase 
domain-containing protein 1 
6.
3 
455 51845 0 13 13 
Q8WX
H0 
SYNE2 SYNE2 Nesprin-2 5.
4 
6885 796457 0 13 13 
Q13263 TRIM28 TRIM28 Transcription 
intermediary factor 1-beta 
5.
8 
835 88550 2 15 13 




508 57116 2 15 13 
P04080 CSTB CSTB Cystatin-B 7.
6 
98 11140 0 13 13 
P37802 TAGLN2 TAGLN2 Transgelin-2 8.
2 
199 22391 2 14 13 
263 
 
P15170 GSPT1 GSPT1 Eukaryotic peptide 
chain release factor GTP-
binding subunit ERF3A 
5.
6 
499 55756 0 12 12 




330 37636 0 12 12 
P46109 CRKL CRKL Crk-like protein 6.
7 
303 33777 0 12 12 




1272 141347 0 12 12 
P30876 POLR2B POLR2B DNA-directed RNA 
polymerase II subunit RPB2 
6.
9 
1174 133896 0 12 12 





935 101559 0 12 12 





795 87302 0 12 12 




118 12712 0 12 12 
P31939 ATIC ATIC Bifunctional purine 
biosynthesis protein PURH 
6.
7 
592 64616 4 15 12 




1264 140466 0 12 12 
Q9BTE
3 





642 72980 0 12 12 




548 59621 2 14 12 
P53618 COPB1 COPB1 Coatomer subunit 
beta 
6 953 107142 1 12 11 
Q9ULA
0 




475 52428 0 11 11 
Q5T4S7 UBR4 UBR4 E3 ubiquitin-protein 
ligase UBR4 
6 5183 573849 0 11 11 




819 93488 0 11 11 




539 57924 0 11 11 




452 50909 1 12 11 




361 41516 0 11 11 
O95373 IPO7 IPO7 Importin-7 4.
8 
1038 119516 0 11 11 
P41250 GARS GARS Glycine--tRNA ligase 7 739 83166 0 11 11 
Q9H0W
8 
SMG9 SMG9 Protein SMG9 7 520 57651 0 11 11 
P29401 TKT TKT Transketolase 7.
7 
623 67878 3 13 11 




924 104738 0 10 10 




608 65854 0 10 10 
264 
 
P61978 HNRNPK HNRNPK Heterogeneous 
nuclear ribonucleoprotein K 
5.
5 
463 50976 0 10 10 
P52597 HNRNPF HNRNPF Heterogeneous 
nuclear ribonucleoprotein F 
5.
6 
415 45672 0 10 10 
P00966 ASS1 ASS1 Argininosuccinate 
synthase 
8 412 46530 3 13 10 
Q9NR0
9 
BIRC6 BIRC6 Baculoviral IAP 
repeat-containing protein 6 
6 4857 530260 0 10 10 





1309 146669 0 10 10 




1262 144498 0 10 10 





1010 107767 0 10 10 





806 89322 3 13 10 
E7EVH
7 
KLC1 KLC1 Kinesin light chain 1 7.
3 
732 83695 0 10 10 
Q12931 TRAP1 TRAP1 Heat shock protein 
75 kDa, mitochondrial 
8.
2 
704 80110 1 11 10 
Q07866 KLC1 KLC1 Kinesin light chain 1 6.
2 
573 65310 0 10 10 
P23443 RPS6KB1 RPS6KB1 Ribosomal protein 
S6 kinase beta-1 
6.
7 
525 59140 0 10 10 




558 63147 2 11 10 




2179 233515 0 10 10 




1176 134466 1 11 10 
P16615 ATP2A2 ATP2A2 
Sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2 
5.
3 
1042 114757 0 10 10 
P13010 XRCC5 XRCC5 X-ray repair cross-
complementing protein 5 
5.
8 
732 82705 0 10 10 




414 45621 0 10 10 
P12814 ACTN1 ACTN1 Alpha-actinin-1 5.
4 
892 103058 4 13 10 




417 44615 3 12 10 
Q9H3U
1 




944 103077 2 11 9 
P11940 PABPC1 PABPC1 Polyadenylate-
binding protein 1 
9.
5 
636 70671 1 10 9 




216 24423 1 10 9 
P18206 VCL VCL Vinculin 5.
7 
1134 123799 1 10 9 




919 103276 2 10 9 
265 
 




874 97718 2 10 9 
Q8WU
M4 
PDCD6IP PDCD6IP Programmed cell 
death 6-interacting protein 
6.
5 
868 96023 1 10 9 




535 57488 2 11 9 




445 50663 2 11 9 




1224 138345 3 11 9 
O43592 XPOT XPOT Exportin-T 5.
4 
962 109964 2 10 9 




654 72333 3 11 8 
P62937 PPIA PPIA Peptidyl-prolyl cis-
trans isomerase A 
7.
8 
165 18012 7 15 8 
O43707 ACTN4 ACTN4 Alpha-actinin-4 5.
4 
911 104854 4 11 7 




245 27745 3 10 7 





338 35503 7 12 6 
P05166 PCCB PCCB Propionyl-CoA 




539 58216 8 12 4 




115 12476 9 11 3 




2458 276539 26 28 2 
Q9BUF
5 
TUBB6 TUBB6 Tubulin beta-6 chain 4.
9 
446 49857 41 32 -9 
 
 
Appendix Table 4.2. Mass Spectrometry data for KSC-65 treated samples. The proteins shown 
are those that displayed an average spectral count of 10 or greater in the KSC-65 treated sample. 
The data is sorted by the spectral count difference between the KSC-65 treated and the DMSO 






















PFKP 6-phosphofructokinase type C 7.6 784 8559
6 
2 546 545 
P114
98 
PC PC Pyruvate carboxylase, mitochondrial 6.8 1178 1296
34 





ACTB Actin, cytoplasmic 1 5.5 375 4173
7 





TUBA1A Tubulin alpha-1A chain 5.1 451 5013
6 

























MCCC1 Methylcrotonoyl-CoA carboxylase 
subunit alpha, mitochondrial 
7.8 725 8047
3 























TUBB Tubulin beta chain 4.9 444 4967
1 





FASN Fatty acid synthase 6.4 2511 2734
24 
17 130 113 
P146
18 
PKM PKM Pyruvate kinase isozymes M1/M2 7.8 531 5793
7 





TUBB4B Tubulin beta-4B chain 4.9 445 4983
1 





MCCC2 Methylcrotonoyl-CoA carboxylase 
beta chain, mitochondrial 
7.7 563 6133
3 














PCBP1 Poly(rC)-binding protein 1 7.1 356 3749
8 





TUBB3 Tubulin beta-3 chain 4.9 450 5043
3 





GLRX3 Glutaredoxin-3 5.4 335 3743
2 
0 65 65 
P136
39 
EEF2 EEF2 Elongation factor 2 6.8 858 9533
8 





TUBA4A Tubulin alpha-4A chain 5.1 448 4992
4 














PFKL 6-phosphofructokinase, liver type 7.5 780 8501
8 





ALDOA Fructose-bisphosphate aldolase A 8.1 364 3942
0 





FLNA Filamin-A 6.1 2647 2807
37 














HSPA8 Heat shock cognate 71 kDa protein 5.5 646 7089
8 





LRPPRC Leucine-rich PPR motif-
containing protein, mitochondrial 
6.1 1394 1579
04 





TUBB6 Tubulin beta-6 chain 4.9 446 4985
7 
41 65 24 
P159
24 
DSP DSP Desmoplakin 6.8 2871 3317
74 





ASNS Asparagine synthetase 6.9 561 6437
0 





RTN4 Reticulon-4 4.5 1192 1299
31 
















CLTC Clathrin heavy chain 1 5.7 1675 1916
13 





EEF1A2 Elongation factor 1-alpha 2 9 463 5047
0 














HSP90B1 Endoplasmin 4.8 803 9246
9 





MYH9 Myosin-9 5.6 1960 2265
30 





TUBA8 Tubulin alpha-8 chain 5.1 449 5009
4 





HMOX2 Heme oxygenase 2 5.4 316 3603
3 





PRDX1 Peroxiredoxin-1 8.1 199 2211
0 
1 19 18 
Q8T
EX9 
IPO4 IPO4 Importin-4 5 1081 1187
15 














ENO1 Alpha-enolase 7.4 434 4716
9 
6 22 17 
P077
37 
PFN1 PFN1 Profilin-1 8.3 140 1505
4 














CCT8 T-complex protein 1 subunit theta 5.6 548 5962
1 





P4HB Protein disulfide-isomerase 4.9 508 5711
6 





HSPB1 Heat shock protein beta-1 6.4 205 2278
3 















YWHAZ 14-3-3 protein zeta/delta 4.8 245 2774
5 





PCBP2 Poly(rC)-binding protein 2 6.8 365 3858
0 














KPNB1 Importin subunit beta-1 4.8 876 9717
0 










1 13 12 
P601
74 
TPI1 TPI1 Triosephosphate isomerase 5.9 286 3079
1 






reticulum calcium ATPase 2 
5.3 1042 1147
57 

























HSPA9 Stress-70 protein, mitochondrial 6.2 679 7368
1 






dissociated protein 1 
5.8 1230 1363
75 





YWHAQ 14-3-3 protein theta 4.8 245 2776
4 





HSPA1B Heat shock 70 kDa protein 1A/1B 5.6 641 7005
2 






associated protein AHNAK 
6.1 5890 6291
14 





GSTO1 Glutathione S-transferase omega-1 6.6 241 2756
6 


















3 12 9 
O00
410 
IPO5 IPO5 Importin-5 4.9 1097 1236
30 





HSPA6 Heat shock 70 kDa protein 6 6.1 643 7102
8 





AARS Alanine--tRNA ligase, cytoplasmic 5.5 968 1068
10 





HSPA4 Heat shock 70 kDa protein 4 5.2 840 9433
1 
3 10 7 
P141
74 









ACACB Acetyl-CoA carboxylase 2 6.5 2458 2765
39 





EEF1A1 Elongation factor 1-alpha 1 9 462 5014
1 





ACACA Acetyl-CoA carboxylase 1 6.4 2346 2655
51 
243 188 -56 
 
